2024/10/02 更新

お知らせ

 

写真a

ババ エイシ
馬場 英司
BABA EISHI
所属
医学研究院 附属総合コホートセンター 教授
九州大学病院 ARO次世代医療センター(併任)
九州大学病院 がんセンター(併任)
医学部 医学科(併任)
医学系学府 医学専攻(併任)
医学系学府 医療経営・管理学専攻(併任)
職名
教授
連絡先
メールアドレス
電話番号
0926426921
プロフィール
医学研究院社会環境医学講座連携腫瘍学分野において、主に悪性腫瘍などを有する患者集団を対象とした診断、治療を評価する臨床研究に取り組んでいる。また健常人、患者集団の臨床検体を用いて診断、治療に関連するバイオマーカー探索研究を行っている。さらに臨床検体解析から得られた情報をもとに、分子生物学、免疫学的解析を行い、橋渡し研究のシーズの探索も実施している。 医学研究院社会環境医学講座連携腫瘍学分野の教員とともに、文部科学省採択事業「次世代のがんプロフェッショナル養成プラン」に携わっている。具体的には九州内の医学系11大学と連携する「次世代の九州がんプロ養成プラン」を、幹事校の代表として運営を担当している。本プランではがん医療に関連する多職種の専門人材育成の教育プログラムを実施している。また全国がんプロ協議会会長として、全国のがんプロ教育拠点の活動の取りまとめも行っている。 九州大学病院がんセンター長として、厚労省指定の都道府県がん診療連携拠点病院である本院の機能を十分に発揮し、福岡県内外のがん診療の充実に貢献できるよう努めている。また同じく厚労省指定のがんゲノム医療中核拠点病院として、九州・西日本の拠点・連携病院と共にがんゲノム医療を推進している。さらに同センター内の希少がん部門において九州沖縄の希少がん診療体制の構築に取り組んでいる。 ・九州大学病院ARO次世代医療センターの副センター長として、本学や他大学の非臨床・臨床研究成果を新規診断や新規治療への応用までのサポートをする体制の充実に努めている。
ホームページ

研究分野

  • ライフサイエンス / 消化器内科学

  • ライフサイエンス / 消化器内科学

学位

  • 医学博士

経歴

  • 九州大学大学院医学研究院 社会環境医学講座 連携社会分野 教授

    2019年3月 - 現在

      詳細を見る

  • 米国ハーバード大学 1997.3-1999.3 琉球大学医学部 1999.4-2001.4

研究テーマ・研究キーワード

  • 研究テーマ:Clinical oncology

    研究キーワード:Clinical oncology

    研究期間: 2024年

  • 研究テーマ:臨床腫瘍学

    研究キーワード:臨床腫瘍学

    研究期間: 2024年

  • 研究テーマ:腫瘍免疫学

    研究キーワード:腫瘍免疫学

    研究期間: 2024年

  • 研究テーマ:Tumor Immunology

    研究キーワード:Tumor Immunology

    研究期間: 2024年

  • 研究テーマ:がんゲノムプロファイル検査による固形腫瘍の個別化医療の開発

    研究キーワード:固形腫瘍、がんゲノム、個別化医療、薬物療法

    研究期間: 2020年4月 - 2024年12月

  • 研究テーマ:消化器癌における腫瘍幹細胞の解析

    研究キーワード:消化器癌、腫瘍幹細胞

    研究期間: 2009年1月 - 2015年12月

  • 研究テーマ:ヒト免疫細胞、腫瘍細胞の産生するエクソゾームの生体内機能と産生調節機構の解明

    研究キーワード:エクソゾーム、HLA、リンパ球、樹状細胞、腫瘍細胞

    研究期間: 2003年4月

  • 研究テーマ:悪性固形腫瘍に対する新たな化学療法の開発

    研究キーワード:固形腫瘍、化学療法、分子標的療法

    研究期間: 2001年3月

  • 研究テーマ:悪性腫瘍に対する宿主の免疫応答の解析

    研究キーワード:腫瘍、リンパ球、樹状細胞、幹細胞移植

    研究期間: 2001年3月

論文

  • Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study

    Yamamoto, Y; Yukami, H; Yamaguchi, T; Ohori, H; Nagasu, S; Kagawa, Y; Sugimoto, N; Sonoda, H; Yamazaki, K; Takashima, A; Okuyama, H; Hasegawa, H; Kondo, C; Baba, E; Matsumoto, T; Kawamoto, Y; Kataoka, M; Shindo, Y; Ishikawa, T; Esaki, T; Kito, Y; Sato, T; Funakoshi, T; Yamaguchi, T; Shimada, Y; Moriwaki, T

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   2024年8月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Background: FOLFOXIRI plus bevacizumab is a standard first-line chemotherapy for patients with metastatic colorectal cancer (mCRC). However, due to the severe toxicities, this regimen is not widely used. There is limited data on the real-world efficacy and safety. Methods: We conducted a retrospective analysis of clinical data from mCRC patients who received FOLFOXIRI plus bevacizumab as first-line chemotherapy at 31 institutions. The initial dose was standardized according to the TRIBE regimen. Induction therapy was defined as a combination of oxaliplatin, irinotecan, and fluorouracil. Results: Out of 104 patients who met the criteria, the median age was 58 years (range, 16–72). 81% of patients had an eastern cooperative oncology group performance status (PS) of 0. An initial dose reduction was observed in 63% of patients. The median number of preplanned induction therapy cycles was 12 (range, 4–12). The completion of scheduled induction therapy cycles was observed in 45% of patients, with treatment-related toxicities being the main reason for discontinuation (63%). The median progression-free survival and overall survival were 12.8 months (95% CI, 10.6–15.0) and 27.9 months (95% CI 21.6–34.2), respectively. The objective response rate and disease control rate were 63.7% and 98.9%, respectively. The R0 resection rate was 21.2%. The main grade 3 or higher toxicities were neutropenia (51%), febrile neutropenia (10%), and nausea/vomiting (5%). No treatment-related deaths were observed. Conclusion: In a real-world clinical setting, FOLFOXIRI plus bevacizumab demonstrated efficacy and safety comparable to previous clinical trials.

    DOI: 10.1007/s10147-024-02613-0

    Web of Science

    Scopus

    PubMed

  • 書評 NTT東日本関東病院流 外来がん薬物療法を支えるチーム医療-各職種・部門の取り組みから多職種連携の実際まで

    馬場 英司

    内科   134 ( 2 )   297 - 297   2024年8月   ISSN:00221961 eISSN:24329452

     詳細を見る

    出版者・発行元:南江堂  

    DOI: 10.15106/j_naika134_297

    CiNii Research

  • Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022

    Nozawa, K; Ozaki, Y; Yoshinami, T; Yokoe, T; Nishio, H; Tsuchihashi, K; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1074 - 1080   2024年8月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Introduction: Chemotherapy for breast cancer can cause neutropenia, increasing the risk of febrile neutropenia (FN) and serious infections. The use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis has been explored to mitigate these risks. To evaluate the efficacy and safety of primary G-CSF prophylaxis in patients with invasive breast cancer undergoing chemotherapy. Methods: A systematic literature review was conducted according to the “Minds Handbook for Clinical Practice Guideline Development” using PubMed, Ichushi-Web, and the Cochrane Library databases. Randomized controlled trials (RCTs) and cohort studies assessing using G-CSF as primary prophylaxis in invasive breast cancer were included. The primary outcomes were overall survival (OS) and FN incidence. Meta-analyses were performed for outcomes with sufficient data. Results: Eight RCTs were included in the qualitative analysis, and five RCTs were meta-analyzed for FN incidence. The meta-analysis showed a significant reduction in FN incidence with primary G-CSF prophylaxis (risk difference [RD] = 0.22, 95% CI: 0.01–0.43, p = 0.04). Evidence for improvement in OS with G-CSF was inconclusive. Four RCTs suggested a tendency for increased pain with G-CSF, but statistical significance was not reported. Conclusions: Primary prophylactic use of G-CSF is strongly recommended for breast cancer patients undergoing chemotherapy, as it has been shown to reduce the incidence of FN. While the impact on OS is unclear, the benefits of reducing FN are considered to outweigh the potential harm of increased pain.

    DOI: 10.1007/s10147-024-02570-8

    Web of Science

    Scopus

    PubMed

  • Nutritional Status Is Associated With Physical Improvement of Palliative Cancer Patients During Cancer Rehabilitation.

    Imajima T, Shirakawa T, Ohtsu Y, Uchihashi H, Otsuka T, Akashi K, Baba E, Mitsugi K

    Cancer diagnosis & prognosis   4 ( 4 )   503 - 509   2024年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.21873/cdp.10355

    PubMed

  • Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology

    Hirose, T; Ito, M; Tsuchihashi, K; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Endo, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1081 - 1087   2024年6月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Background: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, “Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?” and CQ #2, “Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?”. Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019. Two reviewers assessed the extracted papers and analyzed overall survival (OS), febrile neutropenia (FN) incidence, infection-related mortality, quality of life (QOL), and pain. Results: Twenty-five English and five Japanese articles were identified for CQ #1. After screening, a cohort study of vincristine, ifosfamide, doxorubicin, and etoposide chemotherapy with 851 patients was selected. Incidence of FN was 60.8% with G-CSF and 65.8% without; statistical tests were not conducted. Data on OS, infection-related mortality, QOL, or pain was unavailable. Consequently, CQ #1 was redefined as a future research question. As for CQ #2, we found two English and five Japanese papers, of which one high-quality randomized controlled trial on G-CSF use in intensified chemotherapy was included. This trial showed trends toward lower mortality and a significant increase in event-free survival for 2-week interval regimen with the G-CSF primary prophylactic use compared with 3-week interval. Conclusion: This review indicated that G-CSF’s efficacy as primary prophylaxis in Ewing sarcoma, except in children, is uncertain despite its common use. This review tentatively endorses intensified chemotherapy with G-CSF primary prophylaxis for Ewing sarcoma.

    DOI: 10.1007/s10147-024-02572-6

    Web of Science

    Scopus

    PubMed

  • Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology

    Hirose, T; Ito, M; Tsuchihashi, K; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Endo, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1067 - 1073   2024年6月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    Background: Granulocyte colony-stimulating factor (G-CSF) is an essential supportive agent for chemotherapy-induced severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, “Does primary prophylaxis with G-CSF benefit chemotherapy for non-round cell soft tissue sarcoma (NRC-STS)?” and CQ #2, “Does G-CSF-based intensified chemotherapy improve NRC-STS treatment outcomes?” for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology. Methods: A literature search was performed on the primary prophylactic use of G-CSF for NRC-STSs. Two reviewers assessed the extracted papers and analyzed overall survival, incidence of febrile neutropenia, infection-related mortality, quality of life, and pain. Results: Eighty-one and 154 articles were extracted from the literature search for CQs #1 and #2, respectively. After the first and second screening, one and two articles were included in the final evaluation, respectively. Only some studies have addressed these two clinical questions through a literature review. Conclusion: The clinical questions were converted to future research questions because of insufficient available data. The statements were proposed: “The benefit of primary G-CSF prophylaxis is not clear in NRC-STS” and “The benefit of intensified chemotherapy with primary G-CSF prophylaxis is not clear in NRC-STSs.” G-CSF is often administered as primary prophylaxis when chemotherapy with severe myelosuppression is administered. However, its effectiveness and safety are yet to be scientifically proven.

    DOI: 10.1007/s10147-024-02569-1

    Web of Science

    Scopus

    PubMed

  • Clinical landscape of precision oncology for rare cancers among diverse Asian populations: Insights from the MASTER KEY registry.

    Mizoguchi, C; Okuma, HS; Muto, M; Kinoshita, I; Baba, E; Takahashi, M; Ando, M; Hoo, HFS; Yusak, S; Voon, PJ; Ramachandran, R; Thiagarajan, M; Imasa, MSB; Malik, RA; Choi, W; Van Dao, T; Chen, TWW; Yonemori, K; Nakamura, K; Yamamoto, N

    JOURNAL OF CLINICAL ONCOLOGY   42 ( 16 )   2024年6月   ISSN:0732-183X eISSN:1527-7755

     詳細を見る

  • Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology(タイトル和訳中)

    Ito Mamoru, Okumura Yuta, Nio Kenta, Baba Eishi, Ozaki Yukinori, Nishio Hiroshi, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Tsuchihashi Kenji

    International Journal of Clinical Oncology   29 ( 6 )   689 - 699   2024年6月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022(タイトル和訳中)

    Yoshinami Tetsuhiro, Nozawa Kazuki, Yokoe Takamichi, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi

    International Journal of Clinical Oncology   29 ( 6 )   681 - 688   2024年6月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • Therapeutic use of granulocyte colony-stimulating factor(G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology(タイトル和訳中)

    Tsuchihashi Kenji, Ito Mamoru, Okumura Yuta, Nio Kenta, Ozaki Yukinori, Nishio Hiroshi, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Baba Eishi

    International Journal of Clinical Oncology   29 ( 6 )   700 - 705   2024年6月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

    Yuho Najima, Tomoya Maeda, Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miumra, Makoto Endo, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Shingo Yano

    International journal of clinical oncology   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-023-02461-4

  • Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology

    Tsuchihashi, K; Ito, M; Okumura, Y; Nio, K; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Baba, E

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 6 )   700 - 705   2024年5月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    BACKGROUND: Febrile neutropenia represents a critical oncologic emergency, and its management is pivotal in cancer therapy. In several guidelines, the use of granulocyte colony-stimulating factor (G-CSF) in patients with chemotherapy-induced febrile neutropenia is not routinely recommended except in high-risk cases. The Japan Society of Clinical Oncology has updated its clinical practice guidelines for the use of G-CSF, incorporating a systematic review to address this clinical question. METHODS: The systematic review was conducted by performing a comprehensive literature search across PubMed, the Cochrane Library, and Ichushi-Web, focusing on publications from January 1990 to December 2019. Selected studies included randomized controlled trials (RCTs), non-RCTs, and cohort and case-control studies. Evaluated outcomes included overall survival, infection-related mortality, hospitalization duration, quality of life, and pain. RESULTS: The initial search yielded 332 records. Following two rounds of screening, two records were selected for both qualitative and quantitative synthesis including meta-analysis. Regarding infection-related mortality, the event to case ratio was 5:134 (3.73%) in the G-CSF group versus 6:129 (4.65%) in the non-G-CSF group, resulting in a relative risk of 0.83 (95% confidence interval, 0.27-2.58; p = 0.54), which was not statistically significant. Only median values for hospitalization duration were available from the two RCTs, precluding a meta-analysis. For overall survival, quality of life, and pain, no suitable studies were found for analysis, rendering their assessment unfeasible. CONCLUSION: A weak recommendation is made that G-CSF treatment not be administered to patients with febrile neutropenia during cancer chemotherapy. G-CSF treatment can be considered for patients at high risk.

    DOI: 10.1007/s10147-024-02541-z

    Web of Science

    Scopus

    PubMed

    researchmap

  • Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022

    Ozaki, Y; Yokoe, T; Yoshinami, T; Nozawa, K; Nishio, H; Tsuchihashi, K; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 5 )   551 - 558   2024年5月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    INTRODUCTION: The timing of prophylactic pegylated granulocyte colony-stimulating factor (G-CSF) administration during cancer chemotherapy varies, with Day 2 and Days 3-5 being the most common schedules. Optimal timing remains uncertain, affecting efficacy and adverse events. This systematic review sought to evaluate the available evidence on the timing of prophylactic pegylated G-CSF administration. METHODS: Based on the Minds Handbook for Clinical Practice Guideline Development, we searched the PubMed, Ichushi-Web, and Cochrane Library databases for literature published from January 1990 to December 2019. The inclusion criteria included studies among the adult population using pegfilgrastim. The search strategy focused on timing-related keywords. Two reviewers independently extracted and assessed the data. RESULTS: Among 300 initial search results, only four articles met the inclusion criteria. A meta-analysis for febrile neutropenia incidence suggested a potential higher incidence when pegylated G-CSF was administered on Days 3-5 than on Day 2 (odds ratio: 1.27, 95% CI 0.66-2.46, p = 0.47), with a moderate certainty of evidence. No significant difference in overall survival or mortality due to infections was observed. The trend of severe adverse events was lower on Days 3-5, without statistical significance (odds ratio: 0.72, 95% CI 0.14-3.67, p = 0.69) and with a moderate certainty of evidence. Data on pain were inconclusive. CONCLUSIONS: Both Day 2 and Days 3-5 were weakly recommended for pegylated G-CSF administration post-chemotherapy in patients with cancer. The limited evidence highlights the need for further research to refine recommendations.

    DOI: 10.1007/s10147-024-02499-y

    Web of Science

    Scopus

    PubMed

    researchmap

  • Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer 国際誌

    Yamaguchi, K; Ito, M; Isobe, T; Koreishi, S; Taguchi, R; Uehara, K; Ueno, S; Imajima, T; Kitazono, T; Tsuchihashi, K; Ohmura, H; Yoshihiro, T; Tanoue, K; Nishiyori, S; Iwama, E; Maeda, T; Akashi, K; Baba, E

    JCO PRECISION ONCOLOGY   8 ( 8 )   e2300681   2024年5月   eISSN:2473-4284

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JCO Precision Oncology  

    PURPOSE

    The impact of genomic alterations on response and resistance to trastuzumab deruxtecan (T-DXd) has not been elucidated. Thus, we sought to identify factors predicting sensitivity to T-DXd in gastric or gastroesophageal junction (G/GEJ) cancer.

    METHODS

    We conducted a retrospective study using real-world clinical data and next-generation sequencing–based comprehensive genomic profiling (CGP) data from patients with advanced G/GEJ cancers, collected by the nationwide database in Japan. We analyzed the associations between genomic alterations and the patients' survivals after T-DXd treatment.

    RESULTS

    In 114 patients with human epidermal growth factor receptor-2 (HER2)–positive G/GEJ cancer treated with T-DXd, the most frequently altered genes were TP53 (82%), ERBB2 (80%), and CCNE1 (36%). Multivariate Cox regression analysis revealed CCNE1 amplification to be a significant predictor of shorter progression-free survival (PFS) after T-DXd treatment among 91 patients whose CGP samples were obtained before T-DXd (median PFS, 131 days v 189 days; hazard ratio [HR], 1.90 [95% CI, 1.02 to 3.53]; P = .044). Analyses of 1,450 G/GEJ cancers revealed significant CCNE1/ ERBB2 coamplification (41% relative to 11% CCNE1 amplification in ERBB2-nonamplified tumors; P < .0001). ERBB2-activating mutations were also detected in 3.7% of G/GEJ cancers and in 8.8% of HER2-positive G/GEJ cancers treated with T-DXd. Patients with ERBB2-mutated tumors showed shorter PFS than those without ERBB2 mutations after T-DXd treatment (mPFS, 105 v 180 days; P = .046).

    CONCLUSION

    CCNE1 amplification may confer primary resistance to T-DXd in HER2-positive G/GEJ cancer, suggesting that the cell cycle could be a potential therapeutic target in CCNE1/ERBB2 coamplified tumors. ERBB2-activating mutation may also attenuate T-DXd efficacy in HER2-positive G/GEJ cancer.

    DOI: 10.1200/po.23.00681

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.

    Shoji Kimura, Keisuke Shigeta, Shingo Tamura, Keita Uchino, Takahiro Kimura, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Makoto Endo, Shingo Yano, Dai Maruyama, Tetsuhiro Yoshinami, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano, Yuji Miura

    International journal of clinical oncology   29 ( 5 )   559 - 563   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-024-02501-7

  • Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022

    Uchino, K; Tamura, S; Kimura, S; Shigeta, K; Kimura, T; Ozaki, Y; Nishio, H; Tsuchihashi, K; Ichihara, E; Endo, M; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Ochi, N; Kubo, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Miura, Y

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 5 )   545 - 550   2024年5月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    Granulocyte colony-stimulating factor (G-CSF) decreases the incidence, duration, and severity of febrile neutropenia (FN); however, dose reduction or withdrawal is often preferred in the management of adverse events in the treatment of urothelial cancer. It is also important to maintain therapeutic intensity in order to control disease progression and thereby relieve symptoms, such as hematuria, infection, bleeding, and pain, as well as to prolong the survival. In this clinical question, we compared treatment with primary prophylactic administration of G-CSF to maintain therapeutic intensity with conventional standard therapy without G-CSF and examined the benefits and risks as major outcomes. A detailed literature search for relevant studies was performed using PubMed, Ichu-shi Web, and Cochrane Library. Data were extracted and evaluated independently by two reviewers. A qualitative analysis of the pooled data was performed, and the risk ratios with corresponding confidence intervals were calculated and summarized in a meta-analysis. Seven studies were included in the qualitative analysis, two of which were reviewed in the meta-analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) therapy, and one randomized controlled study showed a reduction in the incidence of FN. Primary prophylactic administration of G-CSF may be beneficial, as shown in a randomized controlled study of dose-dense MVAC therapy. However, there are no studies on other regimens, and we made a "weak recommendation to perform" with an annotation of the relevant regimen (dose-dense MVAC).

    DOI: 10.1007/s10147-024-02491-6

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology

    Maeda, T; Najima, Y; Kamiyama, Y; Nakao, S; Ozaki, Y; Nishio, H; Tsuchihashi, K; Ichihara, E; Miumra, Y; Endo, M; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Yano, S

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 5 )   535 - 544   2024年5月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    Although granulocyte colony-stimulating factor (G-CSF) reduces the incidence, duration, and severity of neutropenia, its prophylactic use for acute myeloid leukemia (AML) remains controversial due to a theoretically increased risk of relapse. The present study investigated the effects of G-CSF as primary prophylaxis for AML with remission induction therapy. A detailed literature search for related studies was performed using PubMed, Ichushi-Web, and the Cochrane Library. Data were independently extracted and assessed by two reviewers. A qualitative analysis of pooled data was conducted, and the risk ratio with corresponding confidence intervals was calculated in the meta-analysis and summarized. Sixteen studies were included in the qualitative analysis, nine of which were examined in the meta-analysis. Although G-CSF significantly shortened the duration of neutropenia, primary prophylaxis with G-CSF did not correlate with infection-related mortality. Moreover, primary prophylaxis with G-CSF did not affect disease progression/recurrence, overall survival, or adverse events, such as musculoskeletal pain. However, evidence to support or discourage the use of G-CSF as primary prophylaxis for adult AML patients with induction therapy remains limited. Therefore, the use of G-CSF as primary prophylaxis can be considered for adult AML patients with remission induction therapy who are at a high risk of infectious complications.

    DOI: 10.1007/s10147-023-02465-0

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022(タイトル和訳中)

    Kimura Shoji, Shigeta Keisuke, Tamura Shingo, Uchino Keita, Kimura Takahiro, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Miura Yuji

    International Journal of Clinical Oncology   29 ( 5 )   559 - 563   2024年5月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022(タイトル和訳中)

    Ozaki Yukinori, Yokoe Takamichi, Yoshinami Tetsuhiro, Nozawa Kazuki, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi

    International Journal of Clinical Oncology   29 ( 5 )   551 - 558   2024年5月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology(タイトル和訳中)

    Maeda Tomoya, Najima Yuho, Kamiyama Yutaro, Nakao Shinji, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Miumra Yuji, Endo Makoto, Maruyama Dai, Yoshinami Tatsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Uchino Keita, Kimura Takahiro, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Yano Shingo

    International Journal of Clinical Oncology   29 ( 5 )   535 - 544   2024年5月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022(タイトル和訳中)

    Uchino Keita, Tamura Shingo, Kimura Shoji, Shigeta Keisuke, Kimura Takahiro, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Ichihara Eiki, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Ochi Nobuaki, Kubo Toshio, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Miura Yuji

    International Journal of Clinical Oncology   29 ( 5 )   545 - 550   2024年5月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.

    Tetsuhiro Yoshinami, Kazuki Nozawa, Takamichi Yokoe, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano, Dai Maruyama, Nobuyuki Susumu, Munetaka Takekuma, Takashi Motohashi, Mamoru Ito, Eishi Baba, Nobuaki Ochi, Toshio Kubo, Keita Uchino, Takahiro Kimura, Yutaro Kamiyama, Shinji Nakao, Shinobu Tamura, Hitomi Nishimoto, Yasuhisa Kato, Atsushi Sato, Toshimi Takano

    International journal of clinical oncology   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-024-02504-4

  • Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology

    Ito, M; Okumura, Y; Nio, K; Baba, E; Ozaki, Y; Nishio, H; Ichihara, E; Miura, Y; Endo, M; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ochi, N; Kubo, T; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Tsuchihashi, K

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 6 )   689 - 699   2024年4月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) reportedly reduces the risk of neutropenia and subsequent infections caused by cancer chemotherapy. Although several guidelines recommend using G-CSF in primary prophylaxis according to the incidence rate of chemotherapy-induced febrile neutropenia (FN), the effectiveness of G-CSF in digestive system tumor chemotherapy remains unclear. To address these clinical questions, we conducted a systematic review as part of revising the Clinical Practice Guidelines for the Use of G-CSF 2022 published by the Japan Society of Clinical Oncology. METHODS: This systematic review addressed two main clinical questions (CQ): CQ1: "Is primary prophylaxis with G-CSF effective in chemotherapy?", and CQ2: "Is increasing the intensity of chemotherapy with G-CSF effective?" We reviewed different types of digestive system tumors, including esophageal, gastric, pancreatic, biliary tract, colorectal, and neuroendocrine carcinomas. PubMed, Cochrane Library, and Ichushi-Web databases were searched for information sources. Independent systematic reviewers conducted two rounds of screening and selected relevant records for each CQ. Finally, the working group members synthesized the strength of evidence and recommendations. RESULTS: After two rounds of screening, 5/0/3/0/2/0 records were extracted for CQ1 of esophageal/gastric/pancreatic/biliary tract/colorectal/ and neuroendocrine carcinoma, respectively. Additionally, a total of 2/6/1 records were extracted for CQ2 of esophageal/pancreatic/colorectal cancer, respectively. The strength of evidence and recommendations were evaluated for CQ1 of colorectal cancer; however, we could not synthesize recommendations for other CQs owing to the lack of records. CONCLUSION: The use of G-CSF for primary prophylaxis in chemotherapy for colorectal cancer is inappropriate.

    DOI: 10.1007/s10147-024-02502-6

    Web of Science

    Scopus

    PubMed

    researchmap

    その他リンク: https://link.springer.com/article/10.1007/s10147-024-02502-6/fulltext.html

  • Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

    Ichihara, E; Ochi, N; Makimoto, G; Kudo, K; Harada, D; Ozaki, Y; Nishio, H; Tsuchihashi, K; Miura, Y; Endo, M; Yano, S; Maruyama, D; Yoshinami, T; Susumu, N; Takekuma, M; Motohashi, T; Ito, M; Baba, E; Uchino, K; Kimura, T; Kamiyama, Y; Nakao, S; Tamura, S; Nishimoto, H; Kato, Y; Sato, A; Takano, T; Kubo, T

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 4 )   355 - 362   2024年4月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    BACKGROUND: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer. METHODS: We extracted studies on non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) using the PubMed, Ichushi Web, and Cochrane Library databases. Two reviewers assessed the extracted studies for each type of lung cancer and conducted quantitative and meta-analyses of preplanned outcomes, including overall survival, FN incidence, infection-related mortality, quality of life, and musculoskeletal pain. RESULTS: A limited number of studies were extracted: two on NSCLC and six on SCLC. A meta-analysis was not conducted owing to insufficient data on NSCLC. Two case-control studies explored the efficacy of primary prophylaxis with G-CSF in patients with NSCLC (on docetaxel and ramucirumab therapy) and indicated a lower FN frequency with G-CSF. For SCLC, meta-analysis of five studies showed no significant reduction in FN incidence, with an odds ratio of 0.38 (95% confidence interval 0.03-5.56, P = 0.48). Outcomes other than FN incidence could not be evaluated due to low data availability. CONCLUSION: Limited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy.

    DOI: 10.1007/s10147-024-02469-4

    Web of Science

    Scopus

    PubMed

    researchmap

  • Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022(タイトル和訳中)

    Ichihara Eiki, Ochi Nobuaki, Makimoto Go, Kudo Kenichiro, Harada Daijiro, Ozaki Yukinori, Nishio Hiroshi, Tsuchihashi Kenji, Miura Yuji, Endo Makoto, Yano Shingo, Maruyama Dai, Yoshinami Tetsuhiro, Susumu Nobuyuki, Takekuma Munetaka, Motohashi Takashi, Ito Mamoru, Baba Eishi, Uchino Keita, Kimura Takahiro, Kamiyama Yutaro, Nakao Shinji, Tamura Shinobu, Nishimoto Hitomi, Kato Yasuhisa, Sato Atsushi, Takano Toshimi, Kubo Toshio

    International Journal of Clinical Oncology   29 ( 4 )   355 - 362   2024年4月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • 連載 学会レポ-ト 第20回日本臨床腫瘍学会学術集会を振り返って

    馬場 英司

    Pharma Medica   41 ( 1 )   48 - 49   2024年3月   ISSN:02895803

     詳細を見る

    出版者・発行元:メディカルレビュー社  

    DOI: 10.34449/j0001.41.01_0048-0049

    CiNii Research

  • Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel (Scientific Reports, (2023), 13, 1, (8815), 10.1038/s41598-023-34962-7) 国際誌

    Shirakawa T., Makiyama A., Shimokawa M., Otsuka T., Shinohara Y., Koga F., Ueda Y., Nakazawa J., Otsu S., Komori A., Arima S., Fukahori M., Taguchi H., Honda T., Shibuki T., Nio K., Ide Y., Ureshino N., Mizuta T., Mitsugi K., Akashi K., Baba E.

    Scientific Reports   14 ( 1 )   5311 - 5311   2024年3月

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    The original version of this Article contained an error in the Supplementary Information File, where the Kaplan–Meier curves and numbers at risk were incorrect. The original Supplementary Information file is provided below. The original Article has been corrected.

    DOI: 10.1038/s41598-024-55673-7

    Scopus

    PubMed

    researchmap

  • Liquid biopsy for breast cancer and other solid tumors: a review of recent advances

    Ohmura, H; Hanamura, F; Okumura, Y; Ando, Y; Masuda, T; Mimori, K; Akashi, K; Baba, E

    BREAST CANCER   2024年3月   ISSN:1340-6868 eISSN:1880-4233

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Breast Cancer  

    Liquid biopsy using circulating tumor DNA (ctDNA) has been reported to be less invasive and effective for comprehensive genetic analysis of heterogeneous solid tumors, including decision-making for therapeutic strategies, predicting recurrence, and detecting genetic factors related to treatment resistance in various types of cancers. Breast cancer, colorectal cancer, and lung cancer are among the most prevalent malignancies worldwide, and clinical studies of liquid biopsy for these cancers are ongoing. Liquid biopsy has been used as a companion diagnostic tool in clinical settings, and research findings have accumulated, especially in cases of colorectal cancer after curative resection and non-small cell lung cancer (NSCLC) after curative chemoradiotherapy, in which ctDNA detection helps predict eligibility for adjuvant chemotherapy. Liquid biopsy using ctDNA shows promise across a wide range of cancer types, including breast cancer, and its clinical applications are expected to expand further through ongoing research. In this article, studies on liquid biopsy in breast cancer, colorectal cancer, and NSCLC are compared focusing on ctDNA.

    DOI: 10.1007/s12282-024-01556-8

    Web of Science

    Scopus

    PubMed

    researchmap

  • Myocardial metastasis from ZEB1-and TWIST-positive spindle cell carcinoma of the esophagus: A case report 国際誌

    Shibata, Y; Ohmura, H; Komatsu, K; Sagara, K; Matsuyama, A; Nakano, R; Baba, E

    WORLD JOURNAL OF GASTROENTEROLOGY   30 ( 11 )   1636 - 1643   2024年3月   ISSN:1007-9327 eISSN:2219-2840

     詳細を見る

    記述言語:英語   出版者・発行元:World Journal of Gastroenterology  

    BACKGROUND: Metastatic cardiac tumors are known to occur more frequently than primary cardiac tumors, however, they often remain asymptomatic and are commonly discovered on autopsy. Malignant tumors with a relatively high frequency of cardiac metastasis include mesothelioma, melanoma, lung cancer, and breast cancer, whereas reports of esophageal cancer with cardiac metastasis are rare. CASE SUMMARY: The case of a 60-year-old man who complained of dysphagia is presented. Upper gastrointestinal endoscopy showed a submucosal tumor-like elevated lesion in the esophagus causing stenosis. Contrast-enhanced computed tomography showed left atrial compression due to the esophageal tumor, multiple liver and lung metastases, and a left pleural effusion. Pathological examination of a biopsy specimen from the esophageal tumor showed spindle-shaped cells, raising suspicion of esophageal sarcoma. The disease progressed rapidly, and systemic chemotherapy was deemed necessary, however, due to his poor general condition, administration of cytotoxic agents was considered difficult. Given his high Combined Positive Score, nivolumab was administered, however, the patient soon died from the disease. The autopsy confirmed spindle cell carcinoma (SCC) of the esophagus and cardiac metastasis with similar histological features. Cancer stem cell markers, ZEB1 and TWIST, were positive in both the primary tumor and the cardiac metastasis. CONCLUSION: To the best of our knowledge, there have been no prior reports of cardiac metastasis of esophageal SCC. This case highlights our experience with a patient with esophageal SCC who progressed rapidly and died from the disease, with the autopsy examination showing cardiac metastasis.

    DOI: 10.3748/wjg.v30.i11.1636

    Web of Science

    Scopus

    PubMed

    researchmap

  • Epithelioid hemangioendothelioma-its history, clinical features, molecular biology and current therapy 国際誌

    Tsuchihashi, K; Baba, E

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   54 ( 7 )   739 - 747   2024年3月   ISSN:0368-2811 eISSN:1465-3621

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Journal of Clinical Oncology  

    Epithelioid hemangioendothelioma (EHE) is a remarkably rare tumor arising from endothelial cells that is classified as a vascular tumor in the WHO classification. The tumor is predominantly characterized by the presence of fusion genes, such as WWTR1-CAMTA1 or YAP1-TFE3, with a minority of cases exhibiting other rare fusion genes. EHE exhibits a broad age of onset, typically presenting at ~50 years, but it is not uncommon in pediatric populations. It manifests in a variety of organs, including the liver, lung, soft tissue and bone. Initial multiple-organ involvement is also observed. The tumor's biological behavior and prognosis vary substantially based on the primary site of manifestation. From a therapeutic perspective, initial active surveillance might be considered in selected cases, although surgical intervention remains the mainstay of treatment, especially for localized single-organ involvement. Chemotherapy is administered to patients with progressive unresectable tumors. Recent advances in the biological analysis of EHE fusion genes have elucidated their diverse functions. Additionally, next-generation sequencing has facilitated the identification of other mutations beyond the fusion genes. These continuous efforts to understand the biology of the fusion genes themselves and/or the dysregulated signaling by fusion genes are expected to lead to the development of novel therapeutic strategies for EHE. This article aims to provide a comprehensive review of EHE, encompassing its historical context, clinical manifestations, molecular biology and the current state of treatment.

    DOI: 10.1093/jjco/hyae037

    Web of Science

    Scopus

    PubMed

    researchmap

  • Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. 国際誌

    Tatsunori Shimoi, Kuniko Sunami, Makoto Tahara, Satoshi Nishiwaki, Shota Tanaka, Eishi Baba, Masashi Kanai, Ichiro Kinoshita, Hidekazu Shirota, Hideyuki Hayashi, Naohiro Nishida, Toshio Kubo, Nobuaki Mamesaya, Yayoi Ando, Natsuko Okita, Taro Shibata, Kenichi Nakamura, Noboru Yamamoto

    EClinicalMedicine   69   102447 - 102447   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.eclinm.2024.102447

  • Case report: A rare case of triple negative breast cancer with development of acute pancreatitis due to dexamethasone during adjuvant chemotherapy 国際誌

    Ohmura, H; Tobo, T; Ando, Y; Masuda, T; Mimori, K; Akashi, K; Baba, E

    FRONTIERS IN ONCOLOGY   14   1340419 - 1340419   2024年2月   ISSN:2234-943X

     詳細を見る

    記述言語:英語   出版者・発行元:Frontiers in Oncology  

    Here, we present the case of a 42-year-old female who developed acute pancreatitis due to dexamethasone during adjuvant chemotherapy for early triple negative breast cancer (TNBC). The patient received partial mastectomy and sentinel lymph node biopsy for early TNBC (cT1N0M0, cStage I) of the left breast. Dose-dense doxorubicin plus cyclophosphamide (ddAC) was administered as the adjuvant-chemotherapy; however, epigastralgia appeared on the fifth day of the first administration. A blood test showed a remarkable increase of serum pancreatic enzyme levels and computed tomography (CT) showed the swelling of pancreas and surrounding effusion, and she was diagnosed with moderate acute pancreatitis. As she had no history of excessive alcohol consumption or complication of cholelithiasis, dyslipidemia, or pancreatic neoplasm, drug-induced pancreatitis was suspected. Dexamethasone, which was administered as an antiemetic, was the suspected drug based on the drug administration history and previous report, and dexamethasone was discontinued from the second administration of ddAC. There was subsequently no recurrence of pancreatitis with no increase in serum pancreatic enzyme levels, and it was possible to complete adjuvant-chemotherapy. Alcohol, gallstones, dyslipidemia, and drugs have been reported as causes of pancreatitis; however, steroid-induced acute pancreatitis is extremely rare. We present the first case of acute pancreatitis induced by dexamethasone as the antiemetic.

    DOI: 10.3389/fonc.2024.1340419

    Web of Science

    Scopus

    PubMed

    researchmap

  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

    Shitara, K; Fleitas, T; Kawakami, H; Curigliano, G; Narita, Y; Wang, F; Wardhani, SO; Basade, M; Rha, SY; Zamaniah, WIW; Sacdalan, DL; Ng, M; Yeh, KH; Sunpaweravong, P; Sirachainan, E; Chen, MH; Yong, WP; Peneyra, JL; Ibtisam, MN; Lee, KW; Krishna, V; Pribadi, RR; Li, J; Lui, A; Yoshino, T; Baba, E; Nakayama, I; Pentheroudakis, G; Shoji, H; Cervantes, A; Ishioka, C; Smyth, E

    ESMO OPEN   9 ( 2 )   102226   2024年2月   eISSN:2059-7029

     詳細を見る

    記述言語:英語   出版者・発行元:ESMO Open  

    The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.

    DOI: 10.1016/j.esmoop.2023.102226

    Web of Science

    Scopus

    PubMed

  • A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).

    Arai, H; Inoue, E; Terashima, M; Baba, E; Matsuhashi, N; Muro, K; Yamaguchi, T; Yuki, S; Ichikawa, W; Fujii, M; Sunakawa, Y

    JOURNAL OF CLINICAL ONCOLOGY   42 ( 3_SUPPL )   TPS423 - TPS423   2024年1月   ISSN:0732-183X eISSN:1527-7755

  • 臓器横断的ながん治療の現状と課題・九州大学の診療体制

    馬場 英司

    日本臨床薬理学会学術総会抄録集   2024年1月   eISSN:24365580

     詳細を見る

    記述言語:日本語   出版者・発行元:日本臨床薬理学会  

    セッションID: 44_3-C-S37-2

    CiNii Research

  • Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy.

    Shohei Moriyama, Michinari Hieda, Megumi Kisanuki, Shotaro Kawano, Taku Yokoyama, Mitsuhiro Fukata, Hitoshi Kusaba, Toru Maruyama, Eishi Baba, Koichi Akashi, Haruhisa Fukuda

    Circulation journal : official journal of the Japanese Circulation Society   88 ( 2 )   217 - 225   2024年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1253/circj.CJ-22-0628

  • Both New-Onset and Pre-Existing Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy(タイトル和訳中)

    Moriyama Shohei, Hieda Michinari, Kisanuki Megumi, Kawano Shotaro, Yokoyama Taku, Fukata Mitsuhiro, Kusaba Hitoshi, Maruyama Toru, Baba Eishi, Akashi Koichi, Fukuda Haruhisa

    Circulation Journal   88 ( 2 )   217 - 225   2024年1月   ISSN:1346-9843

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本循環器学会  

  • Trousseau's Syndrome with Advanced Neuroendocrine Carcinoma of Colon: A Case Report 国際誌

    Ohmura, H; Tobo, T; Mimori, K; Baba, E; Horiuchi, T

    CASE REPORTS IN ONCOLOGY   16 ( 1 )   484 - 490   2023年12月   ISSN:1662-6575

     詳細を見る

    記述言語:英語   出版者・発行元:Case Reports in Oncology  

    Here, we present a 69-year-old female with advanced neuroendocrine carcinoma (NEC) of colon with multiple liver, bone, and kidney metastases who developed Trousseau's syndrome. The patient received etoposide plus cisplatin (EP) as the first-line therapy; however, after single administration of EP, she developed the severe lower-limb edema and EP was considered to be intolerable. Etoposide plus carboplatin was administered as the second-line therapy and after 3 cycles of administration, the progressive disease (PD) was confirmed and 5-fluorouracil + leucovorin + irinotecan (FOLFIRI) plus ramucirumab was administered as the third-line therapy. However, PD was confirmed after 3 cycles of the therapy, and she was to receive the best supportive care and was hospitalized in our hospital. Four weeks after hospitalization, mild impaired consciousness and dysarthria were observed. Blood tests showed coagulation abnormalities including elevation of plasma fibrin/fibrinogen degradation products (FDPs) and D-dimer levels, and the diffusion-weighted image of magnetic resonance imaging (MRI) of the head showed multiple cerebral infarcts. She was diagnosed with Trousseau's syndrome due to the progression of NEC and intravenous unfractionated heparin was administered as anticoagulant therapy. After the administration of heparin, plasma FDP and D-dimer levels decreased; however, due to the progression of NEC, the patient died 6 weeks after hospitalization. This is the first report of NEC of the colon that developed Trousseau's syndrome.

    DOI: 10.1159/000530927

    Web of Science

    Scopus

    PubMed

    researchmap

  • Homologous Recombination Repair Gene Alterations Are Associated with Tumor Mutational Burden and Survival of Immunotherapy 国際誌

    Ito, M; Kubo, M; Kawaji, H; Otsubo, Y; Kurata, K; Abutani, H; Suyama, M; Oda, Y; Yoshizumi, T; Nakamura, M; Baba, E

    CANCERS   15 ( 23 )   2023年11月   ISSN:2072-6694 eISSN:2072-6694

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancers  

    BACKGROUND: Comprehensive genomic profiling (CGP) has become generally accepted practice in cancer care since CGP has become reimbursed by national healthcare insurance in Japan in 2019. However, its usefulness for cancer patients is insufficient for several reasons. METHODS: In an observational clinical study of FoundationOne® CDx, potential biomarkers were explored and the cause of testing failure was investigated. A total of 220 cancer patients were enrolled in the study during the period from 2018 to 2019 at Kyushu University Hospital. RESULTS: The primary tumor sites of the 220 cases were breast (115), colon (29), stomach (19), and pancreas (20). The present dataset suggested that homologous recombination repair (HRR) gene alterations were positively associated with tumor mutational burden-high (TMB-high) (p = 0.0099). A public dataset confirmed that patients with HRR gene alterations had a higher TMB and showed significantly longer survival of immunotherapy. In the present study, 18 cases failed sequencing. A lower percentage of tumor cell nuclei was the most common reason for testing failures (p = 0.037). Cases that received neoadjuvant chemotherapy before sampling tended to fail testing. CONCLUSIONS: HRR gene alterations can be a potential biomarker predicting TMB-high and a good response to immunotherapy. For successful sequencing, samples with lower percentages of tumor cell nuclei and previous neoadjuvant chemotherapy should be avoided.

    DOI: 10.3390/cancers15235608

    Web of Science

    Scopus

    PubMed

    researchmap

  • Chemotherapy for advanced urachal carcinoma: A case series of three patients

    Kitazono, T; Ito, M; Tsuchihashi, K; Isobe, T; Matsumura, T; Takigawa, A; Arimizu, K; Ariyama, H; Baba, E

    ANNALS OF ONCOLOGY   34   S1448 - S1448   2023年11月   ISSN:0923-7534 eISSN:1569-8041

  • The possibility of microtubule-related agents as a new treatment option for neuroendocrine carcinoma and small cell lung cancer

    Yamaga, S; Ariyama, H; Imajima, T; Ueno, S; Uehara, K; Koreishi, S; Taguchi, R; Tanoue, K; Baba, E

    ANNALS OF ONCOLOGY   34   S1439 - S1439   2023年11月   ISSN:0923-7534 eISSN:1569-8041

  • Outcomes of genetic aberrations and clinical features in cholangiocarcinoma: Report from the MASTER KEY Project

    Maruki, Y; Morizane, C; Muto, M; Kinoshita, I; Baba, E; Takahashi, M; Sadachi, R; Sumiyoshi, HO; Yonemori, K; Okusaka, T

    ANNALS OF ONCOLOGY   34   S1390 - S1390   2023年11月   ISSN:0923-7534 eISSN:1569-8041

  • Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study

    Isobe, T; Tsuchihashi, K; Ueno, S; Taguchi, R; Ito, M; Nakano, M; Ariyama, H; Hanamura, F; Okumura, Y; Komoda, M; Esaki, T; Arita, S; Nio, K; Kusaba, H; Hashimoto, K; Yoshitake, T; Oda, Y; Akashi, K; Baba, E

    ANNALS OF ONCOLOGY   34   S1409 - S1409   2023年11月   ISSN:0923-7534 eISSN:1569-8041

  • Multicenter retrospective study of vulnerable patients with metastatic colorectal cancer: Results of second-line therapy

    Kawakami, K; Kito, Y; Mitani, S; Hino, K; Izawa, N; Hanamura, F; Yamamoto, Y; Shoji, H; Komori, A; Boku, S; Tsuchihashi, K; Baba, E; Kato, K; Nonagase, Y; Matsumoto, T; Furuta, M; Kawakami, H

    ANNALS OF ONCOLOGY   34   S1406 - S1407   2023年11月   ISSN:0923-7534 eISSN:1569-8041

  • High incidence of cancer therapeutics-related cardiac dysfunction in the patients with cardiac sarcoma

    Uehara, K; Moriyama, S; Kusaba, H; Furukawa, K; Arimizu, K; Oomura, H; Ito, M; Tuchihashi, K; Isobe, T; Ariyama, H; Fukata, M; Akashi, K; Baba, E

    ANNALS OF ONCOLOGY   34   S1410 - S1410   2023年11月   ISSN:0923-7534 eISSN:1569-8041

  • Efficacy and safety of chemotherapy in metastatic malignant phyllodes tumors

    Takigawa, A; Nio, K; Arimizu, K; Ito, M; Tsuchihashi, K; Isobe, D; Ariyama, H; Ide, K; Matsushita, Y; Tanaka, R; Koichi, A; Baba, E

    ANNALS OF ONCOLOGY   34   S1410 - S1411   2023年11月   ISSN:0923-7534 eISSN:1569-8041

  • Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer 国際誌

    Hirofumi Ohmura, Moe Kondo, Masato Uenomachi, Hiroshi Ariyama, Mamoru Ito, Kenji Tsuchihashi, Masahiro Ayano, Hiroaki Niiro, Koichi Akashi, Eishi Baba

    Frontiers in Oncology   13   1260818 - 1260818   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3389/fonc.2023.1260818

  • Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan 国際誌

    Tsuchihashi, K; Ito, M; Arita, S; Kusaba, H; Kusano, W; Matsumura, T; Kitazono, T; Ueno, S; Taguchi, R; Yoshihiro, T; Doi, Y; Arimizu, K; Ohmura, H; Kajitani, T; Nio, K; Nakano, M; Oshima, K; Tamura, S; Shirakawa, T; Shimokawa, H; Uchino, K; Hanamura, F; Okumura, Y; Komoda, M; Isobe, T; Ariyama, H; Esaki, T; Hashimoto, K; Komune, N; Matsuo, M; Matsumoto, K; Asai, K; Yoshitake, T; Yamamoto, H; Oda, Y; Akashi, K; Baba, E

    BMC CANCER   23 ( 1 )   1046 - 1046   2023年10月   eISSN:1471-2407

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMC Cancer  

    Abstract

    Background

    Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy.

    Methods

    We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy.

    Results

    Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 – 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95&#37;CI: 6.0 – 25.8 months): 17.1 months (95&#37;CI: 6.0 – not reached (NR)) for patients with stage I-III and 8.5 months (95&#37;CI: 5.2 – 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5&#37; and 11.3&#37; for all patients. Median OS in all patients was 40.8 months (95&#37;CI: 12.1 months–NR): 40.8 months (95&#37;CI: 12.1 – NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5&#37; for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions.

    Conclusion

    The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.

    DOI: 10.1186/s12885-023-11528-4

    Web of Science

    Scopus

    PubMed

    researchmap

    その他リンク: https://link.springer.com/article/10.1186/s12885-023-11528-4/fulltext.html

  • 【胆道癌と膵癌のリスクファクター】リスクファクターに応じたがんのサーベイランス

    大村 洋文, 馬場 英司

    胆と膵   44 ( 9 )   803 - 806   2023年9月   ISSN:0388-9408 ISBN:9784865175516

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    がん発症のリスクファクターとして生活習慣や環境要因などが報告されており,複数のがん種が共通のリスクファクターを有することが知られている。胆道癌については膵・胆管合流異常や肝内結石症などが,膵癌では家族歴(遺伝性膵癌症候群)や膵管内乳頭粘液性腫瘍などが特徴的なリスクファクターである。また近年がん遺伝子パネルが保険診療で用いられ標的治療や臨床試験へのアクセスを高める試みがなされているが,偶発的に遺伝性腫瘍に関連する生殖細胞系列変異が検出されることもある。リスクファクターに応じた胆道癌や膵臓癌に対する適切なサーベイランスの頻度,期間について確立されたものは限られている。またサーベイランスが長期となる場合は患者の精神的,経済的負担も考慮して行う。(著者抄録)

    researchmap

  • 免疫チェックポイント阻害薬併用療法によるB細胞の分化と抗腫瘍効果ならびに有害事象との関連性について(B cell differentiation by combined immune checkpoint blockade is associated with tumor suppression and adverse events)

    上原 康輝, 田ノ上 絢郎, 山口 享子, 大村 洋文, 伊東 守, 土橋 賢司, 田村 真吾, 磯部 大地, 山元 英崇, 小田 義直, 赤司 浩一, 馬場 英司

    日本癌学会総会記事   82回   1383 - 1383   2023年9月   ISSN:0546-0476

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • Preferential B cell differentiation by combined immune checkpoint blockade for renal cell carcinoma is associated with clinical response and autoimmune reactions 国際誌

    Uehara, K; Tanoue, K; Yamaguchi, K; Ohmura, H; Ito, M; Matsushita, Y; Tsuchihashi, K; Tamura, S; Shimokawa, H; Isobe, T; Shibata, Y; Ariyama, H; Tanaka, R; Kusaba, H; Yamamoto, H; Oda, Y; Akashi, K; Baba, E

    CANCER IMMUNOLOGY IMMUNOTHERAPY   72 ( 11 )   3543 - 3558   2023年8月   ISSN:0340-7004 eISSN:1432-0851

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Immunology, Immunotherapy  

    Combined immune checkpoint blockade (ICB) is effective therapy for renal cell carcinoma (RCC). However, the dynamic changes in circulating B cells induced by combined ICB have not been clarified. The present study prospectively examined 22 patients scheduled to receive ICB for unresectable or metastatic RCC between March 2018 and August 2021. Eleven patients received combined therapy with anti-PD-1 (nivolumab) and anti-CTLA-4 (ipilimumab), and the other 11 patients received nivolumab monotherapy. Comprehensive phenotypes of circulating immune cells obtained prior to and after ICB therapy were analyzed by flow cytometry. Although the proportion of naïve B cells among total B cells was significantly decreased, that of switched memory B cells was significantly increased after combined therapy. In responders, the proportion of B cells among peripheral blood mononuclear cells was significantly higher prior to ICB therapy, and the proportion of switched memory B cells among total B cells tended to increase after ICB therapy. Of note, the proportion of plasmablasts among total B cells was significantly increased after ICB therapy in patients who developed severe immune-related adverse events (irAEs), and the proportion of B cells among peripheral blood decreased significantly. Furthermore, in four of five patients who developed immune-related hypophysitis following combined therapy, anti-pituitary antibody was detected in the serum. These results suggested that immune-related hypophysitis was closely related to the increase in circulating plasmablasts. Collectively, this study suggests that combined ICB promotes the differentiation of B cell populations, which is associated with efficient tumor suppression and development of irAEs.

    DOI: 10.1007/s00262-023-03505-4

    Web of Science

    Scopus

    PubMed

    researchmap

  • Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors

    Mishima, S; Naito, Y; Akagi, K; Hayashi, N; Hirasawa, A; Hishiki, T; Igarashi, A; Ikeda, M; Kadowaki, S; Kajiyama, H; Kato, M; Kenmotsu, H; Kodera, Y; Komine, K; Koyama, T; Maeda, O; Miyachi, M; Nishihara, H; Nishiyama, H; Ohga, S; Okamoto, W; Oki, E; Ono, S; Sanada, M; Sekine, I; Takano, T; Tao, KYK; Terashima, K; Tsuchihara, K; Yatabe, Y; Yoshino, T; Baba, E

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   28 ( 8 )   941 - 955   2023年8月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we developed recommendations for tumor-agnostic treatments in patients with solid tumors with DNA mismatch repair deficient or neurotrophic receptor tyrosine kinase fusions. Recently, immune checkpoint inhibitors have shown efficacy in patient with tumor mutation burden-high (TMB-H) solid tumors and have been established as a third tumor-agnostic agent, making it necessary to develop the guideline prioritized for these patients. Clinical questions regarding medical care were formulated for patients with TMB-H advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. The current guideline describes three clinical questions and seven recommendations for whom, when, and how TMB should be tested, and what is recommended for patients with TMB-H advanced solid tumors. In this guideline, the committee proposed seven recommendations for performing TMB testing properly to select patients who are likely to benefit from immunotherapy.

    DOI: 10.1007/s10147-023-02360-8

    Web of Science

    Scopus

    PubMed

    researchmap

  • Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition

    Mishima, S; Naito, Y; Akagi, K; Hayashi, N; Hirasawa, A; Hishiki, T; Igarashi, A; Ikeda, M; Kadowaki, S; Kajiyama, H; Kato, M; Kenmotsu, H; Kodera, Y; Komine, K; Koyama, T; Maeda, O; Miyachi, M; Nishihara, H; Nishiyama, H; Ohga, S; Okamoto, W; Oki, E; Ono, S; Sanada, M; Sekine, I; Takano, T; Tao, KYK; Terashima, K; Tsuchihara, K; Yatabe, Y; Yoshino, T; Baba, E

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   28 ( 10 )   1237 - 1258   2023年8月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    BACKGROUND: Clinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repair-deficient (dMMR) advanced solid tumors. The accumulated evidence of tumor agnostic agent has been made since PD-1 inhibitor was approved and used in clinical practice. Therefore, we have revised the guideline "Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition". METHODS: Clinical questions regarding medical care were formulated for patients with dMMR advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO and the public comments among all societies' members were done. RESULTS: The current guideline describes two clinical questions and eight recommendations for whom, when, and how MMR status should be tested. CONCLUSION: In this guideline, the committee proposed eight recommendations for performing MMR testing properly to select patients who are likely to benefit from immunotherapy.

    DOI: 10.1007/s10147-023-02397-9

    Web of Science

    Scopus

    PubMed

    researchmap

  • Japanese society of medical oncology/ Japan society of clinical oncology/Japanese society of pediatric hematology/oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, Third Edition 査読 国際誌

    Saori Mishima; Yoichi Naito; Kiwamu Akagi; Naomi Hayashi; Akira Hirasawa; Tomoro Hishiki; Ataru Igarashi; Masafumi Ikeda; Shigenori Kadowaki; Hiroaki Kajiyama; Motohiro Kato; Hirotsugu Kenmotsu; Yasuhiro Kodera; Keigo Komine; Takafumi Koyama; Osamu Maeda; Mitsuru Miyachi; Hiroshi Nishihara; Hiroyuki Nishiyama; Shouihi Ohga; Wataru Okamoto; Eiji Oki; Shigeru Ono; Masashi Sanada; Ikuo Sekine; Tadao Takano; Kayoko Tao; Keita Terashima; Katsuya Tsuchihara; Yasushi Yatabe; Takayuki Yoshino; Eishi Baba

    Int J Clin Oncol   2023年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1007/s10147-023-02397-9

  • Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors 査読 国際誌

    Naito Y, Mishima S, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E

    Int J Clin Oncol   28   827 - 840   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1007/s10147-023-02345-7

  • RHAMMはヒト大腸癌幹細胞のうち増殖性を示す亜集団のマーカーとなる(RHAMM marks proliferative subpopulation of human colorectal cancer stem cells)

    Nakano Michitaka, Taguchi Ryosuke, Kikushige Yoshikane, Isobe Taichi, Miyawaki Kohta, Mizuno Shinichi, Tsuruta Nobuhiro, Hanamura Fumiyasu, Yamaguchi Kyoko, Yamauchi Takuji, Ariyama Hiroshi, Kusaba Hitoshi, Nakamura Masafumi, Maeda Takahiro, Kuo Calvin J., Baba Eishi, Akashi Koichi

    Cancer Science   114 ( 7 )   2895 - 2906   2023年7月   ISSN:1347-9032

     詳細を見る

    記述言語:英語   出版者・発行元:John Wiley & Sons Australia, Ltd  

    大腸癌幹細胞の中で増殖状態にあるものの特徴を決定するため、オルガノイドと大腸癌組織を材料に、それらのトランスクリプトミクスを解析した。その結果、CD44陽性を示す通常のヒト大腸癌幹細胞の分画の中に、ヒアルロン酸媒介運動性受容体(RHAMM)を発現している亜集団があることを発見した。細胞種の多様性を再構成することで腫瘍組織のミニチュア版としたオルガノイドを材料に、単一細胞トランスクリプトミクス解析を施行したところ、増殖性を示し、様々な細胞種の中にあって独特の特徴を示すRHAMM陽性細胞があることに注目された。ヒト大腸癌組織からRHAMM陽性CD44陽性の細胞を予期的に分離した結果、分離された同細胞は他の癌細胞と比較して高い増殖特性と自己新生能を現した。RHAMMを阻害するとin vitroでのオルガノイド形成は強く抑制され、in vivoでは腫瘍成長が阻害された。RHAMMは、通常の癌幹細胞分画内に含まれる増殖性の亜集団への特異的マーカーになりうると考えられた。

  • Phase II trial of dabrafenib and trametinib in patients with BRAFV600E/R or non-BRAFV600 mutated advanced solid tumors: Results from the BELIEVE trial (NCCH1901).

    Tahara, M; Shimoi, T; Nishiwaki, S; Tanaka, S; Baba, E; Muto, M; Kinoshita, I; Sakai, D; Tabata, M; Hayashi, H; Ishioka, C; Mamesaya, N; Yamamoto, N

    JOURNAL OF CLINICAL ONCOLOGY   41 ( 16 )   2023年6月   ISSN:0732-183X eISSN:1527-7755

     詳細を見る

  • An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.

    Okuma, HS; Yonemori, K; Ishioka, C; Baba, E; Kinoshita, I; Muto, M; Imasa, MSB; Voon, PJ; de Almeida, KY; Hoo, HFS; Ichimura, M; Mizoguchi, C; Munakata, W; Kohsaka, S; Shibata, T; Yatabe, Y; Nakamura, K; Mano, H; Yamamoto, N

    JOURNAL OF CLINICAL ONCOLOGY   41 ( 16 )   2023年6月   ISSN:0732-183X eISSN:1527-7755

     詳細を見る

  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer 査読 国際誌

    Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu RH, Mulansari NA, Govind Babu K, Lee MA, Tan CK, Cornelio G, Chong DQ, Chen LT, Tanasanvimon S, Prasongsook N, Yeh KH, Chua C, Sacdalan MD, Sow Jenson WJ, Kim ST, Chacko RT, Syaiful RA, Zhang SZ, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G

    ESMO Open   8   101558   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1016/j.esmoop.2023.101558.

  • Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. 査読 国際誌

    Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E

    Int J Clin Oncol   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1007/s10147-023-02360-8.

  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

    Yoshino, T; Cervantes, A; Bando, H; Martinelli, E; Oki, E; Xu, RH; Mulansari, NA; Babu, KG; Lee, MA; Tan, CK; Cornelio, G; Chong, DQ; Chen, LT; Tanasanvimon, S; Prasongsook, N; Yeh, KH; Chua, C; Sacdalan, MD; Sow, WJ; Kim, ST; Chacko, RT; Syaiful, RA; Zhang, SZ; Curigliano, G; Mishima, S; Nakamura, Y; Ebi, H; Sunakawa, Y; Takahashi, M; Baba, E; Peters, S; Ishioka, C; Pentheroudakis, G

    ESMO OPEN   8 ( 3 )   101558   2023年6月   eISSN:2059-7029

     詳細を見る

    記述言語:英語   出版者・発行元:ESMO Open  

    The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted in December 2022, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with mCRC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with mCRC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian countries. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with mCRC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation, coupled with a disparity in the drug approvals and reimbursement strategies, between the different countries.

    DOI: 10.1016/j.esmoop.2023.101558

    Web of Science

    Scopus

    PubMed

  • Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

    Yamada, T; Kito, Y; Sakai, K; Nishio, K; Yamazaki, K; Shoji, H; Tsushima, T; Mitani, S; Shiraishi, K; Yasui, H; Hara, H; Shimozaki, K; Esaki, T; Shimokawa, H; Tsuzuki, T; Kajiura, S; Masuishi, T; Baba, E; Yoshimura, K; Kawakami, H; Hironaka, S; Muro, K

    ANNALS OF ONCOLOGY   34   S42 - S42   2023年6月   ISSN:0923-7534 eISSN:1569-8041

  • C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel

    Shirakawa, T; Makiyama, A; Shimokawa, M; Otsuka, T; Shinohara, Y; Koga, F; Ueda, Y; Nakazawa, J; Otsu, S; Komori, A; Arima, S; Fukahori, M; Taguchi, H; Honda, T; Shibuki, T; Nio, K; Ide, Y; Ureshino, N; Mizuta, T; Mitsugi, K; Akashi, K; Baba, E

    SCIENTIFIC REPORTS   13 ( 1 )   8815   2023年5月   ISSN:2045-2322

     詳細を見る

    記述言語:英語   出版者・発行元:Scientific Reports  

    There are limited absolute biomarkers for determining the prognosis before first- and second-line palliative chemotherapy in unresectable pancreatic cancer (urPC) patients. To find the best prognostic inflammatory marker, we investigated relationships between overall survival (OS) and six inflammatory markers; C-reactive protein/albumin ratio (CAR), neutrophil–lymphocyte ratio (NLR), prognostic nutrition index (PNI), platelet–lymphocyte ratio (PLR), Glasgow prognostic score (GPS), and prognostic index (PI). We examined 255 patients who received gemcitabine + nab-paclitaxel or FOLFIRINOX as first-line chemotherapy and 159 patients who subsequently underwent second-line chemotherapy. First-line patients with lower CAR had better OS compared to those with a higher CAR (hazard ratio 0.57; 95% confidential index 0.42–77; P < 0.01). Similarly, lower NLR (P = 0.01), higher PNI (P = 0.04), lower PLR (P = 0.03), GPS score of 0 (P < 0.01) and PI score of 0 (P < 0.01) were all associated with better OS. CAR demonstrated the best superiority for determining survival prognosis through the use of area under the curve of time-dependent receiver-operating characteristic curves. Furthermore, a lower CAR before second-line therapy exhibited better OS versus higher CAR (P < 0.01). Therefore, CAR might be a useful biomarker for predicting urPC patient prognosis in both first- and second-line chemotherapy.

    DOI: 10.1038/s41598-023-34962-7

    Web of Science

    Scopus

    PubMed

  • C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel. 査読 国際誌

    Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E

    Sci Rep   13   8815   2023年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1038/s41598-023-34962-7.

  • Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors

    Naito, Y; Mishima, S; Akagi, K; Hayashi, N; Hirasawa, A; Hishiki, T; Igarashi, A; Ikeda, M; Kadowaki, S; Kajiyama, H; Kato, M; Kenmotsu, H; Kodera, Y; Komine, K; Koyama, T; Maeda, O; Miyachi, M; Nishihara, H; Nishiyama, H; Ohga, S; Okamoto, W; Oki, E; Ono, S; Sanada, M; Sekine, I; Takano, T; Tao, K; Terashima, K; Tsuchihara, K; Yatabe, Y; Yoshino, T; Baba, E

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   28 ( 7 )   827 - 840   2023年5月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    BACKGROUND: Clinical trials have reported the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors. The accumulated evidence of tumor-agnostic agent has made since TRK inhibitors were approved and used in clinical practice. Therefore, we have revised the 'Japan Society of Clinical Oncology (JSCO)/Japanese Society of Medical Oncology (JSMO)-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese Society of Pediatric Hematology/Oncology (JSPHO)'. METHODS: Clinical questions regarding medical care were formulated for patients with NTRK fusion-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by JSCO, JSMO, and JSPHO voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. RESULTS: The current guideline describes 3 clinical questions and 14 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors. CONCLUSION: The committee proposed 14 recommendations for performing NTRK testing properly to select patients who are likely to benefit from TRK inhibitors.

    DOI: 10.1007/s10147-023-02345-7

    Web of Science

    Scopus

    PubMed

    researchmap

  • RHAMM marks proliferative subpopulation of human colorectal cancer stem cells 国際誌

    Nakano, M; Taguchi, R; Kikushige, Y; Isobe, T; Miyawaki, K; Mizuno, S; Tsuruta, N; Hanamura, F; Yamaguchi, K; Yamauchi, T; Ariyama, H; Kusaba, H; Nakamura, M; Maeda, T; Kuo, CJ; Baba, E; Akashi, K

    CANCER SCIENCE   114 ( 7 )   2895 - 2906   2023年3月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Science  

    The cancer stem cell (CSC) theory features typically rare self-renewing subpopulation that reconstitute the heterogeneous tumor. Identification of molecules which characterize the feature of CSCs is a key imperative for further understanding of tumor heterogeneity and for the development of novel therapeutic strategies. However, the use of conventional markers of CSCs is still insufficient for the isolation of bona fide CSCs. We investigated organoids which are miniature forms of tumor tissues with reconstructing cellular diversity to identify specific marker to characterize CSCs in heterogeneous tumors. Here, we report that receptor for hyaluronan-mediated motility (RHAMM) expresses in a subpopulation of CD44+ conventional human colorectal CSC fraction. Single-cell transcriptomics of organoids highlighted RHAMM positive proliferative cells that revealed distinct characteristics among the various cell types. Prospectively isolated RHAMM+ CD44+ cells from the human colorectal cancer tissues showed highly proliferative character with self-renewal ability in comparison with the other cancer cells. Furthermore, inhibition of RHAMM strongly suppressed organoids formation in vitro and inhibited the tumor growth in vivo. Our findings suggest that RHAMM is a potential therapeutic target because it is a specific marker of the proliferative subpopulation within the conventional CSC fraction.

    DOI: 10.1111/cas.15795

    Web of Science

    Scopus

    PubMed

    researchmap

  • Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.

    Mitani, S; Kito, Y; Hino, K; Kawakami, K; Izawa, N; Hanamura, F; Yamamoto, Y; Shoji, H; Komori, A; Boku, S; Tsuchihashi, K; Baba, E; Kato, K; Nonagase, Y; Matsumoto, T; Furuta, M; Kawakami, H

    JOURNAL OF CLINICAL ONCOLOGY   41   114 - 114   2023年2月   ISSN:0732-183X eISSN:1527-7755

     詳細を見る

  • Presence and its role of spontaneous epithelial-mesenchymal plasticity in esophageal cancer

    Tsuchihashi, K; Hirata, Y; Yamasaki, J; Suina, K; Tanoue, K; Yae, T; Masuda, K; Baba, E; Akashi, K; Kitagawa, Y; Saya, H; Nagano, O

    CANCER SCIENCE   114   846 - 846   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • DNMT3B maintains the organoid-formation ability of left-sided colorectal cancer derived from patients

    Taguchi, R; Isobe, T; Ueno, S; Kikushige, Y; Tsuchihashi, K; Ariyama, H; Akashi, K; Baba, E

    CANCER SCIENCE   114   1220 - 1220   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Circulating <i>stem</i>-<i>like</i> PD-1+CD8 T cells responding to PD-1 blockade predict clinical outcomes in esophageal cancer

    Tanoue, K; Ohmura, H; Yamaguchi, K; Tsuchihashi, K; Tamura, S; Isobe, T; Ariyama, H; Esaki, T; Akashi, K; Baba, E

    CANCER SCIENCE   114   1179 - 1179   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Circulating <i>stem-like</i> PD-1+CD8 T cells responding to PD-1 blockade predict clinical outcomes in esophageal cancer

    Tanoue, K; Ohmura, H; Yamaguchi, K; Tsuchihashi, K; Tamura, S; Isobe, T; Ariyama, H; Esaki, T; Akashi, K; Baba, E

    CANCER SCIENCE   114   821 - 821   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • The amplification of TPX2 is a potential biomarker of oxaliplatin-susceptibility in colorectal cancer

    Ueno, S; Isobe, T; Taguchi, R; Tsuchihashi, K; Ariyama, H; Akashi, K; Baba, E

    CANCER SCIENCE   114   1449 - 1449   2023年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax. 国際誌

    Hirofumi Ohmura, Takaaki Masuda, Koshi Mimori, Eishi Baba, Takahiko Horiuchi

    International cancer conference journal   12 ( 1 )   31 - 35   2023年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s13691-022-00572-9

  • Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

    Aoki, M; Kadowaki, S; Takahashi, N; Suzuki, T; Oshima, K; Ando, T; Yamamoto, Y; Kawakami, K; Kito, Y; Matsumoto, T; Shimozaki, K; Miyazaki, Y; Yamaguchi, T; Nagase, M; Tamura, T; Amanuma, Y; Esaki, T; Miura, Y; Akiyoshi, K; Baba, E; Makiyama, A; Negoro, Y; Nakashima, K; Sugimoto, N; Nagashima, K; Shoji, H; Boku, N

    GASTRIC CANCER   26 ( 1 )   132 - 144   2023年1月   ISSN:1436-3291 eISSN:1436-3305

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Gastric Cancer  

    BACKGROUND: Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However, progression of non-measurable lesions and new lesions are frequently observed in patients with advanced gastric cancer (AGC). METHODS: This retrospective study involved AGC patients at 24 Japanese institutions who had measurable lesions and received nivolumab after ≥ 2 lines of chemotherapy. HPD was defined as a ≥ two-fold increase in the tumor growth rate of measurable lesions. The pattern of disease progression was classified according to new lesions in different organs and ascites appeared/increase of ascites. RESULTS: Of 245 patients, 147 (60.0%) showed progressive disease (PD) as the best response and 41 (16.7%) showed HPD during nivolumab monotherapy. There was no significant difference in overall survival (OS) between patients with HPD and those with PD other than HPD (median OS 5.0 vs 4.8 months; hazard ratio [HR] 1.0, 95% confidence interval [CI] 0.6-1.5; p = 1.0). Fifty-three patients developed new lesions in different organs and 58 had appearance/increase of ascites; these patients showed shorter OS than those without each of these features (median OS 3.3 vs 7.1 months, HR 1.8, 95% CI 1.2-2.7, p = 0.0031 for new lesions, and 3.0 vs 7.8 months, HR 2.6, 95% CI 1.8-3.8, p < 0.0001 for ascites). Thirty-one patients who had both features showed the worst prognosis (median OS 2.6 months). CONCLUSIONS: New lesions in different organs and appearance/increase of ascites, rather than the original definition of HPD, are the patterns of disease progression associated with poor prognosis in AGC patients receiving nivolumab whose best response was PD.

    DOI: 10.1007/s10120-022-01349-y

    Web of Science

    Scopus

    PubMed

    researchmap

  • Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)

    Baba, E; Terashima, M; Fujishiro, M

    GASTRIC CANCER   26 ( 1 )   1 - 25   2023年1月   ISSN:1436-3291 eISSN:1436-3305

  • 進行胃癌における予後不良と関連したニボルマブ併用サードラインおよびそれ以降の化学療法中の病勢進行パターン 日本における多施設後方視的研究(Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan)

    Aoki Masahiko, Kadowaki Shigenori, Takahashi Naoki, Suzuki Takeshi, Oshima Kotoe, Ando Takayuki, Yamamoto Yoshiyuki, Kawakami Kentaro, Kito Yosuke, Matsumoto Toshihiko, Shimozaki Keitaro, Miyazaki Yasuhiro, Yamaguchi Toshifumi, Nagase Michitaka, Tamura Takao, Amanuma Yusuke, Esaki Taito, Miura Yuji, Akiyoshi Kohei, Baba Eishi, Makiyama Akitaka, Negoro Yuji, Nakashima Koji, Sugimoto Naotoshi, Nagashima Kengo, Shoji Hirokazu, Boku Narikazu

    Gastric Cancer   26 ( 1 )   132 - 144   2023年1月   ISSN:1436-3291

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

    測定可能病変を有し、日本の24施設で2ライン以上の化学療法後にニボルマブ療法を受けた症例を検討対象として、後方視的研究を行った。腫瘍増大(hyperprogressive disease、HPD)は測定可能病変の増殖率が2倍以上に増加した場合と定義した。病勢進行パターンは、異なった臓器での新規病変の出現および腹水の出現や増加に分類した。245名のうち、ニボルマブ単剤治療中に最も奏効した場合が病勢進行(PD)であった症例は147名(60.0%)、HPDを示したのは41名(16.7%)であった。HPD症例とHPD以外のPD症例との間で全生存期間(OS)に有意差は認められなかった(OS中央値5.0ヵ月対4.8ヵ月、ハザード比(HR)1.0、95%信頼区間(CI)0.6-1.5、P=1.0)。53名の患者で異なる臓器に新たな病変が出現し、58名で腹水の出現や増加を認めた。これらの患者は、それ以外の患者よりもOSが短かった(OS中央値3.3月対7.1ヵ月、新規病変出現症例HR 1.8、95%CI 1.2-2.7、P=0.0031、腹水出現および増加例HR 2.6、95%CI 1.8-3.8、P<0.0001)。新規病変と腹水出現ないし増加の両方が認められた31名の患者は、予後が最も悪かった(OS中央値2.6ヵ月)。ニボルマブ療法に対する奏効度がPDまでであった進行胃癌(AGC)患者において、新規病変の出現と腹水の出現や増加は、従来のHPDの定義よりも予後不良に関連する疾患進行のパターンである可能性が示された。

  • 気胸を発症した悪性葉状腫瘍でパゾパニブに反応した1例(A case of malignant phyllodes tumor that responded to pazopanib and developed pneumothorax)

    Ohmura Hirofumi, Masuda Takaaki, Mimori Koshi, Baba Eishi, Horiuchi Takahiko

    International Cancer Conference Journal   12 ( 1 )   31 - 35   2023年1月

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

    症例は59歳女性で、他院にてトリプルネガティブ乳癌(cT3NXM0、cStage IIIB、浸潤性乳管癌)と診断され、左乳房切除術と腋窩リンパ節郭清を受けた。手術検体の病理組織学的検査では悪性葉状腫瘍に一致していた。術後4ヵ月、左胸A・B領域の悪性葉状腫瘍再発、最大径5cmの多発性肺転移、リンパ節転移と診断され、当院で全身化学療法を受けることになった。二次化学療法としてパゾパニブを投与した。治療開始2.5ヵ月後、CT検査で肺病変のサイズと空洞が減少したが、新たに左気胸を認めた。立位胸部X線では気胸の鑑別が困難であった。気胸の典型的な症状や身体所見である呼吸困難、胸痛、呼吸音減弱は認めなかった。気胸は小さく無症状であったため、パゾパニブ投与を中止し、胸部X線とCTで経過観察を行った。1週間後、CTで気胸の改善を確認した。化学療法をエリブリンに変更したが、エリブリン初回投与後に肺病変の急速な増大を認めたため、パゾパニブを再投与した。胸部X線とCTによる慎重な経過観察を行った結果、気胸の再発は認めなかった。

  • 臓器横断的ながん治療の現状と課題・九州大学の診療体制

    馬場 英司

    日本臨床薬理学会学術総会抄録集   44 ( 0 )   3-C-S37-2   2023年   eISSN:24365580

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人 日本臨床薬理学会  

    <p>近年のがんゲノム研究の発展により、新規標的に対する抗腫瘍薬の開発が増すと共に、異なる臓器に生じたがんでも共通の遺伝子異常を有する場合には、同じ抗腫瘍薬の効果が期待できることから、臓器横断的治療の概念が示された。がんゲノムプロファイリング検査の拡大に伴い実臨床での臓器横断的治療の機会は増加している。高頻度マイクロサテライト不安定性や高い腫瘍遺伝子変異量を有するがん、NTRK融合遺伝子を有するがんに対しては、保険診療で免疫チェックポイント阻害薬やTRK阻害薬の使用が可能となった。さらにBRAFやBRCAなどの遺伝子異常も臓器横断的治療の対象として検討可能である。この臓器横断的ながん治療を、特にがんゲノム医療に携わる機関において適切かつ円滑に実施するためには、これまでの臓器特異的な治療主体の診療体制とは異なり、多診療科・部門が協力して対応することが重要である。毎週開催されるエキスパートパネルでは、臓器横断的治療の対象となる遺伝子異常も明らかとなるため、この場において当該遺伝子異常の臨床的意義や治療薬候補について各診療科の視点からの議論が行われている。担当診療科では日常診療で投与しない薬剤が推奨された場合は、主に腫瘍内科が薬物療法を担う場合がある。臓器横断的治療として用いられる免疫チェックポイント阻害薬の免疫関連有害事象は未だ注意を要するため、薬剤部を中心としたチーム会合で支援を行う体制を構築している。さらに胚細胞系列遺伝子異常が同定された場合には、遺伝医療部が説明、カウンセリング、遺伝子検査を担っている。臓器横断的治療は遺伝子異常を有する腫瘍に対する治療選択肢が増す点で期待されているが、臓器毎の臨床的意義や治療薬の効果の差については今後も研究が必要と考えられる。</p>

    DOI: 10.50993/jsptsuppl.44.0_3-c-s37-2

    CiNii Research

  • Hypertension Indicate Favorable Clinical Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy 査読 国際誌

    Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, Akashi K, Fukuda H

    Circ J   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: doi: 10.1253/circj.CJ-22-0628.

  • パンデミックと学会活動

    馬場 英司, 磯部 大地, 有山 寛

    腫瘍内科   30 ( 6 )   681 - 684   2022年12月

     詳細を見る

    記述言語:日本語  

  • Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy. 国際誌

    Shohei Moriyama, Michinari Hieda, Megumi Kisanuki, Shotaro Kawano, Taku Yokoyama, Mitsuhiro Fukata, Hitoshi Kusaba, Toru Maruyama, Eishi Baba, Koichi Akashi, Haruhisa Fukuda

    Open heart   9 ( 2 )   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1136/openhrt-2022-002135

  • Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy 査読 国際誌

    Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, Akashi K, Fukuda H

    Open Heart   9   e002135   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • インスリン様成長因子-1受容体の阻害は大腸癌におけるエリブリン誘発DNA損傷を増強する(Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer)

    Yoshihiro Tomoyasu, Ariyama Hiroshi, Yamaguchi Kyoko, Imajima Takashi, Yamaga Satoru, Tsuchihashi Kenji, Isobe Taichi, Kusaba Hitoshi, Akashi Koichi, Baba Eishi

    Cancer Science   113 ( 12 )   4207 - 4218   2022年12月   ISSN:1347-9032

     詳細を見る

    記述言語:英語   出版者・発行元:John Wiley & Sons Australia, Ltd  

    クロイソカイメンから発見されたハリコンドリンBの誘導体である微小管標的薬エリブリン(Eri)に対する耐性のメカニズムについて検討した。Eri耐性大腸癌由来SW480細胞におけるインスリン様成長因子-1受容体(IGF-1R)/インスリン受容体(INSR)活性化に対するEri処理の影響を分析した。その結果、Eriへの曝露により、リン酸化されたIGF-1R/INSRとその下流エフェクターにおけるAktの蓄積量が増加し、IGFシグナルが活性化された。Eri処理はIGF-1Rの活性化とそれに続く核移行を誘導したが、IGF-1Rの活性化や核移行を阻害した場合、EriはDNA損傷を誘導し、G2/M停止を促進した。さらに、Eri耐性細胞株であるSW480を用いた異種移植マウスモデルにおいて、EriとIGF-1R阻害剤であるリンシチニブの併用は、いずれの単剤よりも腫瘍増殖を抑制した。以上より、EriとIGF-1R阻害剤の併用はEri耐性を克服することが示唆された。

  • 原発不明癌の予後不良サブセットに対する部位特異的治療と経験的治療を比較した多施設共同後ろ向き研究(A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site)

    Nishikawa Kazuo, Hironaka Shuichi, Inagaki Takashi, Komori Azusa, Otsu Satoshi, Mitsugi Kenji, Makiyama Akitaka, Watanabe Koichiro, Tamura Shingo, Okumura Yuta, Kusaba Hitoshi, Esaki Taito, Baba Eishi, Shirao Kuniaki

    Japanese Journal of Clinical Oncology   52 ( 12 )   1416 - 1422   2022年12月   ISSN:0368-2811

     詳細を見る

    記述言語:英語   出版者・発行元:Oxford University Press  

    原発不明癌患者を対象とした多施設共同観察研究を実施し、サブセットごとの治療効果を明らかにするとともに、特に予後不良サブセットにおける経験的治療と部位特異的治療の有効性を比較検討した。2006年から2018年までに8ヶ所の施設で第一選択治療として化学療法または化学放射線療法を受けた原発不明癌患者177例を対象とした。そのうち33例(年齢36~83歳)が予後良好サブセット、144例(年齢35~84歳)が予後不良サブセットに分類された。予後不良サブセットの84例(58.3%)が経験的治療を受け、60例(41.7%)が部位特異的な治療を受けた。全生存期間の中央値は、部位特異的治療群と経験的治療群でそれぞれ10.0ヵ月および10.1ヵ月であり、有意差はなかった(ハザード比1.01、95%CI 0.70~1.45、P=0.95)。多変量解析により、パフォーマンスステータス、転移部位数、低アルブミン血症が、予後不良サブセットにおける全生存期間の独立した予後因子であることが示された。以上より、原発不明癌の予後不良サブセットにおける部位特異的治療群と経験的治療群の全生存期間はほぼ同様であった。

  • パンデミックと学会活動

    馬場 英司, 磯部 大地, 有山 寛

    腫瘍内科   30 ( 6 )   681 - 684   2022年12月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism 国際誌

    Kusaba, H; Moriyama, S; Hieda, M; Ito, M; Ohmura, H; Isobe, T; Tsuchihashi, K; Fukata, M; Ariyama, H; Baba, E

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   52 ( 10 )   1183 - 1190   2022年10月   ISSN:0368-2811 eISSN:1465-3621

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese journal of clinical oncology  

    BACKGROUND: The incidence of venous thromboembolism has been reported as 20% in cancer patients. Anticoagulation therapy is the standard treatment for venous thromboembolism. On the other hand, bleeding should be carefully managed, because advanced cancer, particularly gastrointestinal cancer, carries a high risk of bleeding. However, the optimal management for cancer-associated thromboembolism remains to be clarified. METHODS: We retrospectively examined patients with advanced gastrointestinal cancer, including gastric cancer and colorectal cancer, who were treated with chemotherapy between 2014 and 2018 for the incidence and characteristics of venous thromboembolism and bleeding. RESULTS: In total, 194 patients (120 men, 74 women) were enrolled in this study. The underlying pathology was gastric cancer in 74 cases and colorectal cancer in 120 cases. Of the 194 patients, 40 patients (20.6%) were diagnosed with venous thromboembolism and 10 patients (5.2%) were diagnosed with concomitant pulmonary thromboembolism. Conversely, bleeding was observed in 29 patients (15%). The location of bleeding was the primary tumor in 17 cases, metastatic tumor in 9 and hemorrhagic gastric ulcer in 3. Within the venous thromboembolism group (n = 40), bleeding was observed in 10 patients (25%). Multivariate analysis showed that International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) bleeding score ≥7 correlated significantly with major bleeding (P = 0.01). In patients with a low risk of bleeding, major bleeding was observed in only three patients. CONCLUSIONS: IMPROVE bleeding score may predict the risk for bleeding in gastrointestinal cancer patients with venous thromboembolism. Selecting patients with a low risk of bleeding using with IMPROVE bleeding score is expected to contribute to the safer management of anticoagulation therapy for cancer-associated thromboembolism.

    DOI: 10.1093/jjco/hyac103

    Web of Science

    Scopus

    PubMed

    researchmap

  • 希少がんの治療戦略 信頼と絆に基づく肉腫のチーム医療

    遠藤 誠, 土橋 賢司, 松本 嘉寛, 坂本 節子, 鍋島 央, 飯田 圭一郎, 藤原 稔史, 伊東 守, 磯部 大地, 有山 寛, 赤司 浩一, 馬場 英司, 中島 康晴

    日本癌治療学会学術集会抄録集   60回   WS15 - 3   2022年10月

     詳細を見る

    記述言語:英語  

  • 希少がんの治療戦略 信頼と絆に基づく肉腫のチーム医療

    遠藤 誠, 土橋 賢司, 松本 嘉寛, 坂本 節子, 鍋島 央, 飯田 圭一郎, 藤原 稔史, 伊東 守, 磯部 大地, 有山 寛, 赤司 浩一, 馬場 英司, 中島 康晴

    日本癌治療学会学術集会抄録集   60回   WS15 - 3   2022年10月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌治療学会  

    researchmap

  • IMPROVE出血スコアは静脈血栓塞栓症を有する進行消化器癌患者における大出血を予測する(IMPROVE bleeding score predicts major bleeding in advanced gastrointestinal cancer patients with venous thromboembolism)

    Kusaba Hitoshi, Moriyama Shohei, Hieda Michinari, Ito Mamoru, Ohmura Hirofumi, Isobe Taichi, Tsuchihashi Kenji, Fukata Mitsuhiro, Ariyama Hiroshi, Baba Eishi

    Japanese Journal of Clinical Oncology   52 ( 10 )   1183 - 1190   2022年10月   ISSN:0368-2811

     詳細を見る

    記述言語:英語   出版者・発行元:Oxford University Press  

    癌関連血栓症を有する進行消化器癌患者に対する抗凝固療法の患者選択を改善するため、出血の発生率や危険因子を後方視的に検討した。2014~2018年に化学療法を受けた進行消化器癌患者194例(年齢31~84歳)を対象とした。消化器癌の内訳は胃癌74例、大腸癌120例であった。194例のうち、静脈血栓塞栓症と診断された患者は40例(20.6%)、肺血栓塞栓症を併発した患者は10例(5.2%)であった。出血は29名(15%)に認められた。出血部位は、原発巣17例、転移巣9例、出血性胃潰瘍3例であり、静脈血栓塞栓症群40例のうち10例(25%)に出血が認められた。多変量解析により、International Medical Prevention Registry on Venous Thromboembolism(IMPROVE)出血スコア7以上と大出血は有意に相関していた(P=0.01)。出血リスクの低い患者では大出血は3例のみであった。以上より、IMPROVE出血スコアは静脈血栓塞栓症を有する消化器癌患者における出血リスクを予測する可能性があった。

  • 特集 外来で行う消化器がん薬物療法のコツ - 専門医からのアドバイス 1.がん診療におけるがん薬物療法の位置づけ(2)胃がん

    大村 洋文, 有山 寛, 馬場 英司

    臨床消化器内科   37 ( 11 )   1404 - 1409   2022年9月   ISSN:0911601X eISSN:24332488

     詳細を見る

    出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/cg.0000002384

    CiNii Research

  • A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site 国際誌

    Kazuo Nishikawa, Shuichi Hironaka, Takashi Inagaki, Azusa Komori, Satoshi Otsu, Kenji Mitsugi, Akitaka Makiyama, Koichiro Watanabe, Shingo Tamura, Yuta Okumura, Hitoshi Kusaba, Taito Esaki, Eishi Baba, Kuniaki Shirao

    Japanese Journal of Clinical Oncology   52 ( 12 )   1416 - 1422   2022年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/jjco/hyac143

  • Primary tumor location as a predictor of survival in patients with <i>RAS</i> wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

    Ito, T; Takashima, A; Yamazaki, K; Yukami, H; Uetake, H; Tsuda, M; Suto, T; Moriwaki, T; Sugimoto, N; Ojima, H; Takii, Y; Yasui, H; Esaki, T; Tsuji, A; Goto, M; Saruta, M; Otsu, S; Shinozaki, K; Fujiwara, T; Tamura, T; Baba, E; Shiozawa, M; Denda, T; Ueno, H; Nagashima, K; Shimada, Y

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   27 ( 9 )   1450 - 1458   2022年9月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    BACKGROUND: Primary tumor location is considered a predictor of overall survival (OS) in RAS wild-type (WT) metastatic colorectal cancer (mCRC) treated with bevacizumab (BEV) or an anti-epidermal growth factor antibody (cetuximab or panitumumab [CET/PAN]) as first-line molecularly targeted therapy. BEV is recommended for right-sided mCRC and CET/PAN for left-sided mCRC based on post-hoc analyses of clinical trial data, but real-world evidence is lacking. METHODS: We retrospectively collected data of patients who started BEV or CET/PAN plus 5-fluorouracil-based doublet chemotherapy between January 2013 and December 2016 as first-line treatment for RAS WT mCRC at any of 24 Japanese institutions. OS was compared between the BEV and CET/PAN groups according to primary tumor location by Cox multivariate regression analysis in the full cohort and in a propensity score-matched cohort. RESULTS: In total, 935 patients were enrolled. Median OS was 24.6 months with BEV and 20.9 months with CET/PAN in right-sided mCRC (n = 213; adjusted hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.50-1.06) and 35.7 months and 30.0 months, respectively, in left-sided mCRC (n = 722; adjusted HR 0.92, 95% CI 0.74-1.13). In the propensity score-matched cohort, OS was significantly better in the BEV group than in the CET/PAN group in right-sided mCRC (HR 0.52, 95% CI 0.28-0.96) but was not significantly different in left-sided mCRC (HR 0.78, 95% CI 0.53-1.07). CONCLUSION: Real-world data showed that OS was better with BEV than with CET/PAN in right-sided mCRC. However, there was no significant difference in OS in left-sided mCRC.

    DOI: 10.1007/s10147-022-02208-7

    Web of Science

    Scopus

    PubMed

    researchmap

  • 食道癌における自然な上皮間葉転換可塑性の存在とその意義(Presence and its role of spontaneous epithelial-mesenchymal plasticity in esophageal cancer)

    土橋 賢司, 平田 雄紀, 山崎 淳太郎, 推名 健太郎, 田ノ上 絢郎, 八戸 敏文, 増田 健太, 馬場 英司, 赤司 浩一, 北川 雄光, 佐谷 秀行, 永野 修

    日本癌学会総会記事   81回   E - 2042   2022年9月

     詳細を見る

    記述言語:英語  

  • 【外来で行う消化器がん薬物療法のコツ-専門医からのアドバイス】がん診療におけるがん薬物療法の位置づけ 胃がん

    大村 洋文, 有山 寛, 馬場 英司

    臨床消化器内科   37 ( 11 )   1404 - 1409   2022年9月

     詳細を見る

    記述言語:日本語  

    <文献概要>胃がんは,わが国で罹患率,死亡者数ともに高い悪性腫瘍の一つである.胃がんに対するがん薬物療法は,治癒切除例における再発予防目的および切除不能・再発症例に対する延命・症状緩和目的で選択される.近年薬物療法の開発が進み,pStage III症例に対する術後補助化学療法としてS-1+ドセタキセル(DTX)併用療法の有効性が示された.また切除不能・再発症例の一次治療でニボルマブが化学療法との併用でup-frontに使用されるようになり,またHER2陽性例に対するトラスツズマブ・デルクステカンなど,三次治療においても延命効果が期待される薬剤が開発されている.胃がんにおける薬物療法について解説していく.

  • Inhibition of insulin-like growth factor-1 receptor enhances eribulin-induced DNA damage in colorectal cancer 国際誌

    Yoshihiro, T; Ariyama, H; Yamaguchi, K; Imajima, T; Yamaga, S; Tsuchihashi, K; Isobe, T; Kusaba, H; Akashi, K; Baba, E

    CANCER SCIENCE   113 ( 12 )   4207 - 4218   2022年9月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Science  

    Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies suggest that a subset of patients with CRC, especially those with cancers harboring the BRAF mutation, could benefit from such agents. However, two MTAs, eribulin (Eri) and vinorelbine, have shown limited clinical efficacy. Here, we report that insulin-like growth factor 1 receptor (IGF-1R) signaling is involved in Eri resistance. Using CRC cell lines, we showed that Eri induces activation and subsequent translocation of IGF-1R to the nucleus. When the activation and/or nuclear translocation of IGF-1R was inhibited, Eri induced DNA damage and enhanced G2 /M arrest. In a xenograft model using the Eri-resistant SW480 cell line, the combination of Eri and the IGF-1R inhibitor linsitinib suppressed tumor growth more efficiently than either single agent. Thus, our results indicated that combination dosing with Eri and an IGF-1R inhibitor could overcome Eri resistance and offer a therapeutic opportunity in CRC.

    DOI: 10.1111/cas.15558

    Web of Science

    Scopus

    PubMed

    researchmap

  • in vitroヒト胃印環細胞癌モデルのトランスクリプトーム解析による潜在的な治療標的の発見(Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model)

    Yamaguchi Kyoko, Yoshihiro Tomoyasu, Ariyama Hiroshi, Ito Mamoru, Nakano Michitaka, Semba Yuichiro, Nogami Jumpei, Tsuchihashi Kenji, Yamauchi Takuji, Ueno Shohei, Isobe Taichi, Shindo Koji, Moriyama Taiki, Ohuchida Kenoki, Nakamura Masafumi, Nagao Yoshihiro, Ikeda Tetsuo, Hashizume Makoto, Konomi Hiroyuki, Torisu Takehiro, Kitazono Takanari, Kanayama Tomohiro, Tomita Hiroyuki, Oda Yoshinao, Kusaba Hitoshi, Maeda Takahiro, Akashi Koichi, Baba Eishi

    Gastric Cancer   25 ( 5 )   862 - 878   2022年9月   ISSN:1436-3291

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

    E-カドヘリン欠損胃印環細胞癌(SRCC)における新規治療標的を同定することを目的とした。E-カドヘリンをコードするCDH1遺伝子をノックアウト(KO)したヒト胃オルガノイド(hGO)を用いて、in vitroのE-カドヘリン欠損胃癌モデルを作製し、新規治療標的を探索した。CDH1 KO hGO細胞は、SRCCに類似した特徴的な形態変化と高い細胞運動性を示した。RNA配列解析の結果、CDH1 KO hGO細胞では、野生型と比較して、マトリックスメタロプロテアーゼ(MMP)遺伝子の発現が増加していた。MMP阻害剤は、in vitroでCDH1 KO hGO細胞およびSRCC細胞株の細胞運動を抑制した。95例の臨床胃癌組織を用いた免疫蛍光分析により、MMP-3はE-カドヘリン異常のSRCCに特異的に多く存在することが示された。また、CDH1 KO後、CXCR4分子が細胞膜上に移行した。CXCR4のリガンドであるCXCL12を培養液に添加すると、CDH1 KO hGO細胞の細胞生存率が延長し、CXCR4アンタゴニストであるAMD3100によってその効果が消失した。SRCCの臨床サンプルでは、CXCL12を分泌する線維芽細胞が癌領域に著しく浸潤していることを確認した。以上より、MMPとCXCL12/CXCR4軸は、E-カドヘリン欠損SRCCの新規治療標的として有望な候補であると考えられた。

  • 食道癌における自然な上皮間葉転換可塑性の存在とその意義(Presence and its role of spontaneous epithelial-mesenchymal plasticity in esophageal cancer)

    土橋 賢司, 平田 雄紀, 山崎 淳太郎, 推名 健太郎, 田ノ上 絢郎, 八戸 敏文, 増田 健太, 馬場 英司, 赤司 浩一, 北川 雄光, 佐谷 秀行, 永野 修

    日本癌学会総会記事   81回   E - 2042   2022年9月   ISSN:0546-0476

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • ファーストライン治療として分子標的薬を投与されたRAS野生型大腸癌患者における生存率の予測因子としての原発巣部位 大腸癌研究会による多施設共同実臨床観察研究(Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum)

    Ito Takahiko, Takashima Atsuo, Yamazaki Kentaro, Yukami Hiroki, Uetake Hiroyuki, Tsuda Masahiro, Suto Takeshi, Moriwaki Toshikazu, Sugimoto Naotoshi, Ojima Hitoshi, Takii Yasumasa, Yasui Hisateru, Esaki Taito, Tsuji Akihito, Goto Masahiro, Saruta Masayuki, Otsu Satoshi, Shinozaki Katsunori, Fujiwara Toshiyoshi, Tamura Takao, Baba Eishi, Shiozawa Manabu, Denda Tadamichi, Ueno Hideki, Nagashima Kengo, Shimada Yasuhiro

    International Journal of Clinical Oncology   27 ( 9 )   1450 - 1458   2022年9月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

    ファーストライン治療として抗血管内皮増殖因子抗体製剤ベバシズマブ(BEV)または抗上皮成長因子受容体抗体製剤セツキシマブやパニツムマブ(CET/PAN)を受けたRAS野生型転移性大腸癌(mCRC)患者において、原発巣の部位別に実臨床での有効性を検討した。2013年1月から2016年12月までに日本国内24施設において、BEVまたはCET/PAN+5-フルオロウラシルベースの2剤併用化学療法を開始したRAS野生型mCRC患者935例を対象とした。その結果、右側mCRCの213例の全生存期間(OS)中央値は、BEVで24.6ヵ月、CET/PANで20.9ヵ月であり(調整後HR 0.73、95%CI 0.50~1.06)、左側mCRCの722例のOS中央値は、BEVで35.7ヵ月、CET/PANで30.0ヵ月であった(調整後HR 0.92、95%CI 0.74~1.13)。傾向スコアをマッチさせたコホートでは、右側mCRCではBEV群がCET/PAN群よりもOSが有意に良好であったが、左側mCRCでは有意差はなかった。以上より、実臨床において、右側mCRCに対してはBEV投与の方がCET/PAN投与よりも有効であるが、左側mCRCに対する有効性には差が認められないことが示された。

  • 【外来で行う消化器がん薬物療法のコツ-専門医からのアドバイス】がん診療におけるがん薬物療法の位置づけ 胃がん

    大村 洋文, 有山 寛, 馬場 英司

    臨床消化器内科   37 ( 11 )   1404 - 1409   2022年9月   ISSN:0911-601X eISSN:2433-2488

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本メディカルセンター  

    <文献概要>胃がんは,わが国で罹患率,死亡者数ともに高い悪性腫瘍の一つである.胃がんに対するがん薬物療法は,治癒切除例における再発予防目的および切除不能・再発症例に対する延命・症状緩和目的で選択される.近年薬物療法の開発が進み,pStage III症例に対する術後補助化学療法としてS-1+ドセタキセル(DTX)併用療法の有効性が示された.また切除不能・再発症例の一次治療でニボルマブが化学療法との併用でup-frontに使用されるようになり,またHER2陽性例に対するトラスツズマブ・デルクステカンなど,三次治療においても延命効果が期待される薬剤が開発されている.胃がんにおける薬物療法について解説していく.

    researchmap

  • Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)

    Kito, Y; Yamazaki, K; Shoji, H; Yamada, T; Tsushima, T; Mitani, S; Shiraishi, K; Yasui, H; Hara, H; Shimozaki, K; Esaki, T; Shimokawa, H; Kajiura, S; Masuishi, T; Baba, E; Yoshimura, K; Kawakami, H; Hironaka, S; Muro, K

    ANNALS OF ONCOLOGY   33 ( 7 )   S715 - S715   2022年9月   ISSN:0923-7534 eISSN:1569-8041

  • Presence of spontaneous epithelial-mesenchymal plasticity in esophageal cancer 国際誌

    Tsuchihashi, K; Hirata, Y; Yamasaki, J; Suina, K; Tanoue, K; Yae, T; Masuda, K; Baba, E; Akashi, K; Kitagawa, Y; Saya, H; Nagano, O

    BIOCHEMISTRY AND BIOPHYSICS REPORTS   30   101246 - 101246   2022年7月   ISSN:2405-5808

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Biochemistry and Biophysics Reports  

    Epithelial-mesenchymal plasticity (EMP) refers to the reversible cellular transition between epithelial and mesenchymal status. Spontaneous EMP is also reported in breast and prostate cancer, leading to the acquisition of stem-cell properties and chemoresistance. However, the presence of spontaneous EMP is still not reported in esophageal cancer. We screened 11 esophageal squamous cancer cell (ESCC) cell lines by CD44 isoform expression. KYSE520 was found to comprise heterogenous populations consisting of CD44v+ and CD44v- subpopulations. CD44v+ and CD44v- cells showed the expression of epithelial and mesenchymal markers, respectively. Single-cell sorting of CD44v+ and CD44v- cells revealed both cells gave rise to cell populations consisting of CD44v+ and CD44v- cells, indicating CD44v+ epithelial-like and CD44v- mesenchymal-like cells can generate counterparts, respectively. The ablation of Epithelial splicing regulatory protein 1 (ESRP1), a major regulator of CD44 mRNA splicing, resulted in the shift from CD44v+ to CD44v- cells in KYSE520. However, the expression of epithelial-mesenchymal transition (EMT)-related markers or transcriptional factors were almost not affected, suggesting ESRP1 functions downstream of EMP. Our results revealed the presence of spontaneous EMP in esophageal cancer and KYSE520 is useful model to understand spontaneous EMP.

    DOI: 10.1016/j.bbrep.2022.101246

    Web of Science

    Scopus

    PubMed

    researchmap

  • 【がん免疫療法の展望:免疫チェックポイント阻害薬の併用療法に中心に】免疫チェックポイント阻害薬の併用療法のエビデンス 免疫チェックポイント阻害薬と化学療法

    磯部 大地, 馬場 英司

    腫瘍内科   30 ( 1 )   8 - 17   2022年7月

     詳細を見る

    記述言語:日本語  

  • 【がん免疫療法の展望:免疫チェックポイント阻害薬の併用療法に中心に】免疫チェックポイント阻害薬の併用療法のエビデンス 免疫チェックポイント阻害薬と化学療法

    磯部 大地, 馬場 英司

    腫瘍内科   30 ( 1 )   8 - 17   2022年7月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • Kyushu Promotion Plan for the Platform of Human Resource Development for Cancer

    Ota K., Baba E.

    Gan to kagaku ryoho. Cancer &amp; chemotherapy   49 ( 6 )   642 - 645   2022年6月   ISSN:03850684

     詳細を見る

    出版者・発行元:Gan to kagaku ryoho. Cancer &amp; chemotherapy  

    While it is necessary to provide a detailed cancer treatment according to patient's life stages which are childhood, adolescence and young adulthood, and senior years, there is shortage of human resources who can meet these needs because of few opportunities to train in clinical experience including rare cancers. In addition, since Kyushu has a lot of remote islands and remote areas, it is also important to take measures against elderly cancer patients in such places. On the other hand, the practical application of cancer genomic medicine is accelerating in Japan, however, there is an overwhelming shortage of medical staff who can appropriately apply genomic medicine clinically and who can contribute to the research development of this field. The purpose of"Kyushu Promotion Plan for the Platform of Human Resource Development for Cancer"is to promote the growth of the medical staff specialized for cancer genomic medicine, adolescent and young adult oncology, rare cancers, and measure for cancer depending on the patient's life stage. This plan is consisted with ten universities in Kyushu and we have carried out a variety of events along with these themes above by collaborating with each other for 5 years. These events include lectures, conferences, presentation of their researches, training at the medical center abroad or isolated island, the support system for trainees to get the specialized license for oncologist in Japan. We have run these events successfully and the response from the trainees belonging to this plan was satisfactory. I have confidence that the number of medical staffs who have learned cancer genomic medicine and the cancer treatments depending on the patient's life stage has increased through this project, and they will play an important role as the professional medical staff in the future. We are planning to continue these events even after the end of this plan to keep the number and quality of professional medical staff for cancer.

    Scopus

  • Phase II trial of perioperative chemotherapy of esophageal cancer: PIECE trial.

    Nomura, M; Goto, M; Watanabe, M; Hato, S; Kato, K; Baba, E; Matsubara, H; Mukaida, H; Yoshii, T; Tsuda, M; Tsubosa, Y; Kitagawa, Y; Hideki, I; Muto, M

    JOURNAL OF CLINICAL ONCOLOGY   40 ( 16 )   2022年6月   ISSN:0732-183X eISSN:1527-7755

     詳細を見る

  • Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model

    Yamaguchi, K; Yoshihiro, T; Ariyama, H; Ito, M; Nakano, M; Semba, Y; Nogami, J; Tsuchihashi, K; Yamauchi, T; Ueno, S; Isobe, T; Shindo, K; Moriyama, T; Ohuchida, K; Nakamura, M; Nagao, Y; Ikeda, T; Hashizume, M; Konomi, H; Torisu, T; Kitazono, T; Kanayama, T; Tomita, H; Oda, Y; Kusaba, H; Maeda, T; Akashi, K; Baba, E

    GASTRIC CANCER   25 ( 5 )   862 - 878   2022年6月   ISSN:1436-3291 eISSN:1436-3305

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Gastric Cancer  

    BACKGROUND: Loss of E-cadherin expression is frequently observed in signet ring carcinoma (SRCC). People with germline mutations in CDH1, which encodes E-cadherin, develop diffuse gastric cancer at a higher rate. Loss of E-cadherin expression is thus assumed to trigger oncogenic development. METHODS: To investigate novel therapeutic targets for gastric SRCC, we engineered an E-cadherin-deficient SRCC model in vitro using a human gastric organoid (hGO) with CDH1 knockout (KO). RESULTS: CDH1 KO hGO cells demonstrated distinctive morphological changes similar to SRCC and high cell motility. RNA-sequencing revealed up-regulation of matrix metalloproteinase (MMP) genes in CDH1 KO hGO cells compared to wild type. MMP inhibitors suppressed cell motility of CDH1 KO hGO cells and SRCC cell lines in vitro. Immunofluorescent analysis with 95 clinical gastric cancer tissues revealed that MMP-3 was specifically abundant in E-cadherin-aberrant SRCC. In addition, CXCR4 molecules translocated onto the cell membrane after CDH1 KO. Addition of CXCL12, a ligand of CXCR4, to the culture medium prolonged cell survival of CDH1 KO hGO cells and was abolished by the inhibitor, AMD3100. In clinical SRCC samples, CXCL12-secreting fibroblasts showed marked infiltration into the cancer area. CONCLUSIONS: E-cadherin deficient SRCCs might gain cell motility through upregulation of MMPs. CXCL12-positive cancer-associated fibroblasts could serve to maintain cancer-cell survival as a niche. MMPs and the CXCL12/CXCR4 axis represent promising candidates as novel therapeutic targets for E-cadherin-deficient SRCC.

    DOI: 10.1007/s10120-022-01307-8

    Web of Science

    Scopus

    PubMed

    researchmap

  • [Kyushu Promotion Plan for the Platform of Human Resource Development for Cancer].

    Keiichi Ota, Eishi Baba

    Gan to kagaku ryoho. Cancer & chemotherapy   49 ( 6 )   642 - 645   2022年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  • 悪性軟部腫瘍の希少性と多様性に対して、われわれはどう対峙すべきか 多職種連携の重要性と地域希少がんセンターに求められる役割

    遠藤 誠, 松本 嘉寛, 土橋 賢司, 馬場 英司, 中島 康晴

    日本整形外科学会雑誌   96 ( 6 )   S1295 - S1295   2022年6月

     詳細を見る

    記述言語:日本語  

  • [Kyushu Promotion Plan for the Platform of Human Resource Development for Cancer].

    Keiichi Ota, Eishi Baba

    Gan to kagaku ryoho. Cancer & chemotherapy   49 ( 6 )   642 - 645   2022年6月   ISSN:0385-0684

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    While it is necessary to provide a detailed cancer treatment according to patient's life stages which are childhood, adolescence and young adulthood, and senior years, there is shortage of human resources who can meet these needs because of few opportunities to train in clinical experience including rare cancers. In addition, since Kyushu has a lot of remote islands and remote areas, it is also important to take measures against elderly cancer patients in such places. On the other hand, the practical application of cancer genomic medicine is accelerating in Japan, however, there is an overwhelming shortage of medical staff who can appropriately apply genomic medicine clinically and who can contribute to the research development of this field. The purpose of"Kyushu Promotion Plan for the Platform of Human Resource Development for Cancer"is to promote the growth of the medical staff specialized for cancer genomic medicine, adolescent and young adult oncology, rare cancers, and measure for cancer depending on the patient's life stage. This plan is consisted with ten universities in Kyushu and we have carried out a variety of events along with these themes above by collaborating with each other for 5 years. These events include lectures, conferences, presentation of their researches, training at the medical center abroad or isolated island, the support system for trainees to get the specialized license for oncologist in Japan. We have run these events successfully and the response from the trainees belonging to this plan was satisfactory. I have confidence that the number of medical staffs who have learned cancer genomic medicine and the cancer treatments depending on the patient's life stage has increased through this project, and they will play an important role as the professional medical staff in the future. We are planning to continue these events even after the end of this plan to keep the number and quality of professional medical staff for cancer.

    PubMed

    researchmap

  • [Kyushu Promotion Plan for the Platform of Human Resource Development for Cancer].

    Ota K, Baba E

    Gan to kagaku ryoho. Cancer & chemotherapy   49 ( 6 )   642 - 645   2022年6月   ISSN:0385-0684

     詳細を見る

    記述言語:日本語  

    PubMed

  • 悪性軟部腫瘍の希少性と多様性に対して、われわれはどう対峙すべきか 多職種連携の重要性と地域希少がんセンターに求められる役割

    遠藤 誠, 松本 嘉寛, 土橋 賢司, 馬場 英司, 中島 康晴

    日本整形外科学会雑誌   96 ( 6 )   S1295 - S1295   2022年6月   ISSN:0021-5325

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本整形外科学会  

    researchmap

  • Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study). 国際誌

    22 ( 1 )   515 - 515   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Monitoring proteinuria is important for the management of patients with cancer treated with anti-vascular endothelial growth factor (VEGF) or anti-VEGF receptor (VEGFR) inhibitors (VEGF/Ri). Here we investigated the difference between the urine protein/creatinine ratio (UPCR) and a qualitative value test (QV) on the decision making of treatment continuation and the usefulness of UPCR testing in patients with gastrointestinal cancer treated with anti-VEGF/Ri. METHODS: From January 2017 to December 2018, a survey was conducted based on the medical records of patients with gastrointestinal cancer with a QV of ≥2+ during the use of anti-VEGF/Ri at seven Japanese institutions participating in the Onco-nephrology Consortium. The primary endpoint was the ratio of the worst UPCR < 2.0 (low UPCR) in cases with a QV2+ at the point of the first proteinuria onset. The secondary endpoints were a comparison of low UPCR and worst UPCR ≥2.0 (high UPCR), the concordance rate between UPCR and QV in the Common Terminology Criteria for Adverse Events (CTCAE) grading, and the differences in the decision making for anti-VEGF/Ri continuation. RESULTS: Among the 71 patients enrolled, the proportion of low UPCR in onset QV2+ (n = 53) was 66% (n = 35). In a comparison between low (n = 36) and high UPCR cases (n = 24), body weight (P = 0.036), onset QV status (P = 0.0134), and worst QV status (P < 0.0001) were significantly associated with UPCR levels. The concordance rate for CTCAE Grade 2 of both the QV and UPCR was 83%. Regarding the judgment of anti-VEGF/Ri continuation, treatment was continued in 42.4% of cases when the QV became 3+, whereas only 25% continued treatment when the UPCR value became high. CONCLUSION: Urine dipstick test results may overestimate proteinuria, and the UPCR result tended to be more critical than the QV when deciding the treatment policy. TRIAL REGISTRATION: This study is a multiple institutional retrospectively registered observational trial. CLINICAL TRIAL NUMBER: University Hospital Medical Information Network (UMIN) Clinical Trials Registry (protocol ID UMIN000042545 ).

    DOI: 10.1186/s12885-022-09611-3

  • 【がんに対する新しい治療法と未来型医療】新しいがん治療法 抗体薬物複合体(ADC)

    磯部 大地, 馬場 英司

    腫瘍内科   29 ( 5 )   535 - 543   2022年5月

     詳細を見る

    記述言語:日本語  

  • 【がんに対する新しい治療法と未来型医療】新しいがん治療法 抗体薬物複合体(ADC)

    磯部 大地, 馬場 英司

    腫瘍内科   29 ( 5 )   535 - 543   2022年5月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 特集 希少がんに対する診療提供体制の現状と展望 地域における希少がん診療提供体制

    土橋 賢司, 馬場 英司

    医学のあゆみ   281 ( 4 )   305 - 309   2022年4月   ISSN:00392359

     詳細を見る

    出版者・発行元:医歯薬出版  

    DOI: 10.32118/ayu28104305

    CiNii Research

  • Macrophages are primed to transdifferentiate into fibroblasts in malignant ascites and pleural effusions 国際誌

    Ito, M; Nakano, M; Ariyama, H; Yamaguchi, K; Tanaka, R; Semba, Y; Sugio, T; Miyawaki, K; Kikushige, Y; Mizuno, S; Isobe, T; Tanoue, K; Taguchi, R; Ueno, S; Kawano, T; Murata, M; Baba, E; Akashi, K

    CANCER LETTERS   532   215597 - 215597   2022年4月   ISSN:0304-3835 eISSN:1872-7980

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Cancer Letters  

    Cancer-associated fibroblasts (CAFs) play an important role in cancer progression. However, the origin of CAFs remains unclear. This study shows that macrophages in malignant ascites and pleural effusions (cavity fluid-associated macrophages: CAMs) transdifferentiate into fibroblast-like cells. CAMs obtained from gastrointestinal cancer patients were sorted by flow cytometry and cultured in vitro. CD45+CD14+ CAMs transdifferentiated into CD45-CD90+ fibroblast-like cells that exhibited spindle shapes. Then, cDNA microarray analysis showed that the CD45-CD90+ fibroblast-like cells (macrophage-derived CAFs: MDCAFs) had a fibroblast-specific gene expression signature and produced growth factors for epithelial cell proliferation. Human colon cancer cells transplanted into immunodeficient mice with MDCAFs formed larger tumors than cancer cells alone. Gene ontology analyses showed the involvement of TGFβ signaling and cell-matrix adhesion in MDCAFs, and transdifferentiation of CAMs into MDCAFs was canceled by inhibiting TGFβ and cell adhesion. Furthermore, the acquired genetic alterations in hematopoietic stem cells (HSCs) were shared in CAMs and MDCAFs. Taken together, CAMs could be a source of CAFs and might originate from HSCs. We propose the transdifferentiation process of CAMs into MDCAFs as a new therapeutic target for fibrosis associated with gastrointestinal cancer.

    DOI: 10.1016/j.canlet.2022.215597

    Web of Science

    Scopus

    PubMed

    researchmap

  • Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2 (vol 27, pg 281, 2022)

    Tozawa, A; Kimura, F; Takai, Y; Nakajima, T; Ushijima, K; Kobayashi, H; Satoh, T; Harada, M; Sugimoto, K; Saji, S; Shimizu, C; Akiyama, K; Bando, H; Kuwahara, A; Furui, T; Okada, H; Kawai, K; Shinohara, N; Nagao, K; Kitajima, M; Suenobu, S; Soejima, T; Miyachi, M; Miyoshi, Y; Yoneda, A; Horie, A; Ishida, Y; Usui, N; Kanda, Y; Fujii, N; Endo, M; Nakayama, R; Hoshi, M; Yonemoto, T; Kiyotani, C; Okita, N; Baba, E; Muto, M; Kikuchi, I; Morishige, K; Tsugawa, K; Nishiyama, H; Hosoi, H; Tanimoto, M; Kawai, A; Sugiyama, K; Boku, N; Yonemura, M; Hayashi, N; Aoki, D; Suzuki, N; Osuga, Y

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   27 ( 3 )   635 - 637   2022年3月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   出版者・発行元:International Journal of Clinical Oncology  

    The article, Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2 written by Akiko Tozawa, Fuminori Kimura, Yasushi Takai, Takeshi Nakajima, Kimio Ushijima, Hiroaki Kobayashi, Toyomi Satoh, Miyuki Harada, Kohei Sugimoto, Shigehira Saji, Chikako Shimizu, Kyoko Akiyama, Hiroko Bando, Akira Kuwahara, Tatsuro Furui, Hiroshi Okada, Koji Kawai, Nobuo Shinohara, Koichi Nagao, Michio Kitajima, Souichi Suenobu,Toshinori Soejima, Mitsuru Miyachi, Yoko Miyoshi, Akihiro Yoneda, Akihito Horie,Yasushi Ishida, Noriko Usui, Yoshinobu Kanda, Nobuharu Fujii, Makoto Endo, Robert Nakayama, Manabu Hoshi, Tsukasa Yonemoto, Chikako Kiyotani, Natsuko Okita, Eishi Baba, Manabu Muto, Iwaho Kikuchi, Ken‑ichirou Morishige, Koichiro Tsugawa, Hiroyuki Nishiyama, Hajime Hosoi, Mitsune Tanimoto, Akira Kawai, Kazuhiko Sugiyama, Narikazu Boku, Masato Yonemura, Naoko Hayashi, Daisuke Aoki, Nao Suzuki, Yutaka Osuga was originally published Online First without Open Access. With the author(s)’ decision to opt for Open Choice the copyright of the article changed on February 14, 2022 to © Author(s) 2021 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0. The original article has been corrected.

    DOI: 10.1007/s10147-022-02137-5

    Web of Science

    Scopus

    PubMed

    researchmap

  • A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT)

    Hirata, K; Hamamoto, Y; Shoji, H; Hara, H; Kondoh, C; Yasui, H; Kajiwara, T; Baba, E; Ando, T; Sugimoto, N; Okano, N; Kawakami, H; Katsuya, H; Nagase, M; Moriwaki, T; Yoshimura, K; Ando, M; Yamazaki, K; Hironaka, S; Muro, K

    JOURNAL OF CLINICAL ONCOLOGY   40 ( 4 )   2022年2月   ISSN:0732-183X eISSN:1527-7755

  • Association of disease progression pattern during third-line chemotherapy with nivolumab with poor prognosis in advanced gastric cancer: A multicenter retrospective study in Japan

    Kadowaki, S; Aoki, M; Suzuki, T; Takahashi, N; Shirasu, H; Ando, T; Yamamoto, Y; Kawakami, K; Kito, Y; Matsumoto, T; Shimozaki, K; Miyazaki, Y; Yamaguchi, T; Akiyoshi, K; Baba, E; Makiyama, A; Nakashima, K; Sugimoto, N; Nagashima, K; Boku, N

    JOURNAL OF CLINICAL ONCOLOGY   40 ( 4 )   2022年2月   ISSN:0732-183X eISSN:1527-7755

  • Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1

    Harada, M; Kimura, F; Takai, Y; Nakajima, T; Ushijima, K; Kobayashi, H; Satoh, T; Tozawa, A; Sugimoto, K; Saji, S; Shimizu, C; Akiyama, K; Bando, H; Kuwahara, A; Furui, T; Okada, H; Kawai, K; Shinohara, N; Nagao, K; Kitajima, M; Suenobu, S; Soejima, T; Miyachi, M; Miyoshi, Y; Yoneda, A; Horie, A; Ishida, Y; Usui, N; Kanda, Y; Fujii, N; Endo, M; Nakayama, R; Hoshi, M; Yonemoto, T; Kiyotani, C; Okita, N; Baba, E; Muto, M; Kikuchi, I; Morishige, KI; Tsugawa, K; Nishiyama, H; Hosoi, H; Tanimoto, M; Kawai, A; Sugiyama, K; Boku, N; Yonemura, M; Hayashi, N; Aoki, D; Osuga, Y; Suzuki, N

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   27 ( 2 )   265 - 280   2022年2月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    In 2017, the Japan Society of Clinical Oncology (JSCO) published the JSCO Clinical Practice Guidelines 2017 for Fertility Preservation in Childhood, Adolescent, and Young Adult Cancer Patients. These were the first Japanese guidelines to address issues of oncofertility. In this field of medicine, sustained close cooperation between oncologists and reproductive specialists is essential from the diagnosis of cancer until many years after completion of cancer treatment. These JSCO guidelines were intended to guide multidisciplinary medical staff in considering the availability of fertility preservation options and to help them decide whether to provide fertility preservation to childhood, adolescent, and young adult cancer patients before treatment starts, with the ultimate goal of improving patient survivorship. The guidelines are presented as Parts 1 and 2. This article (Part 1) summarizes the goals of the guidelines and the methods used to develop them and provides an overview of fertility preservation across all oncology areas. It includes general remarks on the basic concepts surrounding fertility preservation and explanations of the impacts of cancer treatment on gonadal function by sex and treatment modality and of the options for protecting/preserving gonadal function and makes recommendations based on 4 clinical questions. Part 2 of these guidelines provides specific recommendations on fertility preservation in 8 types of cancer (gynecologic, breast, urologic, pediatric, hematologic, bone and soft tissue, brain, and digestive).

    DOI: 10.1007/s10147-021-02081-w

    Web of Science

    Scopus

    PubMed

    researchmap

  • Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2

    Tozawa, A; Kimura, F; Takai, Y; Nakajima, T; Ushijima, K; Kobayashi, H; Satoh, T; Harada, M; Sugimoto, K; Saji, S; Shimizu, C; Akiyama, K; Bando, H; Kuwahara, A; Furui, T; Okada, H; Kawai, K; Shinohara, N; Nagao, K; Kitajima, M; Suenobu, S; Soejima, T; Miyachi, M; Miyoshi, Y; Yoneda, A; Horie, A; Ishida, Y; Usui, N; Kanda, Y; Fujii, N; Endo, M; Nakayama, R; Hoshi, M; Yonemoto, T; Kiyotani, C; Okita, N; Baba, E; Muto, M; Kikuchi, I; Morishige, K; Tsugawa, K; Nishiyama, H; Hosoi, H; Tanimoto, M; Kawai, A; Sugiyama, K; Boku, N; Yonemura, M; Hayashi, N; Aoki, D; Suzuki, N; Osuga, Y

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   27 ( 2 )   281 - 300   2022年2月   ISSN:1341-9625 eISSN:1437-7772

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    The Japan Society of Clinical Oncology (JSCO) published the "JSCO Clinical Practice Guidelines 2017 for Fertility Preservation in Childhood, Adolescent, and Young Adult Cancer Patients" in 2017. This was the first guideline in cancer reproductive medicine in Japan. In the field of cancer reproductive medicine, close cooperation between an oncologist and a physician for reproductive medicine is important from before treatment initiation until long after treatment. The guideline takes into consideration disease specificity and provides opinions from the perspective of oncologists and specialists in reproductive medicine that are in line with the current state of the Japanese medical system. It is intended to serve as a reference for medical staff in both fields regarding the availability of fertility preservation therapy before the start of cancer treatment. Appropriate use of this guideline makes it easier to determine whether fertility preservation therapy is feasible and, ultimately, to improve survivorship in childhood, adolescent, and young adult cancer patients. In this article (Part 2), we describe details by organ/system and also for pediatric cancer.

    DOI: 10.1007/s10147-021-02076-7

    Web of Science

    Scopus

    PubMed

    researchmap

  • Increased malignant potential in paclitaxel resistant gastric cancer cells <i>in vitro</i>.

    Ariyama, H; Yamaga, S; Yoshihiro, T; Yamaguchi, K; Akashi, K; Baba, E

    CANCER SCIENCE   113   702 - 702   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Significance of GPT2 in cell proliferation and maintenance of stemness in gastric cancer cells

    Arimizu, K; Ariyama, H; Baba, E; Akashi, K

    CANCER SCIENCE   113   1560 - 1560   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Potential therapeutic targets discovery by transcriptome analysis of in vitro human gastric signet-ring carcinoma model

    Yamaguchi, K; Yoshihiro, T; Ariyama, H; Tsuchihashi, K; Kusaba, H; Baba, E; Akashi, K

    CANCER SCIENCE   113   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • PD-L1 expression is regulated by RNA N6-methyladenosine demethylase FTO in colon cancer cells

    Tsuchihashi, K; Tsuruta, N; Ohmura, H; Yamaguchi, K; Ito, M; Tanoue, K; Isobe, T; Ariyama, H; Kusaba, H; Akashi, K; Baba, E

    CANCER SCIENCE   113   1331 - 1331   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Nuclear translocation of IGF-1 receptor contributes to eribulin resistance in colorectal cancer

    Yoshihiro, T; Ariyama, H; Tsuchihashi, K; Isobe, T; Akashi, K; Baba, E

    CANCER SCIENCE   113   550 - 550   2022年2月   ISSN:1347-9032 eISSN:1349-7006

     詳細を見る

  • Spontaneous Regression of Metachronous Intra-Abdominal Desmoid Tumor in a Patient with Familial Adenomatous Polyposis 国際誌

    Tsuchihashi, K; Yamaguchi, K; Taguchi, R; Kohashi, K; Ijichi, K; Okumura, Y; Nakano, M; Ohno, A; Hioki, T; Shimokawa, H; Ariyama, H; Kusaba, H; Oda, Y; Akashi, K; Baba, E

    CASE REPORTS IN ONCOLOGY   15 ( 1 )   71 - 77   2022年   ISSN:1662-6575

     詳細を見る

    記述言語:英語   出版者・発行元:Case Reports in Oncology  

    Desmoid tumors are clonal fibroblastic neoplasms that arise in soft tissues. Patients with familial adenomatous polyposis (FAP) can develop intra-abdominal desmoid tumors. However, metachronous appearance of intra-abdominal desmoid tumor is rare, and its clinical course is not well known. Here, we report a case of spontaneous regression of metachronous intra-abdominal desmoid tumor in a 36-year-old man with FAP. The patient was diagnosed with FAP and underwent laparoscopic total colorectomy. Intra-abdominal desmoid tumor appeared 2 years later and progressed despite treatment with tamoxifen and sulindac. He received four cycles of combinatory therapy with dacarbazine and adriamycin, resulting in shrinkage and stabilization of the desmoid tumor even after cessation of chemotherapy. A new intra-abdominal desmoid tumor developed 2 years later at a different site from the first lesion and progressed from 65 mm to 70 mm in diameter within a month. The size of the first lesion, however, remained unchanged. We prepared for chemotherapy because the second lesion progressed, but follow-up computed tomography showed spontaneous shrinkage of the second lesion. The patient still has not needed additional therapy as of more than 4 years after the appearance of the second lesion. Immunohistochemical staining showed the presence of macrophages in the second lesion. Although metachronous intra-abdominal desmoid tumor is rare and management protocols have yet to be established, this case suggests that an active surveillance approach may be applicable under careful follow-up in asymptomatic patients.

    DOI: 10.1159/000521920

    Web of Science

    Scopus

    PubMed

    researchmap

  • Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients? 国際誌

    Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu, Nokitaka Setsu, Toshifumi Fujiwara, Keiichiro Iida, Makoto Nakagawa, Takeshi Hirose, Masaya Kanahori, Ryunosuke Oyama, Taichi Isobe, Hiroshi Ariyama, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Yukihide Iwamoto, Koichi Akashi, Eishi Baba, Yasuharu Nakashima

    Journal of clinical medicine   10 ( 21 )   2021年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3390/jcm10214972

  • Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. 国際誌

    Shohei Ueno, Masato Uenomachi, Hitoshi Kusaba, Mamoru Ito, Kunihiro Suzuki, Hirofumi Ohmura, Kenji Tsuchihashi, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    Molecular and clinical oncology   15 ( 4 )   221 - 221   2021年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.3892/mco.2021.2379

  • IGF1受容体の核内移行は大腸癌細胞株においてエリブリン抵抗性を付与する

    吉弘 知恭, 有山 寛, 土橋 賢司, 磯部 大地, 赤司 浩一, 馬場 英司

    日本癌学会総会記事   80回   [P14 - 6]   2021年9月

     詳細を見る

    記述言語:英語  

  • Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.

    Kohei Shitara, Eishi Baba, Kazumasa Fujitani, Eiji Oki, Satoshi Fujii, Kensei Yamaguchi

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   24 ( 4 )   780 - 789   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10120-021-01196-3

  • [Development of Cancer Genomic Medicine in Kyushu Region and the Roles of Kyushu University Hospital as a Core Hospital for Cancer Genomic Medicine].

    Mamoru Ito, Eishi Baba

    Gan to kagaku ryoho. Cancer & chemotherapy   48 ( 7 )   873 - 877   2021年7月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  • ドキソルビシン投与不適の進行軟部肉腫患者に対する一次治療としてのエリブリンの使用経験

    遠藤 誠, 土橋 賢司, 松本 嘉寛, 薛 宇孝, 藤原 稔史, 飯田 圭一郎, 鍋島 央, 木村 敦, 島田 英二郎, 金堀 将也, 吉弘 知恭, 草場 仁志, 赤司 浩一, 馬場 英司, 中島 康晴

    整形外科と災害外科   70 ( Suppl.1 )   89 - 89   2021年5月

     詳細を見る

    記述言語:日本語  

  • Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1).

    Yoichi Naito, Hiroyuki Aburatani, Toraji Amano, Eishi Baba, Toru Furukawa, Tetsu Hayashida, Eiso Hiyama, Sadakatsu Ikeda, Masashi Kanai, Motohiro Kato, Ichiro Kinoshita, Naomi Kiyota, Takashi Kohno, Shinji Kohsaka, Keigo Komine, Itaru Matsumura, Yuji Miura, Yoshiaki Nakamura, Atsushi Natsume, Kazuto Nishio, Katsutoshi Oda, Naoyuki Oda, Natsuko Okita, Kumiko Oseto, Kuniko Sunami, Hideaki Takahashi, Masayuki Takeda, Shimon Tashiro, Shinichi Toyooka, Hideki Ueno, Shinichi Yachida, Takayuki Yoshino, Katsuya Tsuchihara

    International journal of clinical oncology   26 ( 2 )   233 - 283   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-020-01831-6

  • Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab. 国際誌

    Kenro Tanoue, Shingo Tamura, Hitoshi Kusaba, Yudai Shinohara, Mamoru Ito, Kenji Tsuchihashi, Tsuyoshi Shirakawa, Taiga Otsuka, Hirofumi Ohmura, Taichi Isobe, Hiroshi Ariyama, Sakuya Koreishi, Yuzo Matsushita, Hozumi Shimokawa, Risa Tanaka, Kenji Mitsugi, Koichi Akashi, Eishi Baba

    Scientific reports   11 ( 1 )   2741 - 2741   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-021-82448-1

  • Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A).

    26 ( 2 )   345 - 354   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: In a randomized pivotal global phase III study, S-1 and oxaliplatin 100 mg/m2 (SOX100) combination chemotherapy was as effective as S-1 and cisplatin for advanced gastric cancer (AGC) and showed a favorable safety profile. In this phase II study, we analyzed survival outcomes to assess the efficacy and safety of the SOX regimen with oxaliplatin 130 mg/m2 (SOX130) in AGC. METHODS: Patients with HER2-negative AGC received 80 mg/m2/day S-1 orally on days 1-14 and 130 mg/m2 oxaliplatin intravenously on day 1 of each 21-day cycle until the criteria for treatment withdrawal were fulfilled. The primary endpoint was the response rate (RR), and the null hypothesis of RR in the current trial was 45%. The secondary endpoints were progression-free survival (PFS) and overall survival (OS). Adverse events (AEs) were recorded according to CTCAE version 4.0. RESULTS: Seventy-one patients were enrolled from June 2015 to November 2016, but eight were excluded for ineligibility. Therefore, all final analyses were conducted with 63 patients. The confirmed RR was 46.0% (90% confidence interval [CI]: 36.1-56.3), and the disease control rate was 77.8% (90% CI: 68.1-85.1). The median PFS and OS were 4.9 (95% CI: 4.2-7.1) and 14.8 (95% CI: 11.1-18.9) months, respectively. Incidences of grade 3-4 AEs > 10% were anorexia (19.0%), peripheral neuropathy (12.7%), nausea (11.1%), and thrombocytopenia (11.1%). CONCLUSIONS: This study represents the first evaluation of SOX130 in patients with HER2-negative AGC. SOX130 showed an acceptable safety profile, but the prespecified statistical efficacy targets were not achieved.

    DOI: 10.1007/s10147-020-01803-w

  • Comprehensive molecular profiling broadens treatment options for breast cancer patients 国際誌

    Hitomi Kawaji, Makoto Kubo, Nami Yamashita, Hidetaka Yamamoto, Masaya Kai, Atsuko Kajihara, Mai Yamada, Kanako Kurata, Kazuhisa Kaneshiro, Yurina Harada, Saori Hayashi, Akiko Shimazaki, Hitomi Mori, Sayuri Akiyoshi, Eiji Oki, Yoshinao Oda, Eishi Baba, Masaki Mori, Masafumi Nakamura

    Cancer Medicine   10 ( 2 )   529 - 539   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/cam4.3619

  • Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin 国際誌

    Kenji Tsuchihashi, Hitoshi Kusaba, Tomoyasu Yoshihiro, Toshifumi Fujiwara, Nokitaka Setsu, Makoto Endo, Yoshihiro Matsumoto, Takashi Imajima, Yudai Shinohara, Mamoru Ito, Satoru Yamaga, Kenro Tanoue, Kohei Arimizu, Hirofumi Ohmura, Fumiyasu Hanamura, Kyoko Yamaguchi, Taichi Isobe, Hiroshi Ariyama, Yasuharu Nakashima, Koichi Akashi, Eishi Baba

    Scientific Reports   10 ( 1 )   20896 - 20896   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41598-020-77898-y

  • IGF1受容体シグナル阻害は大腸癌細胞株においてエリブリンによるDNA損傷を増強する

    吉弘 知恭, 有山 寛, 磯部 大地, 赤司 浩一, 馬場 英司

    日本癌学会総会記事   79回   PJ14 - 1   2020年10月

     詳細を見る

    記述言語:英語  

  • 微小管阻害薬に関するバイオマーカーの同定

    有山 寛, 山口 享子, 吉弘 知恭, 大村 洋文, 有水 耕平, 山家 覚, 赤司 浩一, 馬場 英司

    日本癌学会総会記事   79回   OJ18 - 3   2020年10月

     詳細を見る

    記述言語:英語  

  • がん幹細胞の根源を探る RHAMM陽性大腸癌がん幹細胞分画の同定

    中野 倫孝, 菊繁 吉謙, 宮脇 恒太, 水野 晋一, 鶴田 展大, 花村 文康, 山口 享子, 山内 拓司, 磯部 大地, 有山 寛, 草場 仁志, 中村 雅史, 前田 高宏, 馬場 英司, 赤司 浩一

    日本癌学会総会記事   79回   S1 - 6   2020年10月

     詳細を見る

    記述言語:英語  

  • RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells 国際誌

    Nobuhiro Tsuruta, Kenji Tsuchihashi, Hirofumi Ohmura, Kyoko Yamaguchi, Mamoru Ito, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Biochemical and Biophysical Research Communications   530 ( 1 )   235 - 239   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.bbrc.2020.06.153

  • Exploratory retrospective study of risk factors for thromboembolism treated with multi-kinase inhibitor pazopanib or lenvatinib

    Kenta Nio, Kenji Tsuchihashi, Keisuke Taguchi, Tomoyasu Yoshihiro, Kyoko Yamaguchi, Mamoru Ito, Shohei Moriyama, Mitsuhiro Fukata, Toshifumi Fujiwara, Nokitaka Setsu, Makoto Endo, Yoshihiro Matsumoto, Yasuharu Nakashima, Takahiro Wakasaki, Ryuji Yasumatsu, Hiroshi Ariyama, Hitoshi Kusaba, Junji Kishimoto, Koichi Akashi, Eishi Baba

    INTERNATIONAL JOURNAL OF SURGERY-ONCOLOGY   5 ( 4 )   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/IJ9.0000000000000089

  • Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). 国際誌

    135   11 - 21   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC). However, it has remained unclear whether panitumumab is effective when combined with irinotecan. We compared efficacies of both regimens in this randomised phase II study. PATIENTS AND METHODS: Patients with wild-type KRAS exon 2 mCRC previously treated with fluorouracil-, oxaliplatin- and irinotecan-based chemotherapies were randomised (1:1) to either panitumumab plus irinotecan (panitumumab arm) or cetuximab plus irinotecan (cetuximab arm). The primary end-point was progression-free survival (PFS). The planned sample size was 120, expecting a hazard ratio (HR) of 1.0 with non-inferiority margin of 1.3 (one-sided alpha error 0.2 and power 0.7). Major secondary end-points were overall survival (OS), response rate and safety. RESULTS: From December 2011 to September 2014, 121 patients were enrolled, and 61 and 59 patients were randomised to the panitumumab and cetuximab arms, respectively (1 patient excluded). Most patients (97%) had received prior chemotherapies containing bevacizumab. The median PFS was 5.42 months in the panitumumab arm and 4.27 months in the cetuximab arm (HR = 0.64, 95% confidence interval [CI] = 0.44-0.94, P < 0.001 for non-inferiority, P = 0.058 for superiority), and median OS was 14.85 and 11.53 months (HR = 0.66, 95% CI = 0.44-1.00, P = 0.050 for superiority), respectively. The incidence of grade 3 or 4 hypomagnesaemia was higher in the panitumumab arm than that in the cetuximab arm (17% vs. 7%). CONCLUSION: Panitumumab may be non-inferior to cetuximab in combination with irinotecan in survival of patients with irinotecan-refractory mCRC.

    DOI: 10.1016/j.ejca.2020.04.014

  • FoundationOne CDxによる進行大腸癌患者の遺伝子変異解析

    倉田 加奈子, 久保 真, 永井 俊太郎, 藤田 逸人, 土橋 賢司, 有山 寛, 永吉 絹子, 貞苅 良彦, 川地 眸, 甲斐 昌也, 伊東 守, 山元 英崇, 小田 義直, 馬場 英司, 中村 雅史

    日本外科学会定期学術集会抄録集   120回   SF - 5   2020年8月

     詳細を見る

    記述言語:日本語  

  • JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

    31 ( 7 )   861 - 872   2020年7月

     詳細を見る

    記述言語:その他   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.annonc.2020.03.299

  • OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody 査読

    Hirofumi Ohmura, Kyoko Yamaguchi, Fumiyasu Hanamura, Mamoru Ito, Akitaka Makiyama, Keita Uchino, Hozumi Shimokawa, Shingo Tamura, Taito Esaki, Kenji Mitsugi, Yoshihiro Shibata, Hisanobu Oda, Kenji Tsuchihashi, Hiroshi Ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba

    British journal of cancer   122 ( 10 )   1507 - 1517   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41416-020-0810-1

  • A human SIRPA knock-in xenograft mouse model to study human hematopoietic and cancer stem cells 国際誌

    Fumiaki Jinnouchi, Takuji Yamauchi, Ayano Yurino, Takuya Nunomura, Michitaka Nakano, Chika Iwamoto, Teppei Obara, Kohta Miyawaki, Yoshikane Kikushige, Koji Kato, Takahiro Maeda, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Katsuto Takenaka

    Blood   135 ( 19 )   1661 - 1672   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1182/blood.2019002194

  • Fluorescence Signal Amplification by Using β-Galactosidase for Flow Cytometry; Advantages of an Endogenous Activity-Free Enzyme 査読

    92 ( 4 )   3069 - 3076   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We previously proposed using a hydrolysis enzyme for fluorescent signal amplification in flow cytometric detection of antigen proteins, which was named the catalyzed reporter penetration (CARP) method. In this method, antigen proteins are labeled with enzyme-modified antibodies, and then fluorophore-modified substrates stain cells by penetrating the cell membrane upon hydrolysis of the substrate. We proved the concept by using alkaline phosphatase (AP) as the hydrolysis enzyme. However, a required prior inactivation process of endogenous AP activity on the cell surface risked disrupting recognition of antigen proteins by antibodies. In this report, the CARP method was extended to β-galactosidase (β-gal) as an amplification enzyme, which circumvented the requirement of an initial inactivation process because endogenous β-gal activity on the surface of examined cells was found to be negligible. The substrate structure for β-gal was optimized and used for the CARP method. The CARP method showed significantly higher fluorescent signals than a conventional method using fluorophore-modified antibodies. Moreover, the degree of amplification of the fluorescence signal was higher for antigens with low expression levels, showing that the CARP method is a suitable signal amplification method over current conventional approaches.

    DOI: 10.1021/acs.analchem.9b04471

  • Activation of memory/effector T cells and association between prognosis and OX40-positive T cells in advanced head and neck cancer patients treated with anti-programmed death-1 antibody.

    Hirofumi Ohmura, Kyoko Yamaguchi, Fumiyasu Hanamura, Tanoue Kenrou, Shiho Kawagoe, Kohei Arimizu, Yuzo Matsushita, Tatsuhiro Kajitani, Shingo Tamura, Hozumi Shimokawa, Keita Uchino, Hisanobu Oda, Yudai Shinohara, Mamoru Ito, Kenji Tsuchihashi, Taichi Isobe, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Journal of Clinical Oncology   38 ( 5_suppl )   35 - 35   2020年2月

     詳細を見る

    記述言語:その他   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1200/jco.2020.38.5_suppl.35

  • Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition 査読

    Saori Mishima, Hiroya Taniguchi, Kiwamu Akagi, Eishi Baba, Yutaka Fujiwara, Akira Hirasawa, Masafumi Ikeda, Osamu Maeda, Kei Muro, Hiroshi Nishihara, Hiroyki Nishiyama, Tadao Takano, Katsuya Tsuchihara, Yasushi Yatabe, Yasuhiro Kodera, Takayuki Yoshino

    International Journal of Clinical Oncology   25 ( 2 )   217 - 239   2020年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-019-01498-8

  • Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer 査読

    Kyoko Yamaguchi, Mamoru Ito, Hirofumi Ohmura, Fumiyasu Hanamura, Michitaka Nakano, Kenji Tsuchihashi, Shuntaro Nagai, Hiroshi Ariyama, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Masafumi Nakamura, Koichi Akashi, Eishi Baba

    OncoImmunology   9 ( 1 )   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1080/2162402X.2020.1724763

  • Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein–Barr virus-associated gastric cancer 査読

    10 ( 1 )   147 - 157   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Epstein–Barr virus (EBV)-associated gastric cancer (GC) is associated with a high degree of DNA methylation. However, the association between chemotherapy susceptibility and tumor DNA methylation in advanced diseases remains unclear. The comprehensive DNA methylation status of GC cells obtained from an advanced EBV-associated GC (EBVGC) case, in which complete response to S-1 plus cisplatin chemotherapy was achieved, was analyzed using a DNA methylation microarray. We compared DNA methylation of GC cells with public data and identified genes with higher methylation in EBVGC cell lines than in normal gastric cells, and genes in which methylation was increased by EBV. Of these genes, ABCG2, AHNAK2, BCL2, FZD1, and TP73 are associated with published evidence for resistance to 5-fluorouracil and cisplatin. Silencing of these genes may be associated with hypersensitivity to chemotherapy.

    DOI: 10.1002/2211-5463.12765

  • Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer 査読 国際誌

    Shiho Kawagoe, Masahiro Nakano, Keita Uchino, Kohei Arimizu, Tatsuhiro Kajitani, Hozumi Shimokawa, Tetsuya Kusumoto, Koji Ikejiri, Eishi Baba

    Molecular and Clinical Oncology   11 ( 3 )   243 - 251   2019年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mco.2019.1894

  • Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients 査読

    Kotoe Takayoshi, Hitoshi Kusaba, Tomomi Aikawa, Sakuya Koreishi, Kosuke Sagara, Michitaka Nakano, Masato Komoda, Mihoko Kono, Mitsuhiro Fukata, Takeshi Arita, Taito Esaki, Koichi Akashi, Eishi Baba

    Gastric Cancer   22 ( 5 )   988 - 998   2019年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10120-019-00930-2

  • Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer 査読

    Tomoyasu Yoshihiro, Hitoshi Kusaba, Akitaka Makiyama, Kazuma Kobayashi, Masato Uenomachi, Mamoru Ito, Yasuhiro Doi, Kenji Mitsugi, Tomomi Aikawa, Kotoe Takayoshi, Taito Esaki, Hozumi Shimokawa, Kenji Tsuchihashi, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    International Journal of Clinical Oncology   24 ( 5 )   508 - 515   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-018-01391-w

  • aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer 査読

    Yoshihiko Fujita, Masataka Taguri, Kentaro Yamazaki, Junji Tsurutani, Kazuko Sakai, Takahiro Tsushima, Michitaka Nagase, Hiroshi Tamagawa, Shinya Ueda, Takao Tamura, Yasushi Tsuji, Kohei Murata, Koichi Taira, Tadamichi Denda, Toshikazu Moriwaki, Sadao Funai, Takako Eguchi Nakajima, Kei Muro, Akihito Tsuji, Motoki Yoshida, Koichi Suyama, Takuya Kurimoto, Naotoshi Sugimoto, Eishi Baba, Nobuhiko Seki, Mikio Sato, Takaya Shimura, Narikazu Boku, Ichinosuke Hyodo, Takeharu Yamanaka, Kazuto Nishio

    Oncologist   24 ( 3 )   327 - 337   2019年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1634/theoncologist.2018-0119

  • Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer 査読

    Michitaka Nakano, Yoshikane Kikushige, Kohta Miyawaki, Yuya Kunisaki, Shinichi Mizuno, Katsuto Takenaka, Shingo Tamura, Yuta Okumura, Mamoru Ito, Hiroshi Ariyama, Hitoshi Kusaba, Masafumi Nakamura, Takahiro Maeda, Eishi Baba, Koichi Akashi

    Oncogene   38 ( 6 )   780 - 793   2019年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/s41388-018-0480-0

  • Activation of central/effector memory T cells in advanced gastric cancer patients treated with antiprogrammed death-1 antibody.

    Hirofumi Ohmura, Kyoko Yamaguchi, Fumiyasu Hanamura, Mamoru Ito, Akitaka Makiyama, Keita Uchino, Hozumi Shimokawa, Taito Esaki, Kenji Mitsugi, Yoshihiro Shibata, Hisanobu Oda, Kenji Tsuchihashi, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Journal of Clinical Oncology   37 ( 4_suppl )   54 - 54   2019年2月

     詳細を見る

    記述言語:その他   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1200/jco.2019.37.4_suppl.54

  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

    30 ( 1 )   19 - 33   2019年1月

     詳細を見る

    記述言語:その他   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/annonc/mdy502

  • Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS 査読 国際誌

    K. Muro, F. Lordick, T. Tsushima, G. Pentheroudakis, E. Baba, Z. Lu, B. C. Cho, I. M. Nor, M. Ng, L. T. Chen, K. Kato, J. Li, M. H. Ryu, W. I. Wan Zamaniah, W. P. Yong, K. H. Yeh, T. E. Nakajima, K. Shitara, H. Kawakami, Y. Narita, T. Yoshino, E. Van Cutsem, E. Martinelli, E. C. Smyth, D. Arnold, H. Minami, J. Tabernero, J. Y. Douillard

    Annals of Oncology   30 ( 1 )   34 - 43   2019年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/annonc/mdy498

  • Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. 査読 国際誌

    Kentaro Suina, Kenji Tsuchihashi, Juntaro Yamasaki, Shohei Kamenori, Subaru Shintani, Yuki Hirata, Shogo Okazaki, Oltea Sampetrean, Eishi Baba, Koichi Akashi, Yoichiro Mitsuishi, Fumiyuki Takahashi, Kazuhisa Takahashi, Hideyuki Saya, Osamu Nagano

    Cancer science   109 ( 12 )   3874 - 3882   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13826

  • Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. 査読 国際誌

    Kenji Tsuchihashi, Mamoru Ito, Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Akitaka Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Kenji Katsumata, Toshiaki Ishikawa, Tomomi Kashiwada, Eiji Oki, Yoshito Komatsu, Hiroyuki Okuyama, Daisuke Sakai, Hideki Ueno, Takao Tamura, Kimihiro Yamashita, Junji Kishimoto, Yasuhiro Shimada, Eishi Baba

    Clinical colorectal cancer   17 ( 4 )   e687-e697 - e697   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.clcc.2018.07.004

  • Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer. 査読 国際誌

    Michitaka Nakano, Mamoru Ito, Risa Tanaka, Hiroshi Ariyama, Kenji Mitsugi, Akitaka Makiyama, Keita Uchino, Taito Esaki, Nobuhiro Tsuruta, Fumiyasu Hanamura, Kyoko Yamaguchi, Yuta Okumura, Kosuke Sagara, Kotoe Takayoshi, Kenta Nio, Kenji Tsuchihashi, Shingo Tamura, Hozumi Shimokawa, Shuji Arita, Kohta Miyawaki, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Cancer science   109 ( 11 )   3461 - 3470   2018年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cas.13777

  • Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. 査読 国際誌

    Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota SI, Wada N, Uchi H, Ariyama H, Kusaba H, Niiro H, Akashi K, Baba E

    Cancer science   109 ( 10 )   3032 - 3042   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.
    Human anti-programmed death-1 (PD-1) antibody possesses the capability to revitalize host T cells and has been an effective therapy for metastatic malignant melanoma (MM). The precise subsets of T cells predominantly activated by anti-PD-1, however, have not yet been clarified. In this study, peripheral blood mononuclear cells obtained from MM patients scheduled to receive anti-PD-1 (nivolumab) therapy, and healthy subjects (HS), were systematically examined on flow cytometry to identify changes in the proportion of immune cell subsets. Compared with HS, MM patients prior to therapy had an increased proportion of activated CD8+ T cells with effector memory phenotypes (Tem), and PD-1 positive subsets of CD4+ central memory T cells (Tcm) and T-helper (Th)17 cells. After a single course of anti-PD-1 therapy, MM patients had an increase in activated Tem and Tcm subsets of CD4+ and CD8+ T cells, and activated Th1 plus T-helper follicular 1 cells. There was no consistent change in the proportion of Tfh cells, B cells, natural killer cells, or dendritic cells. The observed activated phenotypes were attenuated during the course of therapy, but regulatory T cells belonging to the CD3+CD4+CD45RO+CD25high fraction increased at disease progression. Taken together, anti-PD-1 therapy modulates systemic immune reactions and exerts anti-tumor effects, not only by revitalizing Tem and Tcm of CD4+ and CD8+ T cells, but also via a shift to a Th1 phenotype.

    DOI: 10.1111/cas.13758

  • The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. 査読 国際誌

    Kyoko Yamaguchi, Hitoshi Kusaba, Akitaka Makiyama, Kenji Mitsugi, Keita Uchino, Shingo Tamura, Yoshihiro Shibata, Taito Esaki, Mamoru Ito, Kotoe Takayoshi, Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    Cancer chemotherapy and pharmacology   82 ( 4 )   625 - 633   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00280-018-3652-2

  • Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC) WJOG9216G 査読

    Y. Kito, T. Yamada, T. Matsumoto, H. Yasui, K. Murata, A. Makiyama, H. Hara, E. Baba, K. Nishio, K. Yoshimura, S. Hironaka, K. Muro, K. Yamazaki

    Annals of oncology : official journal of the European Society for Medical Oncology   29   viii201   2018年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/annonc/mdy281.151

  • Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (CLM) A post hoc analysis of the WJOG4407G phase III study 査読

    A. Hosokawa, K. Yamazaki, C. Matsuda, S. Ueda, H. Fujii, E. Baba, S. Okamura, M. Tsuda, T. Tamura, K. Shinozaki, T. Tsushima, T. Tsuda, T. Shirakawa, H. Yamashita, S. Morita, K. Muro

    Annals of oncology : official journal of the European Society for Medical Oncology   29   viii171   2018年10月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/annonc/mdy281.058

  • Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report. 査読 国際誌

    Tsuchihashi K, Arita S, Fujiwara M, Iwasaki K, Hirano A, Yoshihiro T, Nio K, Koga Y, Esaki M, Ariyama H, Kusaba H, Moriyama T, Ohuchida K, Nagai E, Nakamura M, Oda Y, Akashi K, Baba E

    Medicine   97 ( 41 )   e12796   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report.
    RATIONALE: Esophageal carcinosarcoma generally comprises 2 histological components: squamous cell carcinoma (SqCC) and sarcoma. Esophageal carcinosarcoma comprising 3 components is extremely rare and no reports have described therapeutic effects for this disease with metastasis. PATIENT CONCERNS: A 76-year-old man with dysphagia presented to a local clinic. Gastrointestinal endoscopy revealed a polypoid tumor in the middle esophagus and he was referred to our hospital. DIAGNOSIS AND INTERVENTIONS: Thoracoscopic esophagectomy with super-extended (D3) nodal dissection and gastric tube reconstitution was performed, which resulted in carcinosarcoma comprising neuroendocrine carcinoma (NEC), SqCC, and sarcoma. Pathological stage was T1bN1M0 stage IIB according to the TNM Classification of Malignant Tumors-7th edition. The NEC component was observed in lymph node. At 47 days after surgery, lymph nodes, liver, and bone metastasis appeared, and tumor markers such as ProGRP and NSE were elevated. Combination chemotherapy with cisplatin and etoposide (EP) adapted to NEC was performed. OUTCOMES: The patient showed complete response within 4 cycles of chemotherapy. However, the disease recurred 5.5 months after the final course of EP chemotherapy. LESSONS: A therapeutic strategy based on assessment of which component caused metastasis might be important for metastatic carcinosarcoma comprising 3 components, although more accumulation of data about the efficacy of chemotherapy is necessary. Moreover, elucidation of the mechanisms underlying generation of carcinosarcoma is expected in the future.

    DOI: 10.1097/MD.0000000000012796

  • PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer. 査読 国際誌

    Nakano M, Ito M, Tanaka R, Yamaguchi K, Ariyama H, Mitsugi K, Yoshihiro T, Ohmura H, Tsuruta N, Hanamura F, Sagara K, Okumura Y, Nio K, Tsuchihashi K, Arita S, Kusaba H, Akashi K, Baba E

    Cancer science   109 ( 9 )   2986 - 2992   2018年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer.
    The liquid biopsy of ascites fluid could be an excellent source of tumor and microenvironment for the study of prognostic biomarkers because of its accessibility. Tumor-infiltrating lymphocytes (TILs) can predict prognosis in multiple malignancies, including the response to immune checkpoint inhibitors, a breakthrough cancer therapy. However, TILs' profiles from malignant ascites have not been extensively studied. Using flow cytometric analysis, we quantified the proportion of exhausted T cells and memory/naive/effector T-cell subsets, among the CD4+ and CD8+ T-cell populations of paired TILs and peripheral blood T cell samples (n = 22). The correlation between CD4+ and CD8+ subset profiles suggested that the combined analysis of CD4+ and CD8+ cells in malignant ascites was clinically significant. We found that cells positive for the exhaustion markers programmed cell death-1 (PD-1), and T-cell immunoglobulin and mucin domain 3 (TIM-3), and cells coexpressing PD-1 and TIM-3 abundantly exist among malignant ascites TILs. Furthermore, patients with high frequency of PD-1+ TIM-3+ cells among the CD4+ and CD8+ T-cell population showed worse clinical outcome in multivariate analysis (n = 27). We propose that exhausted ascites TILs represent a clinically significant prognostic biomarker in advanced gastrointestinal cancer and represent an important target for immune checkpoint inhibitors.

    DOI: 10.1111/cas.13723

  • E‑cadherin regulates proliferation of colorectal cancer stem cells through NANOG. 査読 国際誌

    40 ( 2 )   693 - 703   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/or.2018.6464

  • A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy. 査読 国際誌

    Hozumi Kumagai, Hitoshi Kusaba, Takeharu Yamanaka, Kenta Nio, Kyoko Inadomi, Kotoe Takayoshi, Mamoru Ito, Shingo Tamura, Akitaka Makiyama, Chinatsu Makiyama, Gen Hirano, Yoshihiro Shibata, Tsuyoshi Shirakawa, Kenji Mitsugi, Hiroshi Ariyama, Taito Esaki, Koichi Akashi, Eishi Baba

    Medicine   97 ( 25 )   e11042   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000011042

  • Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case report 査読 国際誌

    Kotoe Takayoshi, Goro Doi, Nobuhiro Tsuruta, Tomoyasu Yoshihiro, Kenta Nio, Kenji Tsuchihashi, Hiroshi Ariyama, Jun Odawara, Shinji Shimoda, Kenichi Kohashi, Yoshinao Oda, Shinji Itoh, Norifumi Harimoto, Yoshihiko Maehara, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Medicine (United States)   97 ( 15 )   e0378   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000010378

  • Chemotherapy in cancer patients undergoing haemodialysis A nationwide study in Japan 査読

    Taro Funakoshi, Takahiro Horimatsu, Michio Nakamura, Koichi Shiroshita, Koichi Suyama, Masashi Mukoyama, Takuro Mizukami, Tsutomu Sakurada, Eishi Baba, Kazuhiko Tsuruya, Akira Nozaki, Kensei Yahata, Yukinori Ozaki, Yoshifumi Ubara, Hisateru Yasui, Akihiro Yoshimoto, Shingo Fukuma, Naoya Kondo, Takeshi Matsubara, Kazuo Matsubara, Shunichi Fukuhara, Motoko Yanagita, Manabu Muto

    ESMO Open   3 ( 2 )   2018年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1136/esmoopen-2017-000301

  • First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study 査読

    Akitaka Makiyama, Kenji Kunieda, Masaaki Noguchi, Takeshi Kajiwara, Takao Tamura, Koji Takeda, Junko Sugiyama, Keiko Minashi, Toshikazu Moriwaki, Naotoshi Sugimoto, Michitaka Nagase, Yuji Negoro, Takashi Tsuda, Hideki Shimodaira, Naohiro Okano, Akihito Tsuji, Daisuke Sakai, Kazuhiro Yanagihara, Shinya Ueda, Shingo Tamura, Satoshi Otsu, Takuya Honda, Yuzo Matsushita, Tatsuya Okuno, Tomomi Kashiwada, Akira Nozaki, Masahide Ebi, Hiroyuki Okuda, Mototsugu Shimokawa, Shuichi Hironaka, Ichinosuke Hyodo, Eishi Baba, Narikazu Boku, Kei Muro, Taito Esaki

    Gastric Cancer   21 ( 5 )   1 - 10   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10120-018-0797-y

  • Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. 査読 国際誌

    18 ( 1 )   57 - 57   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Oxaliplatin + S-1 is a recognized treatment regimen in Japan, but there are no Japanese clinical data on an oxaliplatin dose of 130 mg/m2. The current research involves a single-arm, prospective, phase II clinical trial to examine the efficacy and safety of oxaliplatin + S-1 with an oxaliplatin dose of 130 mg/m2 to treat HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy in Japan. METHODS/DESIGN: The primary endpoint of this trial will be the response rate, and the secondary endpoints will be the safety profile of oxaliplatin + S-1, progression-free survival, the response rate in subjects under the age of 75, overall survival, time to treatment failure, duration of treatment, time to failure of strategy, and dose intensity. The threshold response rate is 45&#37; and the expected response rate is 60&#37;. Assuming that a one-tailed score test will be performed with an α of 0.05, 68 patients are needed to ensure a statistical power of 80&#37;. Planned enrollment is 70 subjects and the total duration of this trial is expected to be 3 years. DISCUSSION: Since replacing cisplatin with oxaliplatin should provide the same level of therapeutic efficacy while limiting adverse events and simplifying treatment, oxaliplatin + S-1 may be increasingly used to treat gastric cancer in Japan. Verifying the efficacy and safety of oxaliplatin + S-1 with an oxaliplatin dose of 130 mg is an important task that the current trial has set out to achieve. TRIAL REGISTRATION: The protocol was registered at the website of the University Hospital Medical Information Network (UMIN), Japan (protocol ID UMIN000017550) on May 29, 2015. The details are available at the following web address: http://www.umin.ac.jp/ctr/ .

    DOI: 10.1186/s12885-017-3937-6

  • Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. 国際誌

    Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yusuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Chinatsu Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Masahiko Sugiyama, Yoshito Komatsu, Hiroyuki Okuyama, Eishi Baba, Daisuke Sakai, Tomoki Watanabe, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Yasuhiro Shimada

    The oncologist   23 ( 1 )   7 - 15   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1634/theoncologist.2017-0275

  • Alkaline Phosphatase-Catalyzed Amplification of a Fluorescence Signal for Flow Cytometry. 査読 国際誌

    Takanobu Nobori, Kenta Tosaka, Akira Kawamura, Taisei Joichi, Kenta Kamino, Akihiro Kishimura, Eishi Baba, Takeshi Mori, Yoshiki Katayama

    Analytical chemistry   90 ( 2 )   1059 - 1062   2018年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1021/acs.analchem.7b03893

  • Metastatic esophageal cancer presenting as shock by injury of vagus nerve mimicking baroreceptor reflex: A case report 査読 国際誌

    Kenji Tsuchihashi, Tomoyasu Yoshihiro, Tomomi Aikawa, Kenta Nio, Kotoe Takayoshi, Taku Yokoyama, Mitsuhiro Fukata, Shuji Arita, Hiroshi Ariyama, Yukiko Shimizu, Yuichiro Yoshida, Takehiro Torisu, Motohiro Esaki, Keita Odashiro, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Medicine (United States)   96 ( 49 )   e8987   2017年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000008987

  • Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer 査読 国際誌

    Tatsuhiro Kajitani, Akitaka Makiyama, Shuji Arita, Hozumi Shimokawa, Hisanobu Oda, Tsuyoshi Shirakawa, Eishi Baba, Taito Esaki

    ANTICANCER RESEARCH   37 ( 11 )   6459 - 6468   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.12101

  • Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer 査読 国際誌

    Mamoru Ito, Hitoshi Kusaba, Satomi Mukaide, Junji Kishimoto, Hozumi Shimokawa, Shingo Tamura, Akitaka Makiyama, Gen Hirano, Hisanobu Oda, Tsuyoshi Shirakawa, Masato Komoda, Keita Uchino, Risa Tanaka, Kenji Mitsugi, Taito Esaki, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    ANTI-CANCER DRUGS   28 ( 10 )   1166 - 1173   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/CAD.0000000000000562

  • Lingual alveolar soft part sarcoma responsive to pazopanib: A case report 査読 国際誌

    Tomoyasu Yoshihiro, Kenji Tsuchihashi, Kenta Nio, Shuji Arita, Takafumi Nakano, Ryuji Yasumatsu, Rina Jiroumaru, Hiroshi Ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba

    MEDICINE   96 ( 44 )   e8470   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000008470

  • A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma 査読

    Takahiro Horimatsu, Norisuke Nakayama, Toshikazu Moriwaki, Yoshinori Hirashima, Mikio Fujita, Masako Asayama, Ichiro Moriyama, Koji Nakashima, Eishi Baba, Hiroshi Kitamura, Takao Tamura, Ayumu Hosokawa, Kenichi Yoshimura, Manabu Muto

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   22 ( 5 )   905 - 912   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10147-017-1138-6

  • Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report 査読 国際誌

    Kenji Tsuchihashi, Hozumi Shimokawa, Kotoe Takayoshi, Kenta Nio, Tomomi Aikawa, Yuzo Matsushita, Iori Wada, Shuji Arita, Hiroshi Ariyama, Hitoshi Kusaba, Koh-Hei Sonoda, Koichi Akashi, Eishi Baba

    MEDICINE   96 ( 42 )   e8285   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000008285

  • A retrospective analysis for thromboembolic events associated with multikinase inhibitors

    Kenta Nio, Kenji Tsuchihashi, Hitoshi Kusaba, Tomoyasu Yoshihiro, Shuji Arita, Hiroshi Ariyama, Takeshi Arita, Keita Odashiro, Koichi Akashi, Eishi Baba

    ANNALS OF ONCOLOGY   28   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(その他学術会議資料等)  

  • Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer 査読

    Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Oda H, Esaki T, Akashi K, Baba E

    Gastric Cancer   21 ( 3 )   464 - 472   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    BACKGROUND: Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. METHODS: Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. RESULTS: A total of 146 patients had prior fluoropyrimidine and taxane therapies, and 75.3&#37; had prior platinum therapy. The median age was 66 (range 27-81) years, and 102 males (69.9&#37;) were included. Performance status (PS) was 0/1/2/3 in 53/70/19/4 patients. Eighty-nine patients (61.0&#37;) had two or more metastatic sites. Irinotecan monotherapy as 3rd-/4th-line therapy was performed in 135/11 (92.5&#37;/7.5&#37;). The median number of administrations was 4 (range 1-62). Forty-six patients (31.5&#37;) required initial dose reduction at the physician's discretion. The overall response rate was 6.8&#37;, and the disease control rate was 43.1&#37;. The median PFS was 3.19 months [95&#37; confidence interval (CI) 2.30-4.08 months], and the median OS was 6.61 months (95&#37; CI 5.94-7.28 months). Grade 3/4 adverse events were hematological toxicity (46 patients, 31.5&#37;) and non-hematological toxicity (50 patients, 34.2&#37;). Hospitalization due to adverse events was required in 31 patients (21.2&#37;). Patients with relative dose intensity (RDI) less than 80&#37; showed similar survival to those with RDI 80&#37; or higher. CONCLUSIONS: Irinotecan monotherapy was relatively safely performed as salvage-line treatment for AGC in Japanese clinical practice. Careful patient selection and intensive modification of the dose of irinotecan might possibly be associated with favorable survival.

    DOI: 10.1007/s10120-017-0759-9.

  • Analysis of a Questionnaire Survey regarding Current Conditions against Exposure to Anticancer Drugs and Reports of Cancer Chemotherapy at Outpatient Departments in Japan 査読

    Tsuyoshi Shirakawa, Tomoko Hara, Kojiro Hata, Kimitaka Suetsugu, Hideki Kakimoto, Kentaro Ogata, Yousuke Ikari, Hidenori Sasaki, Makoto Takahashi, Masaru Fukahori, Miyuki Uoi, Taito Esaki, Mikako Hiraike, Toshinobu Hayashi, Akira Tokunaga, Norio Ureshino, Tsuneo Kuwamura, Hitoshi Kusaba, Kenji Mitsugi, Eishi Baba

    Pharmacology & Pharmacy   140 - 152   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Analysis of a Questionnaire Survey regarding Current Conditions against Exposure to Anticancer Drugs and Reports of Cancer Chemotherapy at Outpatient Departments in Japan

  • Systemic chemotherapy with pronounced efficacy and neutropenia in a granulocyte-colony stimulating factor-producing advanced gastric neuroendocrine carcinoma 査読 国際誌

    Nobuhiro Tsuruta, Kotoe Takayoshi, Shuji Arita, Tomomi Aikawa, Hiroshi Ariyama, Hitoshi Kusaba, Kenoki Ohuchida, Eishi Nagai, Kenichi Kohashi, Minako Hirahashi, Kyoko Inadomi, Mamoru Tanaka, Kosuke Sagara, Yuta Okumura, Kenta Nio, Michitaka Nakano, Masafumi Nakamura, Yoshinao Oda, Koichi Akashi, Eishi Baba

    ONCOLOGY LETTERS   14 ( 2 )   1500 - 1504   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/ol.2017.6299

  • Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer 査読 国際誌

    Kotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, Kenji Mitsugi, Chinatsu Makiyama, Akitaka Makiyama, Keita Uchino, Tsuyoshi Shirakawa, Yoshihiro Shibata, Yudai Shinohara, Kyoko Inadomi, Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Taito Esaki, Koichi Akashi, Eishi Baba

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   80 ( 2 )   333 - 342   2017年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00280-017-3371-0

  • xCT promotes malignant phenotypes in EGFR-expressing glioma 査読

    Tsuchihashi Kenji, Okazaki Shogo, Yoshikawa Momoko, Seishima Ryo, Sampetrean Oltea, Onishi Nobuyuki, Wakimoto Hiroaki, Furnari Frank, Baba Eishi, Akashi Koichi, Saya Hideyuki, Nagano Osamu

    CANCER RESEARCH   77   2017年7月

     詳細を見る

    記述言語:英語  

    xCT promotes malignant phenotypes in EGFR-expressing glioma

    DOI: 10.1158/1538-7445.AM2017-LB-334

  • Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer 査読 国際誌

    Noriko Hidaka, Eiji Iwama, Naoki Kubo, Taishi Harada, Kohta Miyawaki, Kentaro Tanaka, Isamu Okamoto, Eishi Baba, Koichi Akashi, Hiroyuki Sasaki, Yoichi Nakanishi

    LUNG CANCER   108   75 - 82   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.lungcan.2017.02.019

  • Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report. 国際誌

    Tomoyasu Yoshihiro, Kenta Nio, Kenji Tsuchihashi, Hiroshi Ariyama, Kenichi Kohashi, Nobuhiro Tsuruta, Fumiyasu Hanamura, Kyoko Inadomi, Mamoru Ito, Kosuke Sagara, Yuta Okumura, Michitaka Nakano, Shuji Arita, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba

    Molecular and clinical oncology   6 ( 6 )   866 - 870   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mco.2017.1240

  • Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer 査読 国際誌

    Kyoko Inadomi, Hitoshi Kusaba, Yuzo Matsushita, Risa Tanaka, Kenji Mitsugi, Kohei Arimizu, Gen Hirano, Akitaka Makiyama, Hirofumi Ohmura, Keita Uchino, Fumiyasu Hanamura, Yoshihiro Shibata, Miyuki Kuwayama, Taito Esaki, Kotoe Takayoshi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    ANTICANCER RESEARCH   37 ( 5 )   2663 - 2671   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.21873/anticanres.11614

  • Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. 国際誌

    Hirofumi Ohmura, Keita Uchino, Tatsuhiro Kajitani, Naotaka Sakamoto, Eishi Baba

    Molecular and clinical oncology   6 ( 5 )   669 - 675   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mco.2017.1205

  • Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. 国際誌

    Hirofumi Ohmura, Keita Uchino, Tatsuhiro Kajitani, Naotaka Sakamoto, Eishi Baba

    Molecular and clinical oncology   6 ( 5 )   669 - 675   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/mco.2017.1205

  • A phase II study of 5-FU/l-LV/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. 査読

    Horimatsu T, Nakayama N, Moriwaki T, Hirashima Y, Fujita M, Asayama M, Moriyama I, Nakashima K, Baba E, Kitamura H, Tamura T, Hosokawa A, Yoshimura K, Muto M

    Int J Clin Oncol   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A phase II study of 5-FU/l-LV/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.

    DOI: 10.1007/s10147-017-1138-6.

  • Weight Loss During Initial Chemotherapy Predicts Survival in Patients With Advanced Gastric Cancer 査読

    Kotoe Takayoshi, Keita Uchino, Masahiro Nakano, Koji Ikejiri, Eishi Baba

    Nutrition and Cancer   69 ( 3 )   408 - 415   2017年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1080/01635581.2017.1267774

  • Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy 査読 国際誌

    Hitoshi Kusaba, Hozumi Kumagai, Kyoko Inadomi, Tomoya Matsunobu, Katsumi Harimaya, Kotoe Takayoshi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    MEDICINE   95 ( 49 )   e5460   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000005460

  • Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report. 査読 国際誌

    Hanamura F, Shibata Y, Shirakawa T, Kuwayama M, Oda H, Ariyama H, Taguchi K, Esaki T, Baba E

    Molecular and clinical oncology   5 ( 5 )   579 - 582   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report.
    Colorectal cancer (CRC) has a propensity to metastasize to the liver, lungs and regional abdominal lymph nodes, but rarely to the bone marrow. A 60-year-old man presented to the National Hospital Organization Kyushu Cancer Center with a 4-week history of persistent lower back pain, anorexia and difficulty defecating. Complete blood count revealed severe thrombocytopenia and erythroblastosis, suggesting a hematological malignancy. However, the bone marrow examination demonstrated involvement by a moderately to poorly differentiated adenocarcinoma, but no hematopoietic abnormalities. A computed tomography scan revealed thickening of the wall of the sigmoid colon, with para-aortic, hilar, mediastinal and supraclavicular lymphadenopathy. The patient was thus diagnosed with sigmoid colon adenocarcinoma with lymph node and bone marrow metastasis. Modified FOLFOX6 was promptly initiated, with concurrent therapy for disseminated intravascular coagulation (DIC). An increased number of thrombocytes was observed on day 6. After 3 cycles of treatment, the patient recovered from DIC and the levels of serum carcinoembryonic antigen and cytokeratin 19 fragment were decreased. Tumor biopsy during colonoscopy following recovery from DIC demonstrated poorly differentiated adenocarcinoma with mucin production, without mutations in the RAS, BRAF or PIK3CA genes, and a cytokeratin (CK) 7-negative, CK20-positive phenotype. The patient has been treated with chemotherapy for 150 days without disease progression. However, the efficacy of chemotherapy for rarely encountered bone marrow metastasis from CRC is poor. The present case was favorably maintained on chemotherapy and survived for 10 months.

    DOI: 10.3892/mco.2016.1029

  • Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients 査読 国際誌

    Tsuyoshi Shirakawa, Michitaka Nakano, Kenta Nio, Shingo Tamura, Masato Komoda, Hozumi Kumagai, Keita Uchino, Keita Odashiro, Shuji Arita, Yoshihiro Shibata, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    ANTI-CANCER DRUGS   27 ( 9 )   891 - 898   2016年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/CAD.0000000000000392

  • Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae. 査読 国際誌

    Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   11 ( 9 )   1586 - 90   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae.
    INTRODUCTION: Emphysema is thought to be a risk factor for lung cancer in smokers, with emphysematous bullae (EBs), which are believed to have the potential to give rise to lung cancer. The clinical characteristics of patients with lung cancer with EBs have remained incompletely defined, however. METHODS: A total of 488 patients with primary lung cancer with or without EBs as detected by computed tomography were studied retrospectively, and the regional relationship between EBs and the primary cancer was evaluated. RESULTS: EBs were detected in 45 of the 488 patients with lung cancer (9.2&#37;) (in 45 of 339 smokers [13.3&#37;] versus in 0 of 149 never-smokers [0&#37;]). The frequency of lung cancer in an upper lobe was significantly higher in smokers with EBs than in those without EBs (71.1&#37; versus 47.3&#37;, p = 0.0107). The lobar site of primary lung cancer in smokers with EBs was significantly associated with that of the EBs (p < 0.0001). Most primary lung cancers (86.7&#37;) in such patients were found in the area adjoining EBs. Smoking patients with lung cancer with EBs were significantly younger (63.6 versus 67.7 years, p = 0.0179) and had tumors with a lower frequency of epidermal growth factor gene (EGFR) mutations (3.8&#37; versus 24.2&#37;, p = 0.0184) compared with those without EBs. CONCLUSIONS: The clinical characteristics of smoking patients with lung cancer differ according to the absence or presence of EBs, with patients with EBs being potentially more susceptible to the carcinogenic effects of cigarette smoke. Further analysis of genetic alterations is warranted to elucidate the mechanism of carcinogenesis for lung cancer associated with EBs.

    DOI: 10.1016/j.jtho.2016.04.024

  • Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). 国際誌

    K Yamazaki, M Nagase, H Tamagawa, S Ueda, T Tamura, K Murata, T Eguchi Nakajima, E Baba, M Tsuda, T Moriwaki, T Esaki, Y Tsuji, K Muro, K Taira, T Denda, S Funai, K Shinozaki, H Yamashita, N Sugimoto, T Okuno, T Nishina, M Umeki, T Kurimoto, T Takayama, A Tsuji, M Yoshida, A Hosokawa, Y Shibata, K Suyama, M Okabe, K Suzuki, N Seki, K Kawakami, M Sato, K Fujikawa, T Hirashima, T Shimura, K Taku, T Otsuji, F Tamura, E Shinozaki, K Nakashima, H Hara, T Tsushima, M Ando, S Morita, N Boku, I Hyodo

    Annals of oncology : official journal of the European Society for Medical Oncology   27 ( 8 )   1539 - 46   2016年8月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/annonc/mdw206

  • Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus A case report 査読 国際誌

    Kyoko Inadomi, Hozumi Kumagai, Shuji Arita, Nobuhiro Tsuruta, Kotoe Takayoshi, Koji Mishima, Shun-Ichiro Ota, Mamoru Tanaka, Yuta Okumura, Kosuke Sagara, Kenta Nio, Michitaka Nakano, Hiroshi Uchi, Hidetaka Yamamoto, Hiroshi Ariyama, Hitoshi Kusaba, Hiroaki Niiro, Yoshinao Oda, Koichi Akashi, Eishi Baba

    MEDICINE   95 ( 29 )   e4283   2016年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MD.0000000000004283

  • Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan. 査読 国際誌

    Nio K, Higashi D, Kumagai H, Arita S, Shirakawa T, Nakashima K, Shibata Y, Esaki M, Manabe T, Nagai S, Ueki T, Nakano M, Ariyama H, Kusaba H, Hirahashi M, Oda Y, Esaki T, Mitsugi K, Futami K, Akashi K, Baba E

    Anti-cancer drugs   27 ( 5 )   457 - 463   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Efficacy and safety analysis of chemotherapy for advanced colitis-associated colorectal cancer in Japan.
    Chemotherapy for advanced colitis-associated colorectal cancer (CAC) has been insufficiently evaluated. The goal of this study was to clarify the efficacy and safety of chemotherapy for CAC in Japan. CAC patients who were treated with chemotherapy between 2005 and 2015 were retrospectively examined. Twenty-nine patients (median age, 48 years; 23 men) were assessed. Eighteen patients had ulcerative colitis, and 11 had Crohn's disease. Three ulcerative colitis and four Crohn's disease patients were in the active disease phase. Primary tumors were located in the rectum/anus (n=16), the left colon (n=9), or the right colon (n=4). Palliative or adjuvant chemotherapy was performed in 13 and 16 patients, respectively. First-line palliative chemotherapy regimens were as follows: fluorouracil, leucovorin, and oxaliplatin (FOLFOX; n=6), FOLFOX+bevacizumab (n=3), and others (n=4). Adjuvant chemotherapy regimens were S-1 (n=7), oxaliplatin-based (n=4) and others (n=5). In palliative chemotherapy, the objective response rate was 15&#37;, and the median progression-free survival and overall survival were 182 and 315 days, respectively. In adjuvant chemotherapy, the 5-year relapse-free survival rate was 78&#37;. Grade 3/4 adverse events (AEs) were observed in 16 patients (55&#37;). Active and remission inflammatory bowel disease patients suffered grade 3/4 nonhematological AEs at an incidence of 71 and 23&#37;, respectively (P<0.01). Dose reduction was required in 11 patients (38&#37;), eight of whom required it for hematological AEs. Adjuvant chemotherapy for CAC exhibited sufficient efficacy, whereas modest efficacy was shown for palliative chemotherapy for CAC. AEs, particularly nonhematological AEs, were closely associated with disease activity of colitis.

    DOI: 10.1097/CAD.0000000000000338

  • Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors 査読 国際誌

    Mutsunori Murahashi, Yasuki Hijikata, Kazunari Yamada, Yoshihiro Tanaka, Junji Kishimoto, Hiroyuki Inoue, Tomotoshi Marumoto, Atsushi Takahashi, Toshihiko Okazaki, Kazuyoshi Takeda, Masakazu Hirakawa, Hiroshi Fujii, Shinji Okano, Masaru Morita, Eishi Baba, Kazuhiro Mizumoto, Yoshihiko Maehara, Masao Tanaka, Koichi Akashi, Yoichi Nakanishi, Koji Yoshida, Takuya Tsunoda, Kazuo Tamura, Yusuke Nakamura, Kenzaburo Tani

    CLINICAL IMMUNOLOGY   166   48 - 58   2016年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.clim.2016.03.015

  • The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-) 査読 国際誌

    Kenji Tsuchihashi, Shogo Okazaki, Mitsuyo Ohmura, Miyuki Ishikawa, Oltea Sampetrean, Nobuyuki Onishi, Hiroaki Wakimoto, Momoko Yoshikawa, Ryo Seishima, Yoshimi Iwasaki, Takayuki Morikawa, Shinya Abe, Ayumi Takao, Misato Shimizu, Takashi Masuko, Motoo Nagane, Frank B. Furnari, Tetsu Akiyama, Makoto Suematsu, Eishi Baba, Koichi Akashi, Hideyuki Saya, Osamu Nagano

    Cancer Research   76 ( 10 )   2954 - 2963   2016年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/0008-5472.CAN-15-2121

  • Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer. 査読 国際誌

    Arita S, Shirakawa T, Matsushita Y, Shimokawa HK, Hirano G, Makiyama A, Shibata Y, Tamura S, Esaki T, Mitsugi K, Ariyama H, Kusaba H, Akashi K, Baba E

    Anticancer research   36 ( 4 )   1959 - 1966   2016年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
    BACKGROUND: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. PATIENTS AND METHODS: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. RESULTS: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37&#37;) were analyzed. Efficacy was reflected in an objective overall response of 3&#37;, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44&#37;), leukopenia (26&#37;) and anemia (23&#37;). Febrile neutropenia was found in 7&#37;. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. CONCLUSION: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.

  • Immunosuppressant therapy successfully improved regorafenib-induced severe hepatic injury in a patient with metastatic gastrointestinal stromal tumor: A case report 査読 国際誌

    Miyuki Kuwayama, Keita Uchino, Kotoe Takayoshi, Masato Komoda, Motoyuki Kohjima, Makoto Nakamuta, Seiya Momosaki, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    ONCOLOGY LETTERS   11 ( 1 )   85 - 88   2016年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/ol.2015.3853

  • Intraluminal superior vena cava metastasis from adenosquamous carcinoma of the duodenum: A case report 査読 国際誌

    Kotoe Takayoshi, Hiroshi Ariyama, Shingo Tamura, Shunsuke Yoda, Takeshi Arita, Toshihiro Yamaguchi, Keigo Ozono, Hidetaka Yamamoto, Kyoko Inadomi, Hozumi Kumagai, Mamoru Tanaka, Yuta Okumura, Kosuke Sagara, Kenta Nio, Michitaka Nakano, Shuji Arita, Hitoshi Kusaba, Keita Odashiro, Yoshinao Oda, Koichi Akashi, Eishi Baba

    ONCOLOGY LETTERS   11 ( 1 )   605 - 609   2016年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/ol.2015.3938

  • Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report 査読 国際誌

    Kyoko Inadomi, Hozumi Kumagai, Kotoe Takayoshi, Hiroshi Ariyama, Hitoshi Kusaba, Akihiro Nishie, Hidetaka Yamamoto, Ken Takase, Mamoru Tanaka, Kosuke Sagara, Yuta Okumura, Kenta Nio, Michitaka Nakano, Shuji Arita, Yoshinao Oda, Koichi Akashi, Eishi Baba

    ONCOLOGY LETTERS   10 ( 5 )   2981 - 2985   2015年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3892/ol.2015.3708

  • Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: A multicenter, randomized phase III trial (SOS) 査読

    M. H. Ryu, on behalf of the SOS study investigators, E. Baba, K. H. Lee, Y. I. Park, N. Boku, I. Hyodo, B. H. Nam, T. Esaki, C. Yoo, B. Y. Ryoo, E. K. Song, S. H. Cho, W. K. Kang, S. H. Yang, D. Y. Zang, D. B. Shin, S. R. Park, K. Shinozaki, T. Takano, Yoon-Koo Kang

    Annals of Oncology   26 ( 10 )   2097 - 2101   2015年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/annonc/mdv316

  • 大腸がん幹細胞分画におけるE-カドヘリン陽性細胞とE-カドヘリン陰性細胞の病理学的差異についての検討

    田村 真吾, 磯部 大地, 有山 寛, 中野 倫孝, 植木 隆, 高石 繁生, 草場 仁志, 馬場 英司, 赤司 浩一

    日本癌学会総会記事   74回   J - 1124   2015年10月

     詳細を見る

    記述言語:英語  

  • Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR 査読 国際誌

    Eiji Iwama, Koichi Takayama, Taishi Harada, Isamu Okamoto, Fumihiko Ookubo, Junji Kishimoto, Eishi Baba, Yoshinao Oda, Yoichi Nakanishi

    ONCOTARGET   6 ( 24 )   20466 - 20473   2015年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine 査読 国際誌

    Kotoe Takayoshi, Kosuke Sagara, Keita Uchino, Hitoshi Kusaba, Naotaka Sakamoto, Atsushi Iguchi, Eishi Baba

    BMC CANCER   15   426 - 426   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s12885-015-1443-2

  • The fundamental concept of cancer stem cell and the progress in cancer stem cell research 査読

    Eishi Baba, Koichi Akashi

    Nippon rinsho. Japanese journal of clinical medicine   73 ( 5 )   721 - 725   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy. 査読 国際誌

    Nio K, Arita S, Isobe T, Kusaba H, Kohashi K, Kajitani T, Tamura S, Hirano G, Mitsugi K, Makiyama A, Esaki T, Ariyama H, Oda Y, Akashi K, Baba E

    Cancer chemotherapy and pharmacology   75 ( 4 )   829 - 835   2015年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
    Purpose: Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this study was to investigate amrubicin (AMR) monotherapy as a salvage therapy for EPNEC arising from digestive organs. Methods: Patients with EPNEC of the digestive organs who had prior platinum-based chemotherapy and were subsequently treated with AMR between July 2005 and December 2013 at any one of four institutions were retrospectively examined to characterize the safety and efficacy of AMR. Results: Thirteen patients (ten males, three females; median age 64 years) were examined. Primary cancer sites included stomach (n = 6), rectum (n = 3), esophagus (n = 2), liver (n = 1) and pancreas (n = 1). Prior irinotecan- and etoposide-containing chemotherapies were used in ten and six patients, respectively. Median initial dose of AMR was 40 mg/m2/day for three consecutive days, and median of treatment cycles was 4 (range 1-9). The objective response rate (ORR) was 38.5 &#37;. Median progression-free survival (PFS) and overall survival (OS) were 107 (range 22-275) and 215 days (range 71-535), respectively. Common severe adverse events (grade 3/4) were neutropenia (84.6 &#37;) and febrile neutropenia (30.8 &#37;). Patient with longer platinum-free interval (>90 days) exhibited longer PFS and OS than those with shorter platinum-free interval (190 vs. 63 days and 348 vs. 145 days, respectively). Conclusions: AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.

    DOI: 10.1007/s00280-015-2706-y

  • Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. 査読 国際誌

    Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K, Japanese Society of Medical Oncology

    Cancer science   106 ( 3 )   324 - 327   2015年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
    The Japanese guidelines for the testing of KRAS mutations in colorectal cancer have been used for the past 5 years. However, new findings of RAS (KRAS/NRAS) mutations that can further predict the therapeutic effects of anti-epidermal growth factor receptor (EGFR) antibody therapy necessitated a revision of the guidelines. The revised guidelines included the following five basic requirements for RAS mutation testing to highlight a patient group in which anti-EGFR antibody therapy may be ineffective: First, anti-EGFR antibody therapy may not offer survival benefit and/or tumor shrinkage to patients with expanded RAS mutations. Thus, current methods to detect KRAS exon 2 (codons 12 and 13) mutations are insufficient for selecting appropriate candidates for this therapy. Additional testing of extended KRAS/NRAS mutations is recommended. Second, repeated tests are not required for the detection; tissue materials of either primary or metastatic lesions are applicable for RAS mutation testing. Evaluating RAS mutations prior to anti-EGFR antibody therapy is recommended. Third, direct sequencing with manual dissection or allele-specific PCR-based methods is currently applicable for RAS mutation testing. Fourth, thinly sliced sections of formalin-fixed, paraffin-embedded tissue blocks are applicable for RAS mutation testing. One section stained with H&E should be provided to histologically determine whether the tissue contains sufficient amount of tumor cells for testing. Finally, RAS mutation testing must be performed in laboratories with appropriate testing procedures and specimen management practices.

    DOI: 10.1111/cas.12595

  • Anti-vascular endothelial growth factor antibody 査読

    Hozumi Kumagai, Hitoshi Kusaba, Eishi Baba

    Nihon rinsho. Japanese journal of clinical medicine   73   229 - 234   2015年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Platinum drugs 査読

    Hitoshi Kusaba, Eishi Baba

    Nippon rinsho. Japanese journal of clinical medicine   73   143 - 145   2015年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. 査読 国際誌

    Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K, Komoda M, Tanaka R, Matsushita Y, Mitsugi K, Shibata Y, Kumagai H, Arita S, Ariyama H, Kusaba H, Akashi K, Baba E

    Anticancer research   35 ( 1 )   371 - 377   2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    BACKGROUND: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib. PATIENTS AND METHODS: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined. RESULTS: Best objective response rate was 0&#37; and stable disease (SD) was 31&#37;. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53&#37;) patients suffered grade 3 or 4 adverse events including fatigue (13&#37;), anorexia (13&#37;), hand-foot skin reaction (22&#37;) and elevations of alanine aminotransferase/aspartate aminotransferase (19&#37;/16&#37;). One patient with grade 5 liver dysfunction was identified (3&#37;). Twenty-nine (91&#37;) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59&#37;. Regorafenib treatments were terminated because of disease progression (59&#37;) or adverse events (34&#37;). CONCLUSION: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.

  • ESRP1 regulated alternative splicing of CD44mRNA enhances lung colonization of metastatic cancer cell

    Kenji Tsuchihashi, Osamu Nagano, Toshifumi Yae, Takatsugu Ishimoto, Takeshi Motohara, Momoko Yoshikawa, Go J. Yoshida, Takeyuki Wada, Takashi Masuko, Kaoru Mogushi, Hiroshi Tanaka, Tsuyoshi Osawa, Yasuharu Kanki, Takashi Minami, Hiroyuki Aburatani, Mitsuyo Ohmura, Akiko Kubo, Makoto Suematsu, Kazuhisa Takahashi, Eishi Baba, Koichi Akashi, Hideyuki Saya

    CANCER RESEARCH   74 ( 19 )   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(その他学術会議資料等)  

    DOI: 10.1158/1538-7445.AM2014-4967

  • Plasticity of CD44+colorectal cancer stem cells depends on TGF-beta-induced epithelial mesenchymal transition(EMT): Evidences from an ex vivo culture

    Michitaka Nakano, Hiroshi Ariyama, Shingo Tamura, Taichi Isobe, Kohta Miyawaki, Yuta Okumura, Hitoshi Kusaba, Eishi Baba, Koichi Akashi

    CANCER RESEARCH   74 ( 19 )   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(その他学術会議資料等)  

    DOI: 10.1158/1538-7445.AM2014-1947

  • IFOSFAMIDE AND ETOPOSIDE AS A SALVAGE CHEMOTHERAPY FOR SMALL ROUND CELL SARCOMA

    Shingo Tamura, Yuzo Matsushita, Mamoru Tanaka, Hozumi Kumagai, Shuji Arita, Hiroshi Ariyama, Hitoshi Kusaba, Eishi Baba, Koichi Akashi

    ANNALS OF ONCOLOGY   25   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(その他学術会議資料等)  

    DOI: 10.1093/annonc/mdu435.18

  • EXPLORATORY ANALYSIS OF A PROGNOSIS PREDICTIVE MODEL FOR METASTATIC COLORECTAL CANCER TREATED WITH CHEMOTHERAPY

    Mamoru Tanaka, Hozumi Kumagai, Junji Kishimoto, Satomi Mukaide, Hisanobu Oda, Kenji Mitsugi, Akitaka Makiyama, Masato Komoda, Hitoshi Kusaba, Eishi Baba

    ANNALS OF ONCOLOGY   25   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(その他学術会議資料等)  

    DOI: 10.1093/annonc/mdu435.121

  • Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer 査読 国際誌

    Hiroaki Ikesue, Toshikazu Tsuji, Koujiro Hata, Hiroyuki Watanabe, Kazuto Mishima, Mayako Uchida, Nobuaki Egashira, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Koichi Takayama, Yoichi Nakanishi, Eriko Tokunaga, Tatsuro Okamoto, Yoshihiko Maehara, Akira Yokomizo, Seiji Naito, Makoto Kubo, Masao Tanaka, Satohiro Masuda

    ANNALS OF PHARMACOTHERAPY   48 ( 9 )   1159 - 1165   2014年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1177/1060028014539919

  • TGF-B刺激によるEMTを介したCD44陽性大腸がん幹細胞の可塑性 ex vivo培養システムに基づく検討(Plasticity of CD44+ colorectal cancer stem cells depends on TGF-beta-induced epithelial mesenchymal transition (EMT))

    中野 倫孝, 有山 寛, 奥村 祐太, 田村 真吾, 磯部 大地, 宮脇 恒太, 草場 仁志, 植木 隆, 馬場 英司, 赤司 浩一

    日本癌学会総会記事   73回   J - 1093   2014年9月

     詳細を見る

    記述言語:英語  

  • Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: A case report 査読 国際誌

    Kosuke Sagara, Kotoe Takayoshi, Eiji Kusumoto, Keita Uchino, Taisei Matsumura, Hitoshi Kusaba, Seiya Momosaki, Koji Ikejiri, Eishi Baba

    BMC Research Notes   7 ( 1 )   377 - 377   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/1756-0500-7-377

  • Primary and secondary prophylactic administration of granulocyte-colony stimulating factor (G-CSF) for febrile neutropenia 査読

    Keita Uchino, Eishi Baba

    Japanese Journal of Cancer and Chemotherapy   41 ( 6 )   691 - 693   2014年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). 査読

    Kentaro Yamazaki, Michitaka Nagase, Hiroshi Tamagawa, Shinya Ueda, Takao Tamura, Kohei Murata, Takashi Tsuda, Eishi Baba, Masahiro Tsuda, Toshikazu Moriwaki, Taito Esaki, Yasushi Tsuji, Kei Muro, Koichi Taira, Tadamichi Denda, Takahiro Tsushima, Masahiko Ando, Satoshi Morita, Narikazu Boku, Ichinosuke Hyodo

    JOURNAL OF CLINICAL ONCOLOGY   32 ( 15 )   2014年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1200/jco.2014.32.15_suppl.3534

  • Highly sensitive and quantitative detection of EGFR T790M mutationin tumor samples by nanofluidic digital PCR

    Eiji Iwama, Koichi Takayama, Taishi Harada, Isamu Okamoto, Eishi Baba, Yoshinao Oda, Yoichi Nakanishi

    JOURNAL OF CLINICAL ONCOLOGY   32 ( 15 )   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(その他学術会議資料等)  

  • Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan 査読 国際誌

    Taichi Isobe, Keita Uchino, Chinatsu Makiyama, Hiroshi Ariyama, Shuji Arita, Shingo Tamura, Masato Komoda, Hitoshi Kusaba, Tsuyoshi Shirakawa, Taito Esaki, Kenji Mitsugi, Shigeo Takaishi, Koichi Akashi, Eishi Baba

    ANTICANCER RESEARCH   34 ( 4 )   2035 - 2040   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Successful chemoradiotherapy for undifferentiated malignant neoplasm arising from the left pulmonary artery 査読 国際誌

    Hozumi Kumagai, Kenta Nio, Yuta Okumura, Masato Komoda, Tsuyoshi Shirakawa, Hitoshi Kusaba, Shioto Yasuda, Keita Odashiro, Shuji Arita, Hiroshi Ariyama, Yuichi Yamada, Hidetaka Yamamoto, Yoshinao Oda, Katsumasa Nakamura, Koichi Akashi, Eishi Baba

    Case Reports in Oncology   7 ( 2 )   484 - 490   2014年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000365387

  • 非小細胞肺癌における個別化治療

    岩間 映二, 髙山 浩一, 馬場 英司, 中西 洋一

    福岡医学雑誌 = Fukuoka acta medica   105 ( 3 )   57 - 66   2014年3月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    肺癌は小細胞肺癌と非小細胞肺癌の大きく二つに分けられる.非小細胞肺癌は肺癌の約85&#37;を占め,腺癌,扁平上皮癌,大細胞癌に分けられる.非小細胞肺癌に対する治療は手術,放射線,化学療法の大きく三つに分けられるが,近年における化学療法の進歩は目覚ましく,その大きな要因は個別化治療の進歩にあると考えられる.本稿では非小細胞肺癌における化学療法の進歩について個別化治療を中心に概説する.

    DOI: 10.15017/1446200

  • Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer 査読 国際誌

    Shingo Tamura, Hitoshi Kusaba, Naoki Kubo, Kayo Ijichi, Kenji Tsuchihashi, Masato Komoda, Keita Uchino, Hiroshi Ariyama, Koichi Akashi, Eishi Baba

    MEDICAL ONCOLOGY   31 ( 3 )   856 - 856   2014年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12032-014-0856-0

  • Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan 査読

    Hozumi Kumagai, Hitoshi Kusaba, Yuta Okumura, Masato Komoda, Michitaka Nakano, Shingo Tamura, Mayako Uchida, Kenichiro Nagata, Shuji Arita, Hiroshi Ariyama, Shigeo Takaishi, Koichi Akashi, Eishi Baba

    Asian Pacific Journal of Cancer Prevention   15 ( 1 )   461 - 465   2014年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.7314/APJCP.2014.15.1.461

  • Pemetrexed Combined with Platinum-based Chemotherapy for Advanced Malignant Peritoneal Mesothelioma: Retrospective Analysis of Six Cases 査読 国際誌

    Michitaka Nakano, Hitoshi Kusaba, Akitaka Makiyama, Hiroshi Ariyama, Shuji Arita, Hisanobu Oda, Taito Esaki, Kotoe Takayoshi, Keita Uchino, Shingo Tamura, Hozumi Kumagai, Eiji Iwama, Tsuyoshi Shirakawa, Kenji Mitsugi, Shigeo Takaishi, Koichi Akashi, Eishi Baba

    ANTICANCER RESEARCH   34 ( 1A )   215 - 220   2014年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. 査読

    Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association   16 ( 2 )   175 - 182   2013年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
    BACKGROUND: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese patients with mGC have been published to date. The AVAGAST (XP ± bevacizumab in mGC) and ToGA (XP ± trastuzumab in human epidermal growth factor receptor 2 [HER2]-positive mGC) studies were the first two global studies including Japanese mGC patients. The aim of this analysis was to investigate the efficacy and safety of XP in Japanese mGC patients, using AVAGAST and ToGA subgroup data. METHODS: Efficacy and safety analyses were carried out in Japanese patients with mGC receiving XP alone, based on results from the AVAGAST and ToGA studies. There were differences in the target populations between the two studies; for example, the ToGA study limited patients to those with HER2-positive tumors; therefore, efficacy was evaluated separately. RESULTS: Ninety-four Japanese patients in the AVAGAST study and 50 in the ToGA study received XP alone. Median overall and progression-free survivals were 14.2 and 5.7 months, respectively, in the AVAGAST study, and 17.7 and 5.6 months, respectively, in the ToGA study. Overall response rates were 49.2 &#37; in the AVAGAST and 58.5 &#37; in the ToGA study. Adverse events were generally mild; the most common grade 3/4 events were neutropenia, anemia, anorexia, and nausea. CONCLUSIONS: XP is effective and well tolerated in Japanese patients with mGC, and could be one of the standard regimens for the first-line treatment in this cohort.

    DOI: 10.1007/s10120-012-0167-0

  • Erratum: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: Subset analyses of the AVAGAST study and the ToGA study (Gastric Cancer DOI: 10.1007/s10120-012-0167-0) 査読

    Kensei Yamaguchi, Akira Sawaki, Toshihiko Doi, Taroh Satoh, Yasuhide Yamada, Yasushi Omuro, Tomohiro Nishina, Narikazu Boku, Keisho Chin, Yasuo Hamamoto, Hiroya Takiuchi, Yoshito Komatsu, Shigehira Saji, Wasaburo Koizumi, Yoshinori Miyata, Atsushi Sato, Eishi Baba, Takao Tamura, Takashi Abe, Atsushi Ohtsu

    Gastric Cancer   16 ( 2 )   183 - 184   2013年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10120-012-0205-y

  • Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. 査読 国際誌

    Kusaba H, Esaki T, Kishimoto J, Uchino K, Arita S, Kumagai H, Mitsugi K, Akashi K, Baba E

    Cancer chemotherapy and pharmacology   71 ( 1 )   29 - 34   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
    PURPOSE: The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan has been reported to be a promising regimen for advanced colorectal cancer. However, the safety and efficacy of bevacizumab (BV) to combine with irinotecan and S-1 has not been determined. The aim of the study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of BV combined with irinotecan plus S-1, and to observe the safety and efficacy of this regimen as second-line chemotherapy in patients with advanced colorectal cancer. METHODS: This study initially had been planned as a phase I/II study. Eighty mg/m(2) of irinotecan on days 1 and 8, 80 mg/m(2) of S-1 for 14 consecutive days, and two doses of BV (Level 1; 10 mg/kg, Level -1; 7.5 mg/kg) were administered on day 1 every 3 weeks. RESULTS: Fourteen patients were enrolled in phase I of the study between January 2008 and September 2010. Dose-limiting toxicities were diarrhea, abdominal pain, and infection. The MTD and RD of BV were determined to be 10 mg/kg and 7.5 mg/kg, respectively. The main adverse events were leukopenia, anorexia, and diarrhea. There were no treatment-related deaths. An independent review committee was scheduled to evaluate safety in phase I, but this trial closed early due to toxicity. CONCLUSIONS: This study identified the risk of gastrointestinal toxicity with the combination of irinotecan, S-1 and BV as second-line chemotherapy in patients with advanced colorectal cancer.

    DOI: 10.1007/s00280-012-2023-7

  • Systemic chemotherapy for metastatic non-mucinous appendiceal adenocarcinoma: a case report and literature review

    Kenji Tsuchihashi, Kotoe Takayoshi, Keita Uchino, Tsuyoshi Shirakawa, Hozumi Kumagai, Shingo Tamura, Masato Komoda, Taichi Isobe, Shigeo Takaishi, Hitoshi Kusaba, Shinichi Aishima, Koichi Akashi, Eishi Baba

    International Cancer Conference Journal   2 ( 1 )   36 - 40   2013年1月

     詳細を見る

    記述言語:その他   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13691-012-0060-z

  • Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study) 査読 国際誌

    Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, Kentaro Yamazaki, Taito Esaki, Keishi Yamashita, Mutsumi Fukunaga, Yasuhiro Miyake, Kenji Katsumata, Satoshi Kato, Taroh Satoh, Mitsuharu Ozeki, Eishi Baba, Shigemasa Yoshida, Narikazu Boku, Ichinosuke Hyodo

    MEDICAL ONCOLOGY   29 ( 4 )   2842 - 2848   2012年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12032-011-0151-2

  • [Development trends for therapeutic antibody]. 査読

    Baba E, Kusaba H, Nakano S

    Nihon rinsho. Japanese journal of clinical medicine   70 ( 12 )   2098 - 2103   2012年12月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    [Development trends for therapeutic antibody].
    Recent developments for therapeutic antibody have provided new options for cancer treatments. Modification of antibody molecules pursuing improvement of binding efficacy for Fcgamma receptors and enabling efficient recycling of antibody have been performed. Novel constructs of antibody possessing multivalent specificity and conjugated agents have also been developed. Based on exploration of new class of target molecules for therapeutic antibody, antibodies enhancing anti-tumor immunity such as anti-CTLA-4 antibody have appeared. These advancements would achieve more effective and safer therapy for various kinds of cancers.

  • A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer 査読 国際誌

    Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato

    Investigational New Drugs   30 ( 5 )   2026 - 2031   2012年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer
    Currently, no prospective data exists to support a "stop-and-go" modified FOLFOX6 regimen with bevacizumab in metastatic colorectal cancer (mCRC) patients. This study aimed to evaluate the efficacy and safety of this regimen in first-line mCRC patients. Eligible patients (age ≥20 years) had previously untreated mCRC; Eastern Cooperative Oncology Group performance status of 0-2; and adequate hematologic, hepatic, and renal function. The modified FOLFOX6 regimen and bevacizumab (5 mg/kg) was administered intravenously every 2 weeks. After 8 cycles, patients received maintenance therapy with simplified LV5FU2 and bevacizumab until completion of 8 cycles or disease progression. After maintenance therapy, patients received another 8 cycles of modified FOLFOX6 with bevacizumab until completion of 8 cycles or disease progression. We recruited 50 patients between August 2007 and January 2009. The overall response rate was 48&#37; (80&#37; confidence interval [CI]; 38.2-58) with outcomes as follows: complete response, n = 1; partial response, n = 23; stable disease, n = 21; progression, n = 1; and not evaluated, n = 4. Median time to treatment failure was 7.7 months (80&#37; CI: 6.2-8.0), and median progression-free survival was 12.8 months (80&#37; CI: 10.8-14). Grade 3/4 toxicities included neutropenia (40&#37;), nausea (4&#37;), diarrhea (14&#37;), thrombosis (4&#37;), and hypertension (4&#37;) et al. Grade 1, 2, or 3 peripheral neuropathy was reported in 38&#37;, 40&#37;, and 10&#37; of patients, respectively. The stop-and-go modified FOLFOX6 and bevacizumab regimen is effective and well tolerated as first-line chemotherapy for mCRC patients.

    DOI: 10.1007/s10637-011-9779-1

  • Human Nanog pseudogene8 promotes the proliferation of gastrointestinal cancer cells 査読 国際誌

    Keita Uchino, Gen Hirano, Minako Hirahashi, Taichi Isobe, Tsuyoshi Shirakawa, Hitoshi Kusaba, Eishi Baba, Masazumi Tsuneyoshi, Koichi Akashi

    EXPERIMENTAL CELL RESEARCH   318 ( 15 )   1799 - 1807   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.yexcr.2012.04.011

  • Improvement of quality of life and survival using self-expandable metal stent placement for severe malignant stenosis of the gastric body A case report 査読

    Hozumi Kumagai, Kenta Nio, Tsuyoshi Shirakawa, Keita Uchino, Hitoshi Kusaba, Taichi Isobe, Masato Komoda, Shingo Tamura, Ryo Maeyama, Eishi Nagai, Koichi Akashi, Eishi Baba

    Journal of Medical Case Reports   6   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/1752-1947-6-315

  • 大腸癌においてはE-Cadherin陽性細胞、陰性細胞ともにがん幹細胞性をもつ(Both E-Cadherin-positive and negative cells of colorectal cancer stem cell population possess tumor initiating potential)

    田村 真吾, 磯部 大地, 馬場 英司, 中野 倫孝, 薦田 正人, 高石 繁生, 草場 仁志, 植木 隆, 赤司 浩一

    日本癌学会総会記事   71回   244 - 244   2012年8月

     詳細を見る

    記述言語:英語  

  • Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study 査読

    Akira Sawaki, Yasuo Ohashi, Yasushi Omuro, Taroh Satoh, Yasuo Hamamoto, Narikazu Boku, Yoshinori Miyata, Hiroya Takiuchi, Kensei Yamaguchi, Yasutsuna Sasaki, Tomohiro Nishina, Atsushi Satoh, Eishi Baba, Takao Tamura, Takashi Abe, Kiyohiko Hatake, Atsushi Ohtsu

    GASTRIC CANCER   15 ( 3 )   313 - 322   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10120-011-0118-1

  • CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells 査読 国際誌

    Hiroaki Niiro, Siamak Jabbarzadeh-Tabrizi, Yoshikane Kikushige, Takahiro Shima, Kumiko Noda, Shun-ichiro Ota, Hirofumi Tsuzuki, Yasushi Inoue, Yojiro Arinobu, Hiromi Iwasaki, Shinji Shimoda, Eishi Baba, Hiroshi Tsukamoto, Takahiko Horiuchi, Tadayoshi Taniyama, Koichi Akashi

    BLOOD   119 ( 10 )   2263 - 2273   2012年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1182/blood-2011-04-351965

  • Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. 査読 国際誌

    Baba E, Fujishima H, Makiyama A, Uchino K, Tanaka R, Esaki T, Kusaba H, Mitsugi K, Nakano S, Akashi K

    Advances in therapy   29 ( 3 )   287 - 296   2012年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
    INTRODUCTION: Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity. METHODS: A total of 29 patients with metastatic colorectal cancer were included. Our modified Saltz regimen was administered. The primary endpoint was overall response rate. RESULTS: Of the 29 patients, 11 had previous chemotherapy. A partial response occurred in 11 patients, stable disease in 16 patients, and progressive disease in two patients. Disease control rate was 93.1&#37;. Response rates with and without previous treatment were 18.2&#37; and 50&#37;, respectively. Median progression-free survival was 17.3 months. The main hematologic toxicities were leukopenia (22.6&#37;) and neutropenia (45.2&#37;). No treatment-related deaths occurred. CONCLUSION: Our modified Saltz regimen exhibited sufficient efficacy, feasibility, and manageable toxicity as a therapeutic option for selected colorectal cancer patients.

    DOI: 10.1007/s12325-012-0002-3

  • Human STEAP3 maintains tumor growth under hypoferric condition 査読 国際誌

    Taichi Isobe, Eishi Baba, Shuji Arita, Masato Komoda, Shingo Tamura, Tsuyoshi Shirakawa, Hiroshi Ariyama, Shigeo Takaishi, Hitoshi Kusaba, Takashi Ueki, Koichi Akashi

    EXPERIMENTAL CELL RESEARCH   317 ( 18 )   2582 - 2591   2011年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.yexcr.2011.07.022

  • Long-term Vaccine Therapy with Autologous Whole Tumor Cell-pulsed Dendritic Cells for a Patient with Recurrent Rectal Carcinoma 査読 国際誌

    Hideya Onishi, Takashi Morisaki, Eishi Baba, Mitsunari Nakamura, Syoichi Inaba, Hideo Kuroki, Kotaro Matsumoto, Mitsuo Katano

    ANTICANCER RESEARCH   31 ( 11 )   3995 - 4005   2011年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer. 査読 国際誌

    Baba E, Esaki T, Ariyama H, Mitsugi K, Morikita T, Fujishima H, Kusaba H, Nakano S, Akashi K

    Cancer chemotherapy and pharmacology   68 ( 3 )   611 - 617   2011年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
    PURPOSE: This single-arm, phase II clinical study evaluated the efficacy and safety of sequential treatment with S-1 followed by cisplatin in patients with advanced or recurrent gastric cancer. METHODS: Fifty patients with histologically confirmed advanced or recurrent gastric cancer and an Eastern Cooperative Oncology Group performance status of 0-2 who had measurable and/or assessable lesions and gave written informed consent were enrolled. S-1 (40 mg/m(2), bid) was administered on days 1-21, and cisplatin (70 mg/m(2)) was given as an intravenous infusion on day 22 of a 35-day cycle. Treatment was continued until disease progression or intolerable adverse events. Cisplatin was administered for 6 cycles. Adverse events were assessed according to Common Terminology Criteria of Adverse Events version 3.0, and efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.0 for patients with measurable lesions and by the criteria of the Japanese Research Society for Gastric Cancer for all patients. RESULTS: Efficacy could be evaluated in 49 of the 50 enrolled patients. The median age was 62 years. Lesions were measurable in 38 patients and assessable in 11. The response rate was 44.7&#37; in patients with measurable lesions and 40.8&#37; overall. The progression-free survival and overall survival were, respectively, 233 days (7.8 months) and 574 days (19.0 months) in patients with measurable lesions and 192 days (6.4 months) and 402 days (13.4 months) overall. Serious adverse events (grade 3 or higher) included neutropenia (24.5&#37;), anemia (20.4&#37;), and anorexia (20.4&#37;) and were safely managed. CONCLUSION: The safety and effectiveness of sequential treatment with S-1 followed by cisplatin every 35 days is equivalent to that reported for conventional chemotherapeutic regimens in patients with advanced or recurrent gastric cancer.

    DOI: 10.1007/s00280-010-1529-0

  • 骨髄微小環境により選択された乳癌幹細胞はNotch1、CD44、CD49fを高発現する(Breast cancer stem cells selected by bone marrow microenvironment highly express Notch1, CD44 and CD49f)

    白川 剛, 田村 真吾, 薦田 正人, 磯部 大地, 高石 繁生, 草場 仁志, 馬場 英司, 赤司 浩一

    日本癌学会総会記事   70回   228 - 228   2011年9月

     詳細を見る

    記述言語:英語  

  • 骨髄微小環境により選択された乳癌幹細胞の解析と治療への可能性

    白川 剛, 田村 真吾, 薦田 正人, 磯部 大地, 高石 繁生, 草場 仁志, 馬場 英司, 赤司 浩一

    日本癌治療学会誌   46 ( 2 )   465 - 465   2011年9月

     詳細を見る

    記述言語:日本語  

  • 腫瘍内科にて化学療法を施行する患者に合併する精神疾患の実態調査

    白川 剛, 中野 倫孝, 田村 真吾, 薦田 正人, 磯部 大地, 熊谷 穂積, 高石 繁生, 草場 仁志, 馬場 英司, 赤司 浩一

    日本癌治療学会誌   46 ( 2 )   702 - 702   2011年9月

     詳細を見る

    記述言語:日本語  

  • 肺結核との鑑別を要した空洞性病変を伴う大腸がん肺転移の2例

    中野 倫孝, 森崎 裕子, 相良 浩輔, 白川 剛, 熊谷 穂積, 田村 真吾, 薦田 正人, 磯部 大地, 高石 繁生, 草場 仁志, 馬場 英司, 赤司 浩一

    日本癌治療学会誌   46 ( 2 )   841 - 841   2011年9月

     詳細を見る

    記述言語:日本語  

  • がん化学療法中に生じる心血管系有害事象のretrospective studyとその予測・対策

    白川 剛, 中野 倫孝, 田村 真吾, 薦田 正人, 磯部 大地, 熊谷 穂積, 高石 繁生, 草場 仁志, 小田代 敬太, 馬場 英司, 赤司 浩一

    日本癌治療学会誌   46 ( 2 )   688 - 688   2011年9月

     詳細を見る

    記述言語:日本語  

  • 当科にて緩和的放射線治療を施行した症例の後方視的調査による緩和的放射線治療の現状と問題点の検討

    白川 剛, 田村 真吾, 薦田 正人, 磯部 大地, 熊谷 穂積, 高石 繁生, 草場 仁志, 馬場 英司, 赤司 浩一

    日本緩和医療学会学術大会プログラム・抄録集   16回   298 - 298   2011年6月

     詳細を見る

    記述言語:日本語  

  • Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. 査読 国際誌

    Kusaba H, Esaki T, Futami K, Tanaka S, Fujishima H, Mitsugi K, Sakai K, Ariyama H, Tanaka R, Kinugawa N, Ueki T, Mibu R, Baba E, Nakano S, Akashi K

    Cancer science   101 ( 12 )   2591 - 2595   2010年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
    The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer. This study was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of irinotecan combined with S-1 in a 3-week cycle regimen and to observe the safety and efficacy for patients with previously untreated advanced colorectal cancer. Eighty milligrams per m(2) of S-1 was given orally for 14 consecutive days and escalated doses of irinotecan were administered on days 1 and 8 every 3 weeks in the phase I trial. Forty patients were treated at the RD during the phase II trial. Forty-three patients were enrolled between February 2005 and March 2007. The dose-limiting toxicity was diarrhea and abdominal pain. The MTD of irinotecan was 100 mg/m(2) and the RD was determined to be 80 mg/m(2) of irinotecan combined with 80 mg/m(2) of S-1. The phase II trial showed that 22 of 40 patients achieved a complete or partial response and eight had stable disease. The overall response rate was 55.0&#37;. The median progression-free survival time and median survival time were 6.7 and 21 months, respectively. There were no treatment-related deaths. The main toxicities were leukopenia, neutropenia, anorexia and diarrhea. This study suggests the combination of irinotecan and S-1 repeated every 3 weeks is tolerable and effective for patients with previously untreated advanced colorectal cancer.

    DOI: 10.1111/j.1349-7006.2010.01728.x

  • 切除不能進行・再発大腸癌の高齢患者に対するBevacizumab併用化学療法の検討

    藤本 千夏, 熊谷 穂積, 牧山 明資, 在田 修二, 江崎 泰斗, 磯部 大地, 田村 真吾, 薦田 正人, 白川 剛, 内野 慶太, 草場 仁志, 馬場 英司, 赤司 浩一, 三ツ木 健二, 田中 吏佐

    日本癌治療学会誌   45 ( 2 )   815 - 815   2010年9月

     詳細を見る

    記述言語:日本語  

  • In vivo selection systemを用いた骨髄転移細胞内のがん幹細胞の解析(Analysis of cancer stem cells in bone marrow metastasis by use of in vivo selection system)

    白川 剛, 内野 慶太, 草場 仁志, 田村 真吾, 薦田 正人, 磯部 大地, 馬場 英司, 赤司 浩一

    日本癌学会総会記事   69回   488 - 488   2010年8月

     詳細を見る

    記述言語:英語  

  • 癌患者末梢血中エクソソームに含まれるmiRNAの検出と機能解析(Detection and functional analysis of miRNA in peripheral blood exosomes from cancer patients)

    薦田 正人, 馬場 英司, 磯部 大地, 新納 宏昭, 在田 修二, 草場 仁志, 内野 慶太, 白川 剛, 田村 真吾, 赤司 浩一

    日本癌学会総会記事   69回   380 - 380   2010年8月

     詳細を見る

    記述言語:英語  

  • STEAP3によって調節される癌細胞内貯蔵鉄量(The uptake of iron, crucial for cellular proliferation and survival, maintained by STEAP3 in cancer)

    磯部 大地, 馬場 英司, 在田 修二, 薦田 正人, 田村 真吾, 白川 剛, 平野 元, 内野 慶太, 牧山 明資, 草場 仁志, 植木 隆, 赤司 浩一

    日本癌学会総会記事   69回   82 - 83   2010年8月

     詳細を見る

    記述言語:英語  

  • Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. 査読 国際誌

    Shibata Y, Baba E, Ariyama H, Arita S, Isobe T, Kusaba H, Mitsugi K, Nakano S, Akashi K

    Oncology letters   1 ( 3 )   423 - 426   2010年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma.
    Metastatic small intestinal adenocarcinoma (SIA) is rare among digestive tract malignancies, and a standard therapy has yet to be established. The present study described a patient who was treated with irinotecan-based chemotherapy. A 67-year-old woman with a long history of anemia was diagnosed as having SIA using small bowel endoscopy. Tumor invasion of the mesentery and multiple metastases to the lungs and peritoneal lymph nodes were detected. Nine courses of chemotherapy, each consisting of bolus infusion of 5-fluorouracil at 500 mg/m(2), plus infusion of irinotecan at 100 mg/m(2) with l-leucovorin at 20 mg/m(2) on days 1, 8 and 15, were administered at 4-weekly intervals postoperatively. After two courses, the metastatic nodules in the lungs showed a decrease in number and size, and this response continued for over 6 months. Adverse events were manageable during this period. The patient succumbed to the disease 12 months after the initial diagnosis. The present results therefore suggest that irinotecan-based chemotherapy is a potential treatment for metastatic SIA.

    DOI: 10.3892/ol_00000074

  • Cetuximab for patients with metastatic colorectal cancer - From the result of recent clinical trials 査読

    hiroshi ariyama, Hitoshi Kusaba, Eishi Baba

    Japanese Journal of Cancer and Chemotherapy   37 ( 5 )   782 - 786   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy for Pancreatic Cancer 査読 国際誌

    Yasunobu Abe, Tetsuhide Ito, Eishi Baba, Koji Nagafuji, Ken Kawabe, Ilseung Choi, Yoshiyuki Arita, Toshihiro Miyamoto, Takanori Teshima, Shuji Nakano, Mine Harada

    PANCREAS   38 ( 7 )   815 - 819   2009年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/MPA.0b013e3181b576ee

  • Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. 査読

    Shibata Y, Ariyama H, Baba E, Takii Y, Esaki T, Mitsugi K, Tsuchiya T, Kusaba H, Akashi K, Nakano S

    International journal of clinical oncology   14 ( 5 )   397 - 401   2009年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
    BACKGROUND: Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC. With the increasing use of oxaliplatin in Japan, serious adverse events have been experienced other than hematologic and neurologic toxicities. METHODS: In order to clarify the clinical features of allergic reactions to oxaliplatin, we retrospectively investigated CRC patients who had received oxaliplatin-based chemotherapies. RESULTS: One hundred and twenty-five CRC patients who had been treated with FOLFOX regimens (containing oxaliplatin, 5-FU, and LV) were examined, and 21 patients (17&#37;) were found to have developed allergic reactions. Sixteen patients (13&#37;) had grade 1/2 adverse events, classified according to the common terminology criteria for adverse events (CTC-AE) version 3.0 and 5 (4&#37;) had grade 3/4 adverse events. The allergic reaction appeared after a median number of nine cycles (range, 2-15 cycles). Previous chemotherapy included 5-FU/LV, CPT-11, and S-1. All of the patients with allergic reactions recovered completely when treated with antiallergy drugs. Oxaliplatin was reintroduced in 11 patients, with the use of prophylactic agents; allergic reaction to the reintroduction was not observed in 8 patients and grade 1/2 allergic reactions developed in 3 patients. No correlation was identified between allergic reaction and patients' background characteristics such as sex, history of allergy, and profile of other adverse events. CONCLUSION: Allergic reactions to oxaliplatin remain an important issue for patients being able to safely continue effective chemotherapies; further analysis will be needed to establish methods for the prediction and prophylaxis of such reactions.

    DOI: 10.1007/s10147-009-0883-6

  • 切除不能・進行再発大腸癌に対するセツキシマブ使用経験(KRAS検査実施症例を交えて)

    牧山 明資, 藤本 千夏, 在田 修二, 江崎 泰斗, 織田 信弥, 田中 吏佐, 三ツ木 健二, 薦田 正人, 白川 剛, 磯部 大地, 内野 慶太, 有山 寛, 草場 仁志, 馬場 英司, 赤司 浩一

    日本癌治療学会誌   44 ( 2 )   580 - 580   2009年9月

     詳細を見る

    記述言語:日本語  

  • 当科で経験した心臓悪性腫瘍4例の後方視的検討

    白川 剛, 田村 真吾, 薦田 正人, 平野 元, 磯部 大地, 内野 慶太, 有山 寛, 草場 仁志, 小田代 敬太, 馬場 英司

    日本癌治療学会誌   44 ( 2 )   788 - 788   2009年9月

     詳細を見る

    記述言語:日本語  

  • Exosomeを介した細胞間small RNA輸送(Intercellular transfer of functional small RNA via exosomes)

    薦田 正人, 馬場 英司, 磯部 大地, 新納 宏昭, 在田 修二, 有山 寛, 草場 仁志, 赤司 浩一

    日本癌学会総会記事   68回   210 - 210   2009年8月

     詳細を見る

    記述言語:英語  

  • STEAP3は細胞内鉄貯蔵量を調節し、鉄欠乏環境での腫瘍増殖生存を維持する(STEAP3 maintains tumor cell proliferation and survival by regulating intracellular iron storage)

    磯部 大地, 馬場 英司, 在田 修二, 薦田 正人, 白川 剛, 内野 慶太, 有山 寛, 草場 仁志, 赤司 浩一

    日本癌学会総会記事   68回   280 - 281   2009年8月

     詳細を見る

    記述言語:英語  

  • Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. 査読 国際誌

    Baba E, Fujishima H, Kusaba H, Esaki T, Ariyama H, Kato K, Tanaka R, Mitsugi K, Shibata Y, Harada M, Nakano S

    Anticancer research   29 ( 5 )   1727 - 1732   2009年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer.
    The combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) has been reported to be active against metastatic gastric cancer (MGC) and great synergy has been shown in vivo and in vitro when 5-FU precedes CDDP. The sequential combination of S-1 (tegafur, oxonic acid, 5-chloro-2,4-dihydroxypyridine) followed by CDDP for MGC was investigated. A phase I trial applying increasing doses of oral administration of S-1 (65-80 mg/m(2)) for 21 days and increasing doses of CDDP (60-80 mg/m(2)) on day 22 every 35 days was conducted in order to determine the maximum tolerated dose (MTD) and recommended phase II dose. Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study. Three patients were treated at each dose level with escalation based on toxicity. Fifteen patients were included and evaluated for dose-limiting toxicity (DLT) and MTD. DLT included NCICTC grade 3 anorexia and fatigue in patients treated at S-1 80 mg/m(2) and CDDP 80 mg/m(2) (dose level 5). The other toxicities, grade 3 or higher, included neutropenia (grade 3) and nausea/vomiting (grade 3). Non-hematological toxicities were grade 1/2 and included diarrhea, nausea and stomatitis. There was no treatment-related mortality. Therefore, the recommended dose was a combination of S-1 at 80 mg/m(2) and CDDP at 70 mg/m(2). This sequential administration of S-1 and CDDP every 35 days is tolerable and warrants a phase II trial. A multicenter phase II study is currently under way.

  • TSAP6 regulating intracellular iron content maintains tumor cell survival in iron-depleted condition.

    Taichi Isobe, Eishi Baba, Shuji Arita, Masato Komoda, Hiroaki Niiro, Gen Hirano, Keita Uchino, Akitaka Makiyama, Yoshihiro Shibata, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi

    CANCER RESEARCH   69   2009年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(その他学術会議資料等)  

  • [A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy]. 査読

    Tsukasa K, Fujimoto C, Ariyama H, Esaki T, Murakawa M, Syoji T, Baba E, Hiranuma S

    Gan to kagaku ryoho. Cancer & chemotherapy   36 ( 3 )   489 - 492   2009年3月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    [A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy].
    The case was a 64-year-old man. He was diagnosed as gastric cancer, lymph node metastases, brain metastases, bone marrow carcinomas, and disseminated intravascular coagulation(DIC). He was started on methotrexate(MTX)/5- fluorouracil(5-FU)sequential therapy(weekly administration of MTX(100 mg/m(2), iv bolus)followed by 5-FU(600 mg/m(2), iv bolus)with a 3 h interval). DIC was resolved, and the tumor marker decreased remarkably. Four weeks later, he received zoledronic acid 4 mg to prevent skeletal complication. Next day, fatigue and anorexia onset. Six days later, laboratory data showed severe hypocalcemia. He was started on calcium gluconate 3.4 g/day. The calcium level was normalized in twelve days, and the symptoms were improved. MTX /5-FU therapy was resumed, and his condition remained stable. However, after the ninth dosage, he developed fatigue and low back pain, and the DIC relapsed. We started paclitaxel therapy. But it was not effective and he died ten days later. It was considered that careful attention to hypocalcemia is necessary when we use zoledronic acid for the bone marrow carcinomas treated with chemotherapy.

  • Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines. 査読 国際誌

    Makiyama A, Qin B, Uchino K, Shibata Y, Arita S, Isobe T, Hirano G, Kusaba H, Baba E, Akashi K, Nakano S

    Anti-cancer drugs   20 ( 2 )   123 - 130   2009年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
    To define the most effective combination schedule of gemcitabine and oxaliplatin (L-OHP), we investigated the in-vitro interaction between these drugs in a panel of four human gallbladder adenocarcinoma cell lines (HAG-1, GB-d1, NOZ, and G-415). Cytotoxic activity was determined by the WST-1 assay. Different schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation and apoptosis were evaluated by flow cytometry. Simultaneous and sequential treatments of gemcitabine followed by L-OHP exhibited synergistic effects in all four cell lines, whereas the reverse sequence largely showed an antagonism. Gemcitabine exclusively arrested cells at the G0/G1 phase, and L-OHP at the G2/M phase, as measured by flow cytometric analyses. Apoptosis was most prominent when cells were treated simultaneously or in a sequence gemcitabine followed by L-OHP, producing apoptosis in treated cells (27-30&#37;). In contrast, the reverse sequence yielded only 6-7&#37; induction of apoptosis, the rate being not significantly different from those induced by each drug singly. Moreover, this sequence dependence was further confirmed by the experiment, which compared the number of HAG-1 cells 7 days after these combination schedules. These findings suggest that the interaction of gemcitabine and L-OHP is highly schedule dependent, with the most efficacious interaction observed in either simultaneous combination or in a sequence combination of gemcitabine followed by L-OHP.

    DOI: 10.1097/CAD.0b013e3283218080

  • T Cell Leukemia/Lymphoma 1 and Galectin-1 Regulate Survival/Cell Death Pathways in Human Naive and IgM(+) Memory B Cells through Altering Balances in Bcl-2 Family Proteins 査読 国際誌

    Siamak Jabbarzadeh Tabrizi, Hiroaki Niiro, Mariko Masui, Goichi Yoshimoto, Tadafumi Iino, Yoshikane Kikushige, Takahiro Wakasaki, Eishi Baba, Shinji Shimoda, Toshihiro Miyamoto, Toshiro Hara, Koichi Akashi

    JOURNAL OF IMMUNOLOGY   182 ( 3 )   1490 - 1499   2009年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • TC(DC)療法、CPT-11療法が奏効した腹膜癌症例の検討

    白川 剛, 薦田 正人, 磯部 大地, 平野 元, 牧山 明資, 内野 慶太, 在田 修二, 柴田 義宏, 瀧井 康, 草場 仁志, 馬場 英司, 中野 修治, 赤司 浩一

    日本癌治療学会誌   43 ( 2 )   437 - 437   2008年10月

     詳細を見る

    記述言語:日本語  

  • 耳下腺癌術後再発に対してCAP療法が奏効した一例

    薦田 正人, 白川 剛, 磯部 大地, 平野 元, 牧山 明資, 内野 慶太, 在田 修二, 柴田 義宏, 平川 直也, 草場 仁志, 馬場 英司, 赤司 浩一

    日本癌治療学会誌   43 ( 2 )   675 - 675   2008年10月

     詳細を見る

    記述言語:日本語  

  • B細胞におけるTSAP6によるエクソゾームHLA産生及びアポトーシス誘導の調節(TSAP6 regulates exosomal HLA secretion and apoptosis induction in B cells)

    磯部 大地, 馬場 英司, 在田 修二, 薦田 正人, 内野 慶太, 白川 剛, 平野 元, 牧山 明資, 草場 仁志, 赤司 浩一

    日本癌学会総会記事   67回   436 - 436   2008年9月

     詳細を見る

    記述言語:英語  

  • Allo-SCT using reduced-intensity conditioning against advanced pancreatic cancer: A Japanese survey 査読

    Y. Kanda, Y. Omuro, E. Baba, K. Oshima, K. Nagafuji, Y. Heike, Y. Takaue, T. Sasaki, H. Sakamaki, M. Harada

    Bone Marrow Transplantation   42 ( 2 )   99 - 103   2008年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/bmt.2008.94

  • Systemic chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as cardiac tamponade 査読

    Hitoshi Kusaba, Masahiko Fujihara, Ryuichi Nagashima, Yoshikazu Kaji, Eishi Baba, Shuji Nakano

    Medical Oncology   25 ( 2 )   241 - 244   2008年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12032-007-9010-6

  • B cell activation regulates exosomal HLA production 国際誌

    Shuji Arita, Eishi Baba, Yoshihiro Shibata, Hiroaki Niiro, Shinji Shimoda, Taichi Isobe, Hitoshi Kusaba, Shuji Nakano, Mine Harada

    EUROPEAN JOURNAL OF IMMUNOLOGY   38 ( 5 )   1423 - 1434   2008年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1002/eji.200737694

  • MEFV mutation analysis of familial Mediterranean fever in Japan 査読

    Nozomi Tomiyama, Yusushi Higashiuesato, Takaya Oda, Eishi Baba, Mine Harada, Momoyo Azuma, Tomoko Yamashita, Kazuhiro Uehara, Akiko Miyazato, Kazuhiro Hatta, Yuzuke Ohya, Kunitoshi Iseki, Yoshihiro Jinno, Shuichi Takishita

    Clinical and Experimental Rheumatology   26 ( 1 )   13 - 17   2008年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • B細胞から放出されるエクソソームHLAはNF-κBにより産生調節される(Exosomal HLA production of B cells is regulated by NF-κB signaling)

    在田 修二, 馬場 英司, 柴田 義宏, 新納 宏明, 磯部 大地, 下田 慎治, 平野 元, 牧山 明資, 内野 慶太, 草場 仁志, 中野 修治, 原田 実根

    日本癌学会総会記事   66回   156 - 156   2007年8月

     詳細を見る

    記述言語:英語  

  • 胃腸癌細胞におけるNanog偽遺伝子8発現(Nanog pseudogene 8 expression in gastrointestinal cancer cells)

    内野 慶太, 平野 元, 白川 剛, 磯部 大地, 牧山 明資, 在田 修二, 柴田 義宏, 草場 仁志, 馬場 英司, 中野 修治

    日本癌学会総会記事   66回   302 - 302   2007年8月

     詳細を見る

    記述言語:英語  

  • Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin. 査読 国際誌

    Shibata Y, Baba E, Ariyama H, Miki R, Ogami N, Arita S, Qin B, Kusaba H, Mitsugi K, Noshiro H, Yao T, Nakano S

    World journal of gastroenterology : WJG   13 ( 26 )   3634 - 3637   2007年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Metastatic basaloid-squamous cell carcinoma of the esophagus treated by 5-fluorouracil and cisplatin.
    Basaloid squamous cell carcinoma (BSC) of the esophagus is a rare malignant disease. We report here a patient with recurrent esophageal BSC, who was successfully treated by systemic chemotherapy containing 5-fluorouracil (5-FU) and cisplatin (CDDP). A 57-year-old woman was diagnosed as having squamous cell carcinoma of the esophagus upon endoscopic examination. Curative esophagectomy with lymph node dissection was performed under the thoracoscope. The pathological diagnosis of the surgical specimen was BSC. Five months after operation, the patient was diagnosed as having a recurrence of the BSC with metastases to the liver and spleen, and a right paraclavicular lymph node. She was given systemic chemotherapy consisting of continuous infusion of 800 mg/d of 5-FU and 3 h infusion of 20 mg/d of CDDP for 5 consecutive days every 4 wk. The metastatic lesions in the spleen and right paraclavicular lymph node disappeared, and the liver metastasis was apparently reduced in size after 2 courses of chemotherapy. The tumor regression was seen over 6 courses, with progression afterwards. Although subsequent treatment with CPT-11 and CDDP was not effective, docetaxel and vinorelbine temporarily controlled the tumor growth for 2 mo. 5-FU and CDDP combination may be useful for the patients with advanced BSC.

  • Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site 査読

    Hitoshi Kusaba, Yoshihiro Shibata, Shuji Arita, Hiroshi Ariyama, Eishi Baba, Kenji Mitsugi, Mine Harada, Shuji Nakano

    Medical Oncology   24 ( 2 )   259 - 264   2007年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/BF02698049

  • Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. 査読 国際誌

    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S

    Cancer chemotherapy and pharmacology   58 ( 5 )   577 - 584   2006年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    PURPOSE: Although gefitinib, a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has been demonstrated to exhibit its antitumor activity by the blockade of EGF receptor, the role of signaling pathways downstream of EGFR in gefitinib sensitivity remains unknown. In this study, we investigated the mechanistic role of Src and Ras, major oncogene products implicated in the pathogenesis of many human cancers in gefitinib sensitivity. METHODS: Using parental and v-src- or c-H-ras-transfected HAG-1 human gallbladder adenocarcinoma cell lines, effects of gefitinib on cytotoxicity, cell cycle purtubation and apoptosis, and tyrosine phosphorylation of EGFR, Akt, and Erk were determined by WST-1 assay, flow cytometry, and Western blots, respectively. RESULTS: Activated Ras and Src conferred a strong resistance to gefitinib by nearly 30-fold and 200-fold, respectively. Gefitinib induced accumulation of cells in the G0/G1 phase of the cell cycle at 24-h, with progressive expansion of apoptotic cell population in parental HAG-1 cells, but these effects were completely abolished in v-src- or c-H-ras-transfected cell line. Upon gefitinib treatment, EGFR activation and subsequent downstream activation through Erk and Akt were significantly inhibited in HAG-1 cells. By contrast, gefinitib failed to inhibit the activation of both Akt and Erk in v-src-transfected cells and Erk, but not Akt in c-H-ras-transfected cells, despite the blockade of EGFR activation in these respective cell lines. Treatment of v-src-transfected cells with herbimycin A, a Src tyrosine kinase inhibitor, partially reversed the gefitinib resistance, with concomitant inhibition of Akt and Erk. CONCLUSION: Our results suggest that activated Ras and Src could induce gefitinib resistance by activating either or both of Akt and Erk signaling pathways, thus providing a strategic rationale for assessment of these specific signaling molecules downstream of EGFR to customize treatment.

    DOI: 10.1007/s00280-006-0219-4

  • CPT-11/CDDP不応性の進行・再発胃癌に対する二次療法としてのDTX/TS-1療法の実施可能性

    磯部 大地, 内野 慶太, 牧山 明資, 在田 修二, 柴田 義宏, 草場 仁志, 馬場 英司, 中野 修治

    日本癌治療学会誌   41 ( 2 )   397 - 397   2006年9月

     詳細を見る

    記述言語:日本語  

  • 消化器原発進行小細胞癌に対する全身化学療法の検討

    磯部 大地, 柴田 義宏, 在田 修二, 内野 慶太, 牧山 明資, 瀧井 康, 草場 仁志, 馬場 英司, 中野 修治, 原田 実根, 居石 克夫, 八尾 隆史

    日本消化器病学会雑誌   103 ( 臨増大会 )   A927 - A927   2006年9月

     詳細を見る

    記述言語:日本語  

  • Autoreactive T-cell responses in primary biliary cirrhosis are proinflammatory whereas those of controls are regulatory 査読 国際誌

    Shinji Shimoda, Fumihiko Ishikawa, Takashi Kamihira, Atsumasa Komori, Hiroaki Niiro, Eishi Baba, Kenichi Harada, Kumiko Isse, Yasuni Nakanuma, Hiromi Ishibashi, M. Eric Gershwin, Mine Harada

    GASTROENTEROLOGY   131 ( 2 )   606 - 618   2006年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2006.05.056

  • In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells. 査読 国際誌

    Qin B, Tanaka R, Ariyama H, Shibata Y, Arita S, Kusaba H, Baba E, Harada M, Nakano S

    Anti-cancer drugs   17 ( 4 )   439 - 443   2006年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells.
    Although continuous infusion of 5-fluorouracil (5-FU) has been clinically demonstrated to be superior to bolus administration, the mechanistic difference between the treatments still remains unclear. Here, we investigated in vitro whether there were any differences in the metabolism and activity of 5-FU between these schedules. To simulate bolus and infusional treatments of 5-FU, HST-1 human squamous carcinoma cells were treated with short-term, high-doses and long-term, low-doses so that the area under the curve (AUC) of 5-FU became equivalent between both schedules, and compared the cytotoxicity, fluorinated RNA (F-RNA) levels, 5-fluorodeoxyuridine monophosphate (FdUMP) content and thymidylate synthase (TS) activity. F-RNA and FdUMP were measured by capillary gas chromatography-mass spectrometry and competitive ligand-binding assay, respectively. The [H]FdUMP binding site in TS was determined as an index of the amount of TS using the radio-binding assay. Long-term, low-dose treatment of 5-FU was found to be 1.3-1.7 times more cytotoxic than the short-term, high-dose treatment. F-RNA content increased as the AUC of 5-FU was increased and was 2-4 times significantly higher in the cells treated with the long-term, low-dose than those with the short-term, high-dose schedule, indicating that the levels of F-RNA are AUC and schedule dependent. In contrast, there were no significant differences in FdUMP levels, TS activity and TS inhibition rate between the schedules. These data suggest that the superior activity of 5-FU administered long-term, low-dose over short-term, high-dose could be explained by more 5-FU incorporated into RNA during a long-term, low-dose exposure, thus providing a strategic rationale for the clinical advantage of continuous infusion over bolus administration.

    DOI: 10.1097/01.cad.0000203380.22361.6c

  • In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines. 査読 国際誌

    Qin B, Tanaka R, Shibata Y, Arita S, Ariyama H, Kusaba H, Baba E, Harada M, Nakano S

    Anti-cancer drugs   17 ( 4 )   445 - 453   2006年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines.
    In order to define the most effective combination schedule of oxaliplatin (L-OHP) and 5-fluorouracil (5-FU), we investigated the in vitro interaction between these drugs in a panel of four human gastric adenocarcinoma cell lines (MKN-1, NUGC-3, NUGC-5 and AZ-521). Cytotoxic activity was determined by the WST-1 assay. Different schedules of the two drugs were compared and evaluated for synergism, additivity or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation and apoptosis were evaluated by flow cytometry. Simultaneous and sequential treatments of L-OHP followed by 5-FU exhibited synergistic effects in all four cell lines, whereas the reverse sequence yielded a clear antagonism. 5-FU exclusively arrested cells at the G0/G1 phase, and L-OHP at the G0/G1 and G2/M phases. Apoptosis was most prominent when cells were treated simultaneously or in a sequence of L-OHP followed by 5-FU, producing apoptosis in the majority of treated cells (55.5-61.5&#37;). In contrast, the reverse sequence yielded only 20&#37; induction of apoptosis, the rate being not significantly different from those induced by each drug singly. Moreover, this sequence dependence was further confirmed by the experiment which compared the total number of NUGC-3 cells 7 days after these combination schedules. These findings suggest that the interaction of 5-FU and L-OHP could be highly schedule dependent, with the most efficacious interaction observed in simultaneous combination and that 5-FU followed by L-OHP would not be recommended in clinical trials for patients with advanced gastric cancer.

    DOI: 10.1097/01.cad.0000198912.98442.cd

  • Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. 査読 国際誌

    Ariyama H, Qin B, Baba E, Tanaka R, Mitsugi K, Harada M, Nakano S

    Journal of cellular biochemistry   97 ( 4 )   724 - 734   2006年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
    Although gefitinib, a selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has been clinically demonstrated to be effective for certain cancer cell types, the molecular mechanisms of the anti-tumor activity have not been fully elucidated. In this study, we investigated the mechanism of gefitinib-induced growth inhibition and apoptosis in HAG-1 human gallbladder adenocarcinoma cells. Treatment of gefitinib at a dose of 1 microM resulted in a significant growth inhibition, and the cell number irreversibly declined after 72-h incubation, with a progressive expansion of apoptotic cell population over 120-h. Following 2-h treatment, gefitinib significantly inhibited EGFR autophosphorylation and subsequent downstream signaling pathway through Erk and Akt, and induced accumulation of cells in the G0/G1 phase of the cell cycle at 24-h, accompanied by a concomitant increase in p21 transcript and increased expression of p27. Gefitinib did not affect the amount of total and phosphorylated p53 at serine 15, but upregulated the expression of total Bax, with subsequent increase in p18 Bax, an active form of Bax. The expression of Bcl-2 and Bad was unchanged. An increase in gefitinib-induced expression of total Bax might be due to the decreased degradation of Bax, because the level of Bax mRNA has not been altered by gefitinib treatment. Gefitinib promoted the cleavage of full-length p21 Bax into p18 Bax in mitochondrial-enriched fraction, a characteristic feature of Bax activation toward apoptosis. Moreover, blockade of Bax by using anti-Bax small interfering double stranded RNA (siRNA) significantly reduced gefitinib-induced apoptosis. Taken together, these data suggest a critical role of p18 Bax in gefitinib-induced apoptosis.

    DOI: 10.1002/jcb.20678

  • Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer. 査読 国際誌

    Qin B, Kato K, Mitsugi K, Nakamura M, Tanaka R, Baba E, Ariyama H, Kuroiwa T, Harada M, Nakano S

    Cancer chemotherapy and pharmacology   57 ( 1 )   114 - 119   2006年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.
    PURPOSE: A great synergy has been reported in a number of preclinical studies when 5-fluorouracil (5-FU) precedes cisplatin (CDDP). The objective of this study was to determine the feasibility of ambulatory continuous infusion of 5-FU followed by CDDP through hepatic artery for metastatic colorectal cancer. PATIENTS AND METHODS: Seventeen patients with unresectable liver metastases, who underwent primary tumor resection, were treated with 5-FU (450 mg/m2/day) for seven consecutive days followed by CDDP (100 mg/body/week) for seven consecutive days, each administered continuously by using a balloon pump via Infuse-A-Port catheter inserted into common hepatic artery. The doses of drugs were reduced 20&#37; in patients older than 70 years. The treatment was repeated every 4-6 weeks until disease progression. RESULTS: Of 17 assessable patients, nine patients showed PR (53&#37;; 95&#37; CI, 29.3-76.7&#37;) and eight patients had SD (47&#37;; 95&#37; CI, 23.3-70.7&#37;), with disease control rate of 100&#37;. The median overall survival was 26 months (95&#37; CI: 17.5-41 months) and TTP 14 months (95&#37; CI: 11-20.3 months). Two patients (11.8&#37;), who showed progression due to collateral feeding arteries, responded to HAI again after occlusion. Grade 3 toxicity included leukopenia (12&#37;) and anemia (24&#37;). Grade 4 toxicity was absent. Four patients (23.5&#37;) progressed at extrahepatic sites. CONCLUSIONS: This sequential combination of 5-FU followed by CDDP through hepatic artery is active and safe in an outpatient setting, and warrants further multi-institutional study, although prevention of micrometastasis would be mandatory to further prolong overall survival.

    DOI: 10.1007/s00280-005-0021-8

  • Evaluation of a dysfunctional and short-lived subset of monocyte-derived dendritic cells from cancer patients 査読 国際誌

    Hideya Onishi, Takashi Morisaki, Hideo Kuroki, Kotaro Matsumoto, Eishi Baba, Hirotaka Kuga, Masao Tanaka, Mitsuo Katano

    Anticancer Research   25 ( 5 )   3445 - 3451   2005年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. 査読 国際誌

    Tanaka R, Ariyama H, Qin B, Shibata Y, Takii Y, Kusaba H, Baba E, Mitsugi K, Harada M, Nakano S

    Oncology reports   14 ( 3 )   683 - 688   2005年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
    The interaction between CPT-11 and oxaliplatin, a new platinum derivative that has a great antitumor activity against colon cancer, has not been determined in gastric cancer cells. In this study, we investigated in vitro cytotoxic activity of oxaliplatin alone or in combination with SN-38, an active metabolite of CPT-11, using different exposure schedules in three human gastric cancer cell lines (AZ-521, MKN-45, and NUGC-4). Cytotoxicity was determined by WST-1 assay. Different treatment schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation was evaluated by flow cytometry. In 24-h exposure, simultaneous administration of oxaliplatin and SN-38 showed a synergistic effect in AZ-521 and NUGC-4 cells, and an additive effect in MKN-45 cells. Greater than additive effects were observed in all of the cell lines when cells were treated with oxaliplatin followed by SN-38, whereas such effects were observed only in NUGC-4 cells in the reverse sequence. Flow cytometric analyses at IC(50) indicated that apoptosis was most prominent in simultaneous exposures with accumulation of cells in both G(0)/G(1) and S phases. These results suggest that SN-38 may kill the cells recovering from the G(1) block produced by oxaliplatin as they progress into the S phase. Simultaneous administration appears most active in gastric cancer cell lines. These results may provide important information for a clinical trial of oxaliplatin and CPT-11 combination for patients with gastric cancer.

  • In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. 査読 国際誌

    Tanaka R, Takii Y, Shibata Y, Ariyama H, Qin B, Baba E, Kusaba H, Mitsugi K, Harada M, Nakano S

    Cancer chemotherapy and pharmacology   56 ( 3 )   279 - 285   2005年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
    PURPOSE: To define the most effective combination schedule of paclitaxel and nedaplatin, a new platinum derivative, we investigated the in vitro interaction between these drugs in AZ-521 and NUGC-4 gastric adenocarcinoma and KSE-1 esophageal squamous carcinoma cell lines. MATERIALS AND METHODS: Cytotoxic activity was determined by the WST-1 assay. Different treatment schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism using a quantitative method based on the median-effect principle of Chou and Talalay. Cell-cycle perturbation and apoptosis were evaluated by means of flow cytometry. RESULTS: Upon 24-h sequential exposure, the sequence paclitaxel followed by nedaplatin induced greater than additive effects in all of the cell lines, with synergistic interactions in NUGC-4 and KSE-1 cells. By contrast, antagonistic effects were observed with the reverse sequence. Simultaneous treatment resulted in either a synergistic or antagonistic effect, depending on the cell line. Therefore, the sequence paclitaxel followed by nedaplatin appears most active, at least in these three cell lines. Flow cytometric analyses at IC50 indicated that paclitaxel induced G2/M arrest with subsequent induction of apoptosis (56&#37;) in the sub-G1 phase. When paclitaxel preceded nedaplatin, apoptosis was most prominent (70&#37;) with pronounced G2/M arrest. By contrast, the reverse sequence yielded only 28&#37; induction of apoptotic cells, with almost identical cell-cycle distribution patterns to those observed with nedaplatin alone, indicating that the activity of paclitaxel is abolished by pretreatment with nedaplatin. CONCLUSIONS: Our findings suggest that the interaction of nedaplatin and paclitaxel is highly schedule dependent and that the sequential administration of paclitaxel followed by nedaplatin should be thus incorporated into the design of a clinical trial.

    DOI: 10.1007/s00280-004-0991-y

  • Non-myeloablative allogeneic haemopoietic stem-cell transplantation for treatment of metastatic invasive thymoma 査読 国際誌

    Akihiko Numata, Keiko Yasuda, Takahiro Fukuda, Eishi Baba, Satoshi Yamasaki, Ken Takase, Toshihiro Miyamoto, Koji Nagafuji, Shuji Nakano, Mine Harada

    Lancet Oncology   6 ( 8 )   626 - 628   2005年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/S1470-2045(05)70285-0

  • In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. 査読 国際誌

    Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, Harada M, Nakano S

    Cancer chemotherapy and pharmacology   55 ( 6 )   595 - 601   2005年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
    PURPOSE: In order to define the most effective administration schedule of the combination of paclitaxel and oxaliplatin, we investigated the in vitro interaction between these drugs in a panel of three human cancer cell lines (AZ-521 gastric adenocarcinoma cell line, HST-1 tongue squamous carcinoma cell line, and KSE-1 esophageal squamous carcinoma cell line). MATERIALS AND METHODS: Cytotoxic activity was determined by the WST-1 assay. Different administration schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation and apoptosis were evaluated by flow cytometry. RESULTS: Simultaneous treatment of cells with paclitaxel and oxaliplatin showed greater than additive effects. Upon 24-h sequential exposure, the sequence of paclitaxel followed by oxaliplatin showed synergistic effects in AZ-521 and HST-1 cells, and greater than additive effects in KSE-1 cells, while the opposite sequence yielded marked antagonistic effects in all three cell lines. Flow cytometric analysis indicated that paclitaxel induced G(2)/M arrest with subsequent induction of apoptosis in the sub-G(1) phase. Apoptosis was most prominent when paclitaxel preceded oxaliplatin, which produced apoptosis in the majority of treated cells (75&#37;). By contrast, the reverse sequence yielded only 39&#37; induction of apoptotic cells, the rate being not different from those induced by each drug singly. CONCLUSIONS: Our findings suggest that the interaction of paclitaxel and oxaliplatin is highly schedule-dependent and that the sequential administration of paclitaxel followed by oxaliplatin should thus be incorporated into the design of a clinical trial.

    DOI: 10.1007/s00280-004-0966-z

  • Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/β2-microglobulin null mice 査読

    19 ( 8 )   1384 - 1390   2005年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1038/sj.leu.2403829

  • Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-α through IL-12/TNF-α/NF-κB autocrine loop 査読 国際誌

    53 ( 12 )   1093 - 1100   2004年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This study focused on the question of how monocyte-derived dendritic cells (Mo-DCs) that capture dead tumor cells (Mo-DCs-Tum) secrete interleukin 12 (IL-12) and tumor necrosis factor α (TNF-α). Mo-DCs-Tum showed higher secretions of IL-12 and TNF-α than were shown by Mo-DCs. Enhanced nuclear factor-kappa B (NF-κB) activation was also induced in MoDCs-Tum within 6 h. The NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC), suppressed both IL-12 and TNF-α secretions from Mo-DCs-Tum. Administration of recombinant TNF-α or IL-12 enhanced IL-12 or TNF-α secretion respectively in Mo-DCs-Tum. Addition of anti-TNF-α or anti-IL-12 neutralizing antibody decreased NF-κB activation and IL-12 or TNF-α secretion in Mo-DCs-Tum. These results suggest that TNF-α or IL-12 secretion induces NF-κB activation, and it stimulates further TNF-α and IL-12 secretions, i.e., an IL-12/TNF-α/NF-κB autocrine loop, in Mo-DCs-Tum. Thus, Mo-DCs-Tum secrete a large amount of IL-12 and TNF-α through accelerated NF-κB activation induced by the IL-12/TNF-α/NF- κB autocrine loop. © Springer-Verlag 2004.

    DOI: 10.1007/s00262-004-0568-y

  • Exosomes secreted from monocyte-derived dendritic cells support in vitro naive CD4+ T cell survival through NF-κB activation 査読 国際誌

    231 ( 1-2 )   20 - 29   2004年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We investigated the effect of exosomes secreted from human monocyte-derived dendritic cells (Mo-DCs), which are generated from PBMCs in response to treatment with GM-CSF and IL-4, on naive CD4+ T cell survival in vitro. Exosomes isolated from culture supernatants of Mo-DCs (&gt
    90&#37; purity) were purified with anti-HLA-DP, -DQ, -DR-coated paramagnetic beads. Purified exosomes prolonged the survival of naive CD4+ T cells (&gt
    98&#37; purity) in vitro. Treatment with neutralizing mAb against HLA-DR significantly decreased the supportive effect of purified exosomes on CD4+ T cell survival. Exosomes increased nuclear translocation of NF-κB in naive CD4+ T cells, and NF-κB activation was significantly suppressed by anti-HLA-DR mAb or NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC). In addition, PDTC inhibited the effect of exosomes on naive CD4+ T cell survival. Thus, exosomes secreted by Mo-DCs appear to support naive CD4+ T cell survival via NF-κB activation induced by interaction of HLA-DR and TCRs. © 2004 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.cellimm.2004.11.002

  • Protection against methotrexate toxicity by a soybean protein- and omega-3 fatty acid-containing diet: comparative study with a casein-containing diet. 査読 国際誌

    Mitsugi K, Nakamura T, Kashiwabara N, Ariyama H, Tanaka R, Baba E, Nakamura M, Harada M, Nakano S

    Oncology reports   12 ( 1 )   41 - 45   2004年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Protection against methotrexate toxicity by a soybean protein- and omega-3 fatty acid-containing diet: comparative study with a casein-containing diet.
    Effects of two clinically used liquid diets on toxicity and antitumor activity of methotrexate (MTX) were investigated in Sprague-Dawley (SD) rats and tumor-bearing mice, respectively. Diets tested were commercially available formulas enriched either with soybean and omega-3 fatty acids or with casein. The soybean-containing diet offered significant protection against MTX toxicity in rats compared with the casein-containing diet, completely alleviating MTX-induced anorexia, diarrhea, and weight loss, when ingested as the sole diet and fed 7 days prior to and 7 days following intraperitoneal MTX injection. As a result, 90&#37; of rats were alive on soybean-containing diet while all rats were dead on casein-containing diet. Histologic examination of the small intestine of MTX-treated rats revealed that the soybean-containing diet significantly prevented loss of mucosal villus tips compared to the casein-containing diet. Pharmocokinetic examination indicated that plasma MTX concentrations were similar for rats in the two diet-defined groups. No significant differences were observed between diets in survival of mice injected with L1210 mouse leukemia cells and subsequently with MTX. Thus the soybean-containing diet appeared to be superior to the casein-containing diet in preventing gastrointestinal toxicity while preserving antitumor activity. A soybean diet enriched in omega-3 fatty acids may be a useful adjunct to MTX treatment of human cancers.

  • Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer. 査読

    Fujishima H, Kikuchi I, Miyanaga O, Ueda A, Baba E, Mitsugi K, Harada M, Nakano S

    International journal of clinical oncology   9 ( 2 )   92 - 97   2004年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    BACKGROUND: Irinotecan (CPT-11) and bolus 5-fluorouracil (5-FU)/leucovorin (LV) administered weekly for 4 weeks every 42 days (Saltz regimen) is active but substantially toxic in patients with metastatic colorectal cancer (CRC). The efficacy and toxicity of this regimen, however, have not been determined in Japanese patients with metastatic CRC. METHODS: We investigated the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose (RD) for CPT-11 given i.v. (90-min infusion) and bolus 5-FU plus biologically active l-LV administered weekly for 3 weeks every 28 days (modified Saltz regimen) in Japanese patients with metastatic CRC. Eighteen patients with measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, and adequate organ functions were enrolled. RESULTS: At dose level 2 (CPT-11, 100 mg/m(2); 5-FU, 400 mg/m(2); and l-LV, 25 mg/body), 1 of 6 patients had DLT (febrile neutropenia). At dose level 3 (CPT-11, 100 mg/m(2); 5-FU, 500 mg/m(2); and l-LV, 25 mg/body), 2 of 6 patients had DLT (febrile neutropenia and grade 4 neutropenia lasting more than 4 days). To determine whether level 3 was the MTD level, an additional 3 patients were treated at this level, but no DLT was observed. Consequently, 2 of 9 patients had DLT at level 3, this level thus being considered as the RD. At this level, grade 3-4 neutropenia was common but manageable. Nonhematological toxicities were mild. Seven partial responses were observed in the 18 enrolled patients (response rate [RR], 39&#37;), and 8 patients (44&#37;) experienced stable disease. CONCLUSION: This CPT-11/5-FU/ l-LV regimen administered weekly for 3 weeks every 28 days has substantial antitumor activity, with manageable toxicities. A multicenter phase II study is currently underway. Irinotecan (CPT-11) and bolus 5-fluorouracil (5-FU)/leucovorin (LV) administered weekly for 4 weeks every 42 days (Saltz regimen) is active but substantially toxic in patients with metastatic colorectal cancer (CRC). The efficacy and toxicity of this regimen, however, have not been determined in Japanese patients with metastatic CRC.

    DOI: 10.1007/s10147-003-0371-3

  • Three-dimensional two-layer collagen matrix gel culture model for evaluating complex biological functions of monocyte-derived dendritic cells 査読 国際誌

    Akira Tasaki, Naoki Yamanaka, Makoto Kubo, Kotaro Matsumoto, Hideo Kuroki, Katsuya Nakamura, Chihiro Nakahara, Hideya Onishi, Hirotaka Kuga, Eishi Baba, Masao Tanaka, Takashi Morisaki, Mitsuo Katano

    Journal of Immunological Methods   287 ( 1-2 )   79 - 90   2004年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jim.2004.01.014

  • Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients rationale, current progress, and perspectives. 査読

    Takashi Morisaki, Kotaro Matsumoto, Hideya Onishi, Hideo Kuroki, Eishi Baba, Akira Tasaki, Makoto Kubo, Mitsunari Nakamura, Syoichi Inaba, Koji Yamaguchi, Masao Tanaka, Mitsuo Katano

    Human cell : official journal of Human Cell Research Society   16 ( 4 )   175 - 182   2003年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/j.1749-0774.2003.tb00151.x

  • Combination of Adoptive Immunotherapy with Herceptin for Patients with HER2-expressing Breast Cancer 査読 国際誌

    Makoto Kubo, Takashi Morisaki, Hideo Kuroki, Akira Tasaki, Naoki Yamanaka, Kotaro Matsumoto, Katsuya Nakamura, Hideya Onishi, Eishi Baba, Mitsuo Katano

    Anticancer Research   23 ( 6 A )   4443 - 4449   2003年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)  

  • Cyclosporin-A Enhances Docetaxel-Induced Apoptosis through Inhibition of Nuclear Factor-κB Activation in Human Gastric Carcinoma Cells 査読 国際誌

    9 ( 14 )   5409 - 5416   2003年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Purpose: We sought to determine whether cyclosporin-A (CsA) enhances docetaxel [Taxotere (TXT)]-induced apoptosis in human gastric carcinoma cells, and, if so, to determine the relation between this apoptosis and nuclear factor-κB (NF-κB) activation. Experimental Design: Two human gastric carcinoma cell lines (GCTM-1 and MK-1), a human embryonic pulmonary fibroblast cell line, and human umbilical vein endothelial cells were used as drug targets. Apoptotic cell death was verified morphologically by nuclear fragmentation assay with Hoechst staining. Electrophoretic mobility shift assays were performed to check for nuclear translocation of NF-κB. The therapeutic effects of a combination of TXT and CsA were assessed in a mouse peritoneal dissemination model. Results: A combination of CsA (5 μM) and TXT (10 nM) significantly enhanced apoptotic cell death in both carcinoma cell lines but not in nonmalignant cell lines in comparison with the single-agent treatment alone. This effect was not related to drug uptake, efflux, or MDR1 expression. These effects were also observed in freshly obtained TXT-resistant gastric carcinoma cells isolated from a patient with malignant ascites. TXT alone induced NF-κB activation in both carcinoma cell types, and this activation was suppressed by CsA. A combination of TXT and NF-κB decoy, a well-known NF-κB inhibitor, also enhanced apoptotic cell death in the carcinoma cells. A combination of CsA and TXT significantly suppressed peritoneal dissemination in vivo relative to the single-agent effect. Conclusions: Treatment with CsA and TXT in combination may be an effective therapeutic strategy for patients with gastric carcinoma.

  • Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion 査読 国際誌

    T Morisaki, K Matsumoto, H Kuroki, M Kubo, E Baba, H Onishi, A Tasaki, M Nakamura, S Inaba, M Katano

    ANTICANCER RESEARCH   23 ( 6A )   4459 - 4465   2003年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Streptococcal preparation OK-432: A new maturation factor of monocyte-derived dendritic cells for clinical use 査読 国際誌

    Hideo Kuroki, Takashi Morisaki, Kotaro Matsumoto, Hideya Onishi, Eishi Baba, Masao Tanaka, Mitsuo Katano

    Cancer Immunology, Immunotherapy   52 ( 9 )   561 - 568   2003年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00262-003-0394-7

  • Distinct Costimulation Dependent and Independent Autoreactive T-Cell Clones in Primary Biliary Cirrhosis 査読

    Takashi Kamihira, Shinji Shimoda, Kenichi Harada, Akira Kawano, Mizuki Handa, Eishi Baba, Koichi Tsuneyama, Minoru Nakamura, Hiromi Ishibashi, Yasuni Nakanuma, M. Eric Gershwin, Mine Harada

    Gastroenterology   125 ( 5 )   1379 - 1387   2003年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.gastro.2003.07.013

  • Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer 査読 国際誌

    Hideya Onishi, Takashi Morisaki, Eishi Baba, Hirotaka Kuga, Hideo Kuroki, Kotaro Matsumoto, Masao Tanaka, Mitsuo Katano

    Clinical Immunology   105 ( 3 )   286 - 295   2002年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1006/clim.2002.5293

  • Simulated microgravity culture system for a 3-D carcinoma tissue model 査読

    K. Nakamura, H. Kuga, T. Morisaki, E. Baba, N. Sato, K. Mizumoto, K. Sueishi, M. Tanaka, Mitsuo Katano

    BioTechniques   33 ( 5 )   1068 - 1076   2002年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Functional CD4 T cells after intercellular molecular transfer of OX40 ligand

    E Baba, Y Takahashi, J Lichtenfeld, R Tanaka, A Yoshida, K Sugamura, N Yamamoto, Y Tanaka

    JOURNAL OF IMMUNOLOGY   167 ( 2 )   875 - 882   2001年7月

     詳細を見る

    記述言語:英語  

  • N-linked carbohydrate on human leukocyte antigen-C and recognition by natural killer cell inhibitory receptors

    E Baba, R Erskine, JE Boyson, GB Cohen, DM Davis, P Malik, O Mandelboim, HT Reyburn, JL Strominger

    HUMAN IMMUNOLOGY   61 ( 12 )   1202 - 1218   2000年12月

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/S0198-8859(00)00184-1

  • Biotinylation of class I MHC molecules abrogates recognition by W6/32 antibody 査読

    P Malik, E Baba, JL Strominger

    TISSUE ANTIGENS   53 ( 6 )   576 - 579   1999年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • The transmembrane sequence of human histocompatibility leukocyte antigen (HLA)-C as a determinant in inhibition of a subset of natural killer cells

    DM Davis, O Mandelboim, Luque, I, E Baba, J Boyson, JL Strominger

    JOURNAL OF EXPERIMENTAL MEDICINE   189 ( 8 )   1265 - 1274   1999年4月

     詳細を見る

    記述言語:英語  

    DOI: 10.1084/jem.189.8.1265

  • Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: A combined clinical, virological and immunological study 査読

    Kenji Yamasaki, Jun-Ichi Kira, Yoshio Koyanagi, Yuji Kawano, Naoko Miyano-Kurosaki, Minoru Nakamura, Eishi Baba, Jun Suzuki, Akifumi Yamamoto, Naoki Yamamoto, Takuro Kobayashi

    Journal of the Neurological Sciences   147 ( 2 )   135 - 144   1997年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/S0022-510X(96)05319-1

  • The association of antibodies against human T cell lymphotropic virus type I (HTLV-I) pX gene mutant products with HTLV-I-associated myelopathy/tropical spastic paraparesis 査読

    Jun Suzuki, Jun Ichi Kira, Eishi Baba, Minoru Nakamura, Yoshio Koyanagi, Tatsufumi Nakamura, Yuji Kawano, Kenji Yamasaki, Susumu Shirabe, Naoya Hatano, Kenshi Hayashi, Naoki Yamamoto, Takuro Kobayashi

    Journal of Infectious Diseases   173 ( 5 )   1115 - 1122   1996年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/infdis/173.5.1115

  • Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. 査読

    Masumoto N, Nakano S, Esaki T, Tatsumoto T, Fujishima H, Baba E, Nakamura M, Niho Y

    Anticancer research   15 ( 2 )   405 - 409   1995年3月

     詳細を見る

    記述言語:その他  

    Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.

  • A PEPTIDE-BASED HUMAN T-CELL LEUKEMIA-VIRUS TYPE-I VACCINE CONTAINING T-CELL AND B-CELL EPITOPES THAT INDUCES HIGH TITERS OF NEUTRALIZING ANTIBODIES

    E BABA, M NAKAMURA, K OHKUMA, J KIRA, Y TANAKA, S NAKANO, Y NIHO

    JOURNAL OF IMMUNOLOGY   154 ( 1 )   399 - 412   1995年1月

     詳細を見る

    記述言語:英語  

  • Characterization of a newly established human gallbladder carcinoma cell line. 査読

    Nakano S, Tatsumoto T, Esaki T, Nakamura M, Baba E, Kimura A, Ohshima K, Niho Y

    In vitro cellular & developmental biology. Animal   30A ( 11 )   729 - 732   1994年11月

     詳細を見る

    記述言語:その他  

    Characterization of a newly established human gallbladder carcinoma cell line.

  • Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization 査読

    Yuetsu Tanaka, Reiko Tanaka, Eiji Terada, Yoshio Koyanagi, Naoko Miyano-Kurosaki, Naoki Yamamoto, Eishi Baba, Minoru Nakamura, Hisatoshi Shida

    Journal of Virology   68 ( 10 )   6323 - 6331   1994年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Sequence heterogeneity of HTLV‐I proviral DNA in the central nervous system of patients with HTLV‐I–associated myelopathy 査読

    Jun‐ichi ‐i Kira, Yoshio Koyanagi, Takeshi Yamada, Yasuto Itoyama, Jun Tateishi, Shin‐ichiro ‐i Akizuki, Masao Kishikawa, Eishi Baba, Minoru Nakamura, Jun Suzuki, Tatsufumi Nakamura, Naomi Nakamura, Naoki Yamamoto, Ikuo Goto

    36 ( 2 )   149 - 156   1994年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The nucleotide sequence of human T‐lymphotropic virus type I (HTLV‐I) in central nervous system tissue was determined in 3 autopsy cases with HTLV‐I–associated myelopathy (HAM)/tropical spastic paraparesis (TSP) and 1 seropositive carrier without HAM/TSP but with multiple sclerosis. All HAM/TSP samples (3 spinal cords and 2 brains) and the sample from the seropositive carrier without HAM/TSP (brain) were positive for HTLV‐I env (5146–6681), pX5′ (6549–7494), and pX3′ (7354–8276) regions by the two‐step polymerase chain reaction method. A nucleotide sequence analysis of the pX5′ and pX3′ polymerase chain reaction products from nucleotides 6631 to 8259 revealed heterogeneity of the HTLV‐I genome in all cases. It is notable that 13 of 50 clones derived from the pX3′ polymerase chain reaction products were defective in the tax open reading frame while 7 were defective in the rex open reading frame in the HAM/TSP samples. All 17 clones from 1 HAM/TSP case were defective in the pX open reading frame II. One nucleotide insertion at 7784 creating a frame shift in both tax and rex was seen in all 3 HAM/TSP cases but not in the HTLV‐I carrier without HAM/TSP. The pX‐defective mutants found frequently in the central nervous system may contribute to the neural damage, since the pX gene products are essential for the transactivation of various cellular genes as well as for viral replication.

    DOI: 10.1002/ana.410360206

  • Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies A basis for the design of an HTLV-1 peptide vaccine 査読

    E. Baba, M. Nakamura, Y. Tanaka, M. Kuroki, Y. Itoyama, S. Nakano, Y. Niho

    Journal of Immunology   151 ( 2 )   1013 - 1024   1993年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

  • Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1 査読

    M. Kuroki, M. Nakamura, Y. Itoyama, Y. Tanaka, H. Shiraki, E. Baba, T. Esaki, T. Tatsumoto, S. Nagafuchi, S. Nakano, Y. Niho

    Journal of Immunology   149 ( 3 )   940 - 948   1992年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

▼全件表示

書籍等出版物

  • 転移性食道癌患者の管理のための汎アジア適応ESMO診療ガイドライン

    馬場 英司

    2019年1月 

     詳細を見る

    記述言語:その他  

講演・口頭発表等

  • MSI-High固形癌の新たな治療戦略 招待

    馬場 英司

    第78回日本癌学会学術総会  2019年9月 

     詳細を見る

    開催年月日: 2019年9月

    記述言語:日本語   会議種別:口頭発表(一般)  

    開催地:国立京都国際会館   国名:日本国  

  • New drugs in GI cancer for future Asian trial 招待 国際会議

    Eishi Baba

    WJOG 4th international symposium on clinical trials  2012年4月 

     詳細を見る

    開催年月日: 2012年4月

    記述言語:その他   会議種別:シンポジウム・ワークショップ パネル(公募)  

    国名:日本国  

  • Best of ASCO Japan 2011 胃癌 招待

    馬場英司

    日本臨床腫瘍学会/米国臨床腫瘍学会ジョイントセミナー  2011年7月 

     詳細を見る

    開催年月日: 2011年7月

    記述言語:その他   会議種別:口頭発表(一般)  

    国名:日本国  

  • これからの切除不能進行胃癌の臨床課題「global III相をうけて」:SOS study 招待

    馬場英司

    第83回日本胃癌学会  2011年3月 

     詳細を見る

    開催年月日: 2011年3月

    記述言語:その他  

    開催地:青森県三沢市   国名:日本国  

  • Best of ASCO 2009 大腸癌 招待

    馬場英司

    Best of ASCO 2009 in Japan:日本臨床腫瘍学会/ASCOジョイント教育コース  2009年7月 

     詳細を見る

    開催年月日: 2010年7月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:東京   国名:日本国  

  • Best of ASCO 2010 大腸癌 招待

    馬場英司

    Best of ASCO 2010 in Japan:日本臨床腫瘍学会/ASCOジョイント教育コース  2010年7月 

     詳細を見る

    開催年月日: 2010年7月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:東京   国名:日本国  

  • Exosomeを介した細胞間 small RNA 輸送

    薦田正人, 馬場英司, 磯部大地, 新納宏昭, 在田修二, 有山 寛, 草場仁志, 赤司浩一

    第68回日本癌学会学術総会  2009年10月 

     詳細を見る

    開催年月日: 2009年10月

    記述言語:その他  

    開催地:横浜   国名:日本国  

  • A phase II study of sequential administration of S-1 and cisplatin (CDDP) in patients with metastatic gastric cancer (MGC). 国際会議

    E. Baba, K. Tsukasa, H. Ariyama, T. Esaki, K. Sakai, H. Fujishima, K. Mitsugi, H. Kusaba, K. Akashi, S. Nakano

    American Society of Clinical Oncology 2008  2008年6月 

     詳細を見る

    開催年月日: 2008年6月

    記述言語:その他  

    国名:アメリカ合衆国  

  • The Update of Japanese gastric cancer guidelines: Chemotherapy for unresectable advanced/recurrent gastric cancer in the 6th edition (2021) 招待 国際会議

    Eishi Baba

    Chinese Society of Clinical Oncology, Gastrointestinal Cancer Immunotherapy Forum 2021  2021年5月 

     詳細を見る

    開催年月日: 2021年5月

    記述言語:英語   会議種別:口頭発表(一般)  

    国名:日本国  

  • 点滴反応・アナフィラキシーに対する支持療法 招待

    馬場英司, 草場仁志, 赤司浩一, 高石繁生

    日本臨床腫瘍学会  2011年7月 

     詳細を見る

    開催年月日: 2011年7月

    記述言語:その他   会議種別:シンポジウム・ワークショップ パネル(公募)  

    国名:日本国  

  • SOS study: Overview of Protocol 招待 国際会議

    Eishi Baba

    West Japan Oncology Group SOS study Kick-Off Meeting in Japan  2010年5月 

     詳細を見る

    開催年月日: 2011年5月

    記述言語:その他   会議種別:口頭発表(一般)  

    国名:日本国  

  • 切除不能胃癌に対する化学療法Up to date 2010 招待

    馬場英司

    長崎オンコロジー薬剤師研究会  2010年9月 

     詳細を見る

    開催年月日: 2010年9月

    記述言語:その他   会議種別:口頭発表(招待・特別)  

    開催地:国立病院機構長崎医療センター   国名:日本国  

  • 切除不能高度肝転移に対する化学療法-Conversion therapy- 招待

    馬場英司

    2010年9月 

     詳細を見る

    開催年月日: 2010年9月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:東京   国名:日本国  

  • SOS study: From Japanese Investigator 招待 国際会議

    Eishi Baba

    SOS study meeting  2010年8月 

     詳細を見る

    開催年月日: 2010年8月

    記述言語:その他  

    国名:日本国  

  • 切除不能大腸癌に対する化学療法Up to date 招待

    馬場英司

    第95回日本消化器病学会九州支部例会  2010年6月 

     詳細を見る

    開催年月日: 2010年6月

    記述言語:その他   会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

    開催地:福岡県北九州市   国名:日本国  

  • Medical Oncologists 九州大学病院血液・腫瘍内科の取組み 招待

    馬場英司

    財団法人大分県産業創造機構 第290回日本経済勉強会  2010年5月 

     詳細を見る

    開催年月日: 2010年5月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:財団法人大分県産業創造機構   国名:日本国  

  • 日本臨床腫瘍学会 がん薬物療法専門医のための症例報告の書き方 招待

    馬場英司

    九州がんプロフェッショナル養成協議会平成22年度第1回講演会  2010年5月 

     詳細を見る

    開催年月日: 2010年5月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:九州大学   国名:日本国  

  • 消化器がん化学療法と血栓塞栓症発症の相関関係を考える-D‐dimerは本当に有用か?

    白川 剛, 田村真吾, 薦田正人, 平野 元, 磯部大地, 内野慶太, 草場仁志, 馬場英司, 赤司浩一

    第8回日本臨床腫瘍学会学術集会  2010年3月 

     詳細を見る

    開催年月日: 2010年3月 - 2010年4月

    記述言語:その他  

    開催地:東京   国名:日本国  

  • 癌患者末梢血中エクソソームに含まれるmiRNAの検出と機能解析

    薦田正人, 馬場英司, 磯部大地, 新納宏昭, 在田修二, 内野慶太, 白川 剛, 有山 寛, 草場仁志, 赤司浩一

    第8回日本臨床腫瘍学会学術集会  2010年3月 

     詳細を見る

    開催年月日: 2010年3月

    記述言語:その他  

    開催地:東京   国名:日本国  

  • 巨大縦隔腫瘤として発見された悪性中皮腫の一例

    藤本雄一, 内野慶太, 田村真吾, 有山 寛, 草場仁志, 馬場英司, 赤司浩一

    第288回内科学会九州地方会  2010年1月 

     詳細を見る

    開催年月日: 2010年1月

    記述言語:その他  

    国名:日本国  

  • アバスチン使用状況と安全性についての後方視的検討 招待

    馬場英司

    がん化学療法セミナー in 福岡  2009年11月 

     詳細を見る

    開催年月日: 2009年11月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:福岡   国名:日本国  

  • Clinical Study of S-1and CDDP for Metastatic Gastric Cancer 招待 国際会議

    Eishi Baba

    1st International Forum of Regional and Targeting Therapies for Cancer  2009年11月 

     詳細を見る

    開催年月日: 2009年11月

    記述言語:その他   会議種別:口頭発表(一般)  

    国名:中華人民共和国  

  • 当科で経験した心臓悪性腫瘍4例の後方視的検討

    白川 剛, 田村真吾, 薦田正人, 平野 元, 磯部大地, 中司 元, 安田潮人, 小田代敬太, 内野慶太, 有山 寛, 草場仁志, 馬場英司

    第47回日本癌治療学会学術集会  2009年10月 

     詳細を見る

    開催年月日: 2009年10月

    記述言語:その他  

    開催地:横浜   国名:日本国  

  • Human Nanog P8 promotes the proliferation of gastrointestinal cancer cells. 国際会議

    K. Uchino, G. Hirano, M. Hirahashi, T. Shirakawa, H. Kusaba, M. Tsuneyoshi, E. Baba, K. Akashi;

    34th European Society of Medical Oncology Congress  2009年9月 

     詳細を見る

    開催年月日: 2009年9月

    記述言語:その他  

    国名:ドイツ連邦共和国  

  • 消化器癌の化学療法 招待

    馬場英司

    対馬市学術講演会  2009年9月 

     詳細を見る

    開催年月日: 2009年9月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:対馬市   国名:日本国  

  • 口腔扁平苔癬にて発症した大腸癌の1例

    田村真吾, 内野慶太, 有山 寛, 草場仁志, 馬場英司, 赤司浩一

    第286回日本内科学会九州地方会  2009年8月 

     詳細を見る

    開催年月日: 2009年8月

    記述言語:その他  

    開催地:鹿児島   国名:日本国  

  • セツキシマブの使用経験と副作用対策 招待

    馬場英司

    大分大腸癌治療セミナー  2009年7月 

     詳細を見る

    開催年月日: 2009年7月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:大分   国名:日本国  

  • 消化器がんの化学療法と地域連携 招待

    馬場英司

    第4回がん地域連携研究会  2009年6月 

     詳細を見る

    開催年月日: 2009年6月

    記述言語:その他  

    開催地:福岡   国名:日本国  

  • がん化学療法患者における精神症状発現のスクリーニング法としてのHospital Anxiety And Depression Scaleの妥当性の検討

    内野慶太, 白川 剛, 薦田正人, 有山 寛, 草場仁志, 馬場英司, 赤司浩一, 臼杵理人, 光安博志, 川嵜弘詔, 岸本淳司

    第14回日本緩和医療医療総会  2009年6月 

     詳細を見る

    開催年月日: 2009年6月

    記述言語:その他   会議種別:口頭発表(一般)  

    開催地:大阪   国名:日本国  

  • ベバシズマブ承認後の切除不能・再発大腸癌の化学療法の現況 招待

    馬場英司

    大腸癌ガイドライン講座  2009年4月 

     詳細を見る

    開催年月日: 2009年4月

    記述言語:その他  

    開催地:福岡   国名:日本国  

  • 切除不能進行再発大腸癌に対するFOLFIRI+ラムシルマブ療法の安全性と有効性の検討

    馬場 英司

    第16回日本臨床腫瘍学会総会  2018年7月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 切除不能進行大腸癌に対する抗VEGF抗体併用化学療法における早期腫瘍縮小率(Early Tumor Shrinkage; ETS)の臨床的有用性

    馬場 英司

    第111回日本消化器病学会九州支部例会  2018年6月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 化学療法施行患者における静脈血栓塞栓症の臨床的検討

    馬場 英司

    第1回腫瘍循環器学会総会  2018年11月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 化学療法高度感受性Epstein-Barr virus 関連進行胃癌におけるDNAメチル化の統合的データベース解析

    馬場 英司

    福岡癌化学療法研究会  2018年2月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 大腸癌化学療法の現況と展望

    馬場 英司

    鹿児島消化器癌集学的治療講演会  2018年2月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 実臨床に即した切除不能・進行再発消化器がんに対する適切な治療戦略 切除不能・進行再発胃癌治療の近未来予想図

    馬場 英司

    第104回日本消化器病学会総会  2018年4月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 慢性期に再増悪を来したトラスツズマブ関連心筋症の1例

    馬場 英司

    第16回日本臨床腫瘍学会総会  2018年7月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 無症候性の重症冠攣縮性狭心症を呈したフルオロウラシル投与患者

    馬場 英司

    第1回腫瘍循環器学会総会  2018年11月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 直腸癌に対するAflibercept併用化学療法により重症肺血栓塞栓症を来たした1例

    馬場 英司

    第1回腫瘍循環器学会総会  2018年11月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 胃がん治療における免疫チェックポイント阻害剤の有用性

    馬場 英司

    第97回 聖マリア病院地域医療支援講演会  2018年4月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 腫瘍生物学におけるエクソソーム研究の現状と展望:Discussion

    馬場 英司

    第77回日本癌学会学術総会  2018年9月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 進行再発大腸癌に対する新規薬剤ラムシルマブ併用療法の安全性と有効性

    馬場 英司

    第111回日本消化器病学会九州支部例会  2018年6月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • Current progress and issues of cancer genomic medicine in Kyushu University Hospital

    Mamoru Ito, Hitomi Kawaji, Makoto Kubo, Eiji Oki, Eiji Iwama, Takahiro Maeda, Masanobu Ogawa, Masayuki Ochiai, Sawako Shikada, Hidetaka Yamamoto, Maya Suzuki, Koji Todaka, Naoki Nakashima, Minako Yoshihara, Mikita Suyama, Eishi Baba, Koichi Akashi, Yoichi Nakanishi

    ANNALS OF ONCOLOGY  2019年10月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Predictive value of primary tumor location: Results from randomized phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)

    T. Tamura, D. Sakai, N. Sugimoto, S. Tokunaga, A. Tsuji, H. Ishida, S. Otsu, T. Moriwaki, H. Satake, K. Uchino, S. Matsumoto, E. Baba, M. Sato, H. Taniguchi, J. Kishimoto, N. Boku, I. Hyodo, K. Muro

    ANNALS OF ONCOLOGY  2017年9月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • ASCOのnet health benefit (NHB)について (特集 新しい臨床試験デザインと結果の評価)

    髙吉 琴絵, 有山 寛, 馬場 英司

    腫瘍内科 = Clinical oncology  2016年4月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 肺がん治療における血管新生阻害薬 (特集 肺がんの個別化医療)

    岩間 映二, 馬場 英司

    最新医学  2015年12月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 胃がんに対する血管新生阻害薬 : ベバシズマブとラムシルマブの臨床効果の違い (特集 消化管がん(食道がん,胃がん,大腸がん等)の新しい標準的治療に対する考察)

    髙吉 琴絵, 草場 仁志, 馬場 英司

    腫瘍内科 = Clinical oncology  2015年10月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 切除不能進行大腸がんに対する薬物療法選択の標準的考え方 (特集 大腸がん治療の新戦略)

    有山 寛, 草場 仁志, 馬場 英司

    腫瘍内科  2014年7月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 胃がんに対する抗体療法 (特集 抗体によるがん分子標的治療) -- (臓器別がんに対する抗体療法)

    柴田 義宏, 草場 仁志, 馬場 英司

    最新医学  2014年3月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 胃がんに対する個別化医療 (特集 標準治療となった個別化治療)

    白川 剛, 草場 仁志, 馬場 英司

    腫瘍内科  2012年1月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • Epithelial-mesenchymal transition(EMT)--上皮間葉転換

    草場 仁志, 高石 繁生, 馬場 英司

    腫瘍内科  2011年3月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • その他の小分子物質(多標的薬を含む) (特集 血管新生阻害剤の効果と功罪) -- (小分子物質)

    馬場 英司, 草場 仁志

    腫瘍内科  2010年6月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • がん薬物療法専門医講座 がん薬物療法専門医のための模擬テスト(10)解答と解説

    馬場 英司

    腫瘍内科  2009年12月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 症例 Gemcitabine+Cisplatin併用療法が奏効した腎盂移行上皮癌と肺扁平上皮癌との重複癌の1例

    薦田 正人, 草場 仁志, 馬場 英司

    腫瘍内科  2009年2月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • SEQUENCE HETEROGENEITY OF HUMAN T-LYMPHOTROPIC VIRUS TYPE I(HTLV-I) PROVIRAL DNA IN THE CENTRAL-NERVOUS-SYSTEM OF PATIENTS WITH HTLV-I-ASSOCIATED MYELOPATHY AND THE POSSIBLE EXPRESSION OF THE MUTANT PX GENE-PRODUCTS IN-VIVO

    J KIRA, J SUZUKI, E BABA, Y KOYANAGI, N YAMAMOTO, T KOBAYASHI

    ANNALS OF NEUROLOGY  1995年8月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • 切除不能進行・再発大腸癌の化学療法 招待

    馬場 英司

    第61回九州支部生涯教育講演会  2018年1月 

     詳細を見る

    記述言語:日本語  

    国名:その他  

  • 進行・再発胃癌に対するS-1+CDDP併用化学療法第I/II相試験

    馬場英司, 藤島弘光, 草場仁志, 江崎泰斗, 有山寛, 加藤健, 田中吏佐, 柴田義宏, 在田修二, 三ツ木健二, 原田実根, 中野修治

    日本消化器病学会総会  2005年10月 

     詳細を見る

    記述言語:その他  

    開催地:神戸   国名:日本国  

  • 難治性固形腫瘍に対する骨髄非破壊的前処置を用いた同種末梢血幹細胞移植の検討

    馬場英司, 長藤宏司, 宮本敏浩, 福田隆浩, 草場仁志, 安部康信, 伊藤鉄英, 牟田耕一郎, 名和田新, 中野修治, 原田実根

    日本臨床腫瘍学会総会  2005年3月 

     詳細を見る

    記述言語:その他  

    開催地:横浜   国名:日本国  

  • エクソゾームに集積するHLA分子の糖鎖解析

    馬場英司, 在田修二, 柴田義宏, 草場仁志, 中野修治, 原田実根

    第34回日本免疫学会総会・学術集会  2004年12月 

     詳細を見る

    記述言語:その他  

    開催地:札幌   国名:日本国  

  • ヒト免疫細胞におけるエクソソーム産生動態の検討

    在田修二, 馬場英司, 柴田義宏, 草場仁志, 中野修治, 原田実根

    第34回日本免疫学会総会・学術集会  2004年12月 

     詳細を見る

    記述言語:その他  

    開催地:札幌   国名:日本国  

  • 固形癌に対する骨髄非破壊的移植前治療を用いた同種末梢血幹細胞移植療法の検討

    馬場英司, 長藤宏司, 宮本敏浩, 福田隆浩, 三ツ木健二, 安部康信, 伊藤鉄英, 牟田耕一郎, 名和田新, 中野修治, 原田実根

    第42回日本癌治療学会  2004年10月 

     詳細を見る

    記述言語:その他   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:京都   国名:日本国  

  • 同種末梢血幹細胞移植後の固形腫瘍患者におけるmHA反応性リンパ球の検討

    柴田義宏, 馬場英司, 在田修二, 有山 寛, 三ツ木健二, 長藤宏司, 中野修治, 原田実根, 塩原信太郎

    日本癌学会  2004年10月 

     詳細を見る

    記述言語:その他  

    開催地:福岡   国名:日本国  

  • 固形癌に対する骨髄非破壊的移植前治療を用いた同種末梢血幹細胞移植療法の検討

    馬場英司, 長藤宏司, 宮本敏浩, 福田隆浩, 草場仁志, 安部康信, 伊藤鉄英, 牟田耕一郎

    日本臨床腫瘍学会総会  2004年3月 

     詳細を見る

    記述言語:その他  

    開催地:東京   国名:日本国  

  • Exosomal HLA released from B cells are regulated by NF-kB signaling

    Arita Shuji, Baba E, Shibata Y, Niiro H, Shimoda S, Isobe T, Hirano G, Makiyama A, Uchino K, Kusaba H, Nakano S, Harada M

    2006年12月 

     詳細を見る

    記述言語:その他  

    国名:日本国  

  • 消化器原発進行小細胞癌に対する全身化学療法の検討

    磯部大地, 柴田義宏, 在田修二, 内野慶太, 牧山明資, 瀧井康, 草場仁志, 馬場英司, 中野修治, 原田実根, 居石克夫, 八尾隆史

    第14回 日本消化器関連学会週間 (JDDW)  2006年10月 

     詳細を見る

    記述言語:その他  

    開催地:札幌   国名:日本国  

  • CPT-11/CDDP不応性の進行・再発胃癌に対する二次療法としてのDTX/TS-1療法の実施可能性

    磯部大地, 内野慶太, 牧山明資, 在田修二, 柴田義宏, 草場仁志, 馬場英司, 中野修治

    第44回 日本癌治療学会総会  2006年10月 

     詳細を見る

    記述言語:その他  

    開催地:Tokyo   国名:日本国  

  • 進行・再発大腸癌に対するFOLFOX療法によるアレルギー反応の検討

    柴田義宏, 馬場英司, 瀧井康, 内野慶太, 牧山明資, 在田修二, 草場仁志, 中野修治, 原田実根, 有山寛, 江崎泰斗, 土屋丹二, 田中吏佐

    第14回 日本消化器関連学会週間  2006年10月 

     詳細を見る

    記述言語:その他  

    開催地:札幌   国名:日本国  

  • 進行・再発大腸癌に対するCPT-11+TS-1併用第I/II相臨床試験

    柴田義宏, 草場仁志, 馬場英司, 江崎泰斗, 有山寛, 藤島弘光, 二見喜太郎, 田中伸之介, 境健爾, 田中吏佐, 植木隆, 壬生隆一, 中野修治

    第44回 日本癌治療学会総会  2006年10月 

     詳細を見る

    記述言語:その他  

    開催地:東京   国名:日本国  

  • A phase I study of sequential administration of S-1 and cisplatin (CDDP) in patients with metastatic gastric cancer (MGC) 国際会議

    Eishi Baba, Hiromitsu Fujishima, Hitoshi Kusaba, Taito Esaki, Hiroshi Ariyama, Ken Kato, Risa Tanaka, Kenji Sakai, Mine Harada, Shuji Nakano

    Annual Meeting of American Society of Clinical Oncology (ASCO 2006)  2006年6月 

     詳細を見る

    記述言語:その他  

    国名:アメリカ合衆国  

  • 進行・再発胃癌に対するS-1+CDDP併用化学療法第I/II相試験

    馬場英司, 藤島弘光, 草場仁志, 江崎泰斗, 有山寛, 境健爾, 加藤健, 田中吏佐, 柴田義宏, 在田修二, 三ツ木健二, 原田実根, 中野修治

    第4回日本臨床腫瘍学会総会  2006年3月 

     詳細を見る

    記述言語:その他  

    開催地:大阪   国名:日本国  

  • 切除不能進行・再発腺様嚢胞癌(ACC)に対するニボルマブの有効性および安全性の後方視的検討

    上ノ町 優仁, 上野 翔平, 近藤 萌, 伊東 守, 土橋 賢司, 有山 寛, 草場 仁志, 馬場 英司, 田中 吏佐, 三ツ木 健二

    日本内科学会雑誌  2019年2月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • CD168陽性細胞による大腸がん幹細胞の純化(CD168 expression marks a highly-concentrated human colorectal cancer stem cell population)

    中野 倫孝, 菊繁 吉謙, 鶴田 展大, 宮脇 恒太, 水野 晋一, 山口 享子, 山内 拓司, 土橋 賢司, 有山 寛, 草場 仁志, 前田 高宏, 馬場 英司, 赤司 浩一

    日本癌学会総会記事  2018年9月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Eカドヘリンの発現抑制は胃印環細胞癌特有の形態変化を誘導する(Loss of E-cadherin expression is the morphological determinant of human gastric signet ring cell carcinoma)

    山口 享子, 有山 寛, 吉弘 知恭, 土橋 賢司, 大内田 研宙, 長尾 吉泰, 副島 雄二, 草場 仁志, 前田 高宏, 中村 雅史, 橋爪 誠, 馬場 英司, 赤司 浩一

    日本癌学会総会記事  2018年9月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Loss of E-cadherin expression is the morphological determinant of human gastric signet ring cell carcinoma

    Kyoko Yamaguchi, Hiroshi Ariyama, Tomoyasu Yoshihiro, Kenji Tsuchihashi, Kenoki Ohuchida, Yoshihiro Nagao, Yuji Soejima, Hitoshi Kusaba, Takahiro Maeda, Masafumi Nakamura, Makoto Hashizume, Eishi Baba, Koichi Akashi

    CANCER SCIENCE  2018年12月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • パクリタキセル耐性胃癌細胞株におけるエリブリンによるアポトーシス誘導機序の解析(The mechanism of apoptosis induced by eribulin in paclitaxel-refractory gastic cancer cell line)

    有山 寛, 山口 享子, 吉弘 知恭, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2018年9月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • 実臨床に即した切除不能・進行再発消化管がんに対する最適な治療戦略 切除不能・進行再発胃がん治療の近未来予想図

    馬場 英司, 有山 寛, 赤司 浩一

    日本消化器病学会雑誌  2018年4月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 胃癌の集学的治療 胃癌に対するConversion therapy 腫瘍内科医の視点から

    馬場 英司

    日本癌治療学会学術集会抄録集  2018年10月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • 腔水症検体を用いたTAMからCAFへの分化機構の解明(Macrophages in ascites from cancer patients are primed to transdifferentiate into fibroblasts)

    伊東 守, 中野 倫孝, 有山 寛, 山口 享子, 仙波 雄一郎, 杉尾 健志, 宮脇 恒太, 菊繁 吉謙, 水野 晋一, 田中 吏佐, 馬場 英司, 赤司 浩一

    日本癌学会総会記事  2018年9月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • 腫瘍生物学におけるエクソソーム研究の現状と展望(The Exosome Biology in Cancer: Current Topics and Perspectives)

    山本 雄介, 馬場 英司

    日本癌学会総会記事  2018年9月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • 進行再発胃癌におけるオキサリプラチン併用療法の血小板減少、末梢神経障害のリスク因子に関する探索的研究(The risk factors for oxaliplatin-induced thrombocytopenia and neuropathy in advanced gastric cancer)

    稲富 享子, 草場 仁志, 牧山 明資, 三ツ木 健二, 内野 慶太, 田村 真吾, 柴田 義宏, 江崎 泰斗, 土橋 賢司, 在田 修二, 有山 寛, 馬場 英司

    日本胃癌学会総会記事  2018年3月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • 非小細胞肺癌患者において大部分のT790MはEGFR活性型遺伝子変異と同じアレル上に存在する

    日高 典子, 岩間 映二, 久保 直樹, 原田 大志, 宮脇 恒太, 田中 謙太郎, 岡本 勇, 馬場 英司, 赤司 浩一, 佐々木 裕之, 中西 洋一

    日本呼吸器学会誌  2018年3月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 頭頸部原発横紋筋肉腫の臨床病理学的検討

    橋本 和樹, 安松 隆治, 佐藤 方宣, 山元 英崇, 古賀 友紀, 馬場 英司, 大賀 才路, 中川 尚志

    頭頸部癌  2018年5月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • レンバチニブ投与中に意識障害をきたした甲状腺乳頭癌の2例

    田村 真吾, 内野 眞也, 薦田 正人, 内野 慶太, 草場 仁志, 馬場 英司, 堀内 孝彦

    日本内分泌学会雑誌  2017年12月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • EGFRはアミノ酸トランスポーターxCTを介して脳腫瘍の悪性化を促進する

    土橋 賢司, 岡崎 章悟, 大村 光代, サンペトラ・オルテア, 大西 伸幸, 吉川 桃子, 清島 亮, 益子 高, 末松 誠, 馬場 英司, 赤司 浩一, 佐谷 秀行, 永野 修

    日本癌学会総会記事  2016年10月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Epithelial mesenchymal transition generates cancer stem cells in CD44-colorectal cancer cells

    Michitaka Nakano, Mamoru Tanaka, Taichi Isobe, Kohta Miyawaki, Yoshikane Kikushige, Hitoshi Kusaba, Shigeo Takaishi, Takashi Ueki, Eishi Baba, Koichi Akashi

    CANCER RESEARCH  2016年7月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Macrophage-to-fibroblast transition promotes cancer progression in peritoneal carcinomatosis of gastrointestinal cancer patient

    Mamoru Tanaka, Michitaka Nakano, Hiroshi Ariyama, Kyoko Inadomi, Risa Tanaka, Shigeo Takaishi, Hitoshi Kusaba, Eishi Baba, Koichi Akashi

    CANCER RESEARCH  2016年7月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • TGF-beta regulates CD44 expression of cancer cells through epithelial-to-mesenchymal transition in malignant ascites

    Michitaka Nakano, Mamoru Tanaka, Risa Tanaka, Akitaka Makiyama, Keita Uchino, Taito Esaki, Kenji Mitsuki, Eishi Baba

    ANNALS OF ONCOLOGY  2016年7月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Epithelial to mesenchymal transition by TGF-beta induced cancer stem-like properties in primary colorectal cancer

    Michitaka Nakano, Hiroshi Ariyama, Shingo Tamura, Taichi Isobe, Kohta Miyawaki, Yuta Okumura, Hitoshi Kusaba, Takashi Ueki, Eishi Baba, Koichi Akashi

    ANNALS OF ONCOLOGY  2015年11月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Exploratory analysis of a prognosis predictive formula for metastatic colorectal cancer treated with chemotherapy.

    Mamoru Tanaka, Hitoshi Kusaba, Satomi Mukaide, Junji Kishimoto, Hozumi Kumagai, Akitaka Makiyama, Tsuyoshi Shirakawa, Hisanobu Oda, Masato Komoda, Kenji Mitsugi, Koichi Akashi, Eishi Baba

    JOURNAL OF CLINICAL ONCOLOGY  2015年1月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Plasticity of CD44+colorectal cancer stem cells depends on TGF-beta-induced epithelial mesenchymal transition (EMT): evidences from ex vivo culture system

    Michitaka Nakano, Hioshi Ariyama, Shingo Tamura, Taichi Isobe, Kohta Miyawaki, Yuta Okumura, Hitoshi Kusaba, Takashi Ueki, Eishi Baba, Koichi Akashi

    CANCER RESEARCH  2015年8月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer.

    Michitaka Nagase, Kentaro Yamazaki, Hiroshi Tamagawa, Shinya Ueda, Takao Tamura, Kohei Murata, Takashi Tsuda, Eishi Baba, Masahiro Tsuda, Toshikazu Moriwaki, Taito Esaki, Yasushi Tsuji, Kei Muro, Koichi Taira, Tadamichi Denda, Masahiko Ando, Satoshi Morita, Narikazu Boku, Ichinosuke Hyodo

    JOURNAL OF CLINICAL ONCOLOGY  2015年1月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • Trifluridine-tipiracil for multidrug-resistant advanced colorectal cancer: A multicenter retrospective study

    Shuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, Hozumi Kumagai, Gen Hirano, Akitaka Makiyama, Yoshihiro Shibata, Shingo Tamura, Hitoshi Kusaba, Eishi Baba

    ANNALS OF ONCOLOGY  2015年11月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • がん治療におけるG-CSF適正使用ガイドラインとその改訂

    馬場 英司, 内野 慶太

    血液内科 = Hematology  2015年7月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 切除不能・進行大腸癌の化学療法 (第68回日本交通医学会総会) -- (ランチョンセミナー)

    馬場 英司, 有山 寛, 草場 仁志

    交通医学  2014年7月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 進行・再発癌に対する薬物療法 (特集 消化管がん診療の新しいエビデンス)

    有山 寛, 草場 仁志, 馬場 英司

    臨牀と研究  2014年2月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • A STUDY OF THE RELATIONSHIP BETWEEN GASTROINTESTINAL CANCER CHEMOTHERAPY AND THROMBOEMBOLISM; IS D-DIMER REALLY USEFUL?

    Tsuyoshi Shirakawa, Shingo Tamura, Masato Komoda, Gen Hirano, Taichi Isobe, Keita Uchino, Hitoshi Kusaba, Eishi Baba, Koichi Akashi

    ANNALS OF ONCOLOGY  2010年11月 

     詳細を見る

    記述言語:英語  

    国名:日本国  

  • 進行膵癌に対する免疫療法としての骨髄非破壊的同種造血幹細胞移植

    安部 康信, 伊藤 鉄英, 馬場 英司, 長藤 宏司, 河邊 顕, 崔 日承, 有田 好之, 宮本 敏浩, 豊嶋 崇徳, 中野 修治, 原田 実根

    膵臓 = The Journal of Japan Pancreas Society  2010年2月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • 切除不能進行・再発大腸癌の高齢患者に対するBevacizumab併用化学療法の検討

    藤本千夏, 牧山明資, 在田修二, 江崎泰斗, 磯部大地, 有山寛, 薦田正人, 白川剛, 内野慶太, 草場仁志, 馬場英司, 赤司浩一, 三ツ月健二, 田中吏佐, 中野修治

    日本癌治療学会誌  2009年9月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • ヒト胆嚢癌細胞株を用いたTrastuzumab/5‐FU及びGEM/I‐OHPの薬剤感受性の検討

    牧山明資, 内野慶太, 磯部大地, 平野元, 在田修二, 柴田義宏, 草場仁志, 馬場英司, 中野修治

    日本癌学会学術総会記事  2007年8月 

     詳細を見る

    記述言語:日本語  

    国名:日本国  

  • Classification of BRAF mutated colorectal cancer based on microsatellite stability

    Gastrointestinal Cancers Symposium  2019年1月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Classification of BRAF mutated colorectal cancer based on microsatellite stability

  • Single-cell transcriptomics identifies RHAMM positive proliferative cells within human colorectal cancer stem cells

    Keystone Symposia  2019年2月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Single-cell transcriptomics identifies RHAMM positive proliferative cells within human colorectal cancer stem cells

  • CD168 expression marks a highly-concentrated human colorectal cancer stem cell population

    2018年9月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    CD168 expression marks a highly-concentrated human colorectal cancer stem cell population

  • Clinical application of immunotherapy for advanced gastric cancer in Japan

    2018 Annual Meeting of Chinese Medical Association-Taipei  2018年6月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Clinical application of immunotherapy for advanced gastric cancer in Japan

  • Immune-related adverse events (irAE) management in Japanes clinical practice

    2018年6月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Immune-related adverse events (irAE) management in Japanes clinical practice

  • Loss of E-cadherin expression is the morphological determinant of human gastric signet ring cell carcinoma

    2018年9月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Loss of E-cadherin expression is the morphological determinant of human gastric signet ring cell carcinoma

  • Macrophages in ascites from cancer patients are primed to transdifferentiate into fibroblasts

    2018年9月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Macrophages in ascites from cancer patients are primed to transdifferentiate into fibroblasts

  • Management of chemotherapy-induced cardiomyopathy

    2018年7月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Management of chemotherapy-induced cardiomyopathy

  • Progressive sarcopenia during initial chemotherapy predicts survival in patients with advanced gastric cancer

    2018年7月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • Seoul Immunotherapy for advanced gastric cancer: Analysis of immune cell subsets

    Korea-Japan Joint Symposium  2018年2月 

     詳細を見る

    記述言語:その他  

    国名:その他  

    Seoul Immunotherapy for advanced gastric cancer: Analysis of immune cell subsets

  • がん免疫療法ガイドライン改定の概略

    馬場 英司

    第16回日本臨床腫瘍学会学術集会  2018年7月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • がん患者における下大静脈フィルターの安全性・有用性の検討

    馬場 英司

    第3回日本がんサポーティブケア学会総会  2018年8月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • ニトログリセリンが奏効したフルオロウラシル関連狭心症に伴う心房細動の一例

    馬場 英司

    第1回腫瘍循環器学会総会  2018年11月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • 免疫チェックポイント阻害剤を用いた消化器がん治療

    馬場 英司

    第111回日本消化器病学会九州支部例会、第105回日本消化器内視鏡学会九州支部例会  2018年6月 

     詳細を見る

    記述言語:その他  

    国名:その他  

  • DNMT3Bは患者由来の左側大腸癌オルガノイド形成能を維持する(DNMI3B maintains the organoid-formation ability of left-sided colorectal cancer derived from patients)

    田口 綾祐, 磯部 大地, 上野 翔平, 菊繁 吉謙, 土橋 賢司, 有山 寛, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2022年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • C-CAT利活用による腫瘍遺伝子変異量(TMB)に関する研究

    久保 真, 森崎 隆史, 溝口 公久, 中垣 環, 馬場 英司, 中村 雅史

    日本外科学会定期学術集会抄録集  2023年4月  (一社)日本外科学会

     詳細を見る

    記述言語:日本語  

  • 食道癌における自然な上皮間葉転換可塑性の存在とその意義(Presence and its role of spontaneous epithelial-mesenchymal plasticity in esophageal cancer)

    土橋 賢司, 平田 雄紀, 山崎 淳太郎, 推名 健太郎, 田ノ上 絢郎, 八戸 敏文, 増田 健太, 馬場 英司, 赤司 浩一, 北川 雄光, 佐谷 秀行, 永野 修

    日本癌学会総会記事  2022年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • 食道がんにおける免疫療法の潜在的な標的としてCD39+CD8+T細胞は空間的、表現型的に異なるフェノタイプから構成される(Spatially and phenotypically distinct CD39+CD8+Tcells as potential target of immunotherapy in esophageal cancer)

    田ノ上 絢郎, 大村 洋文, 篠原 雄大, 上原 康輝, 伊東 守, 山口 享子, 土橋 賢司, 田村 真吾, 下川 穂積, 磯部 大地, 有山 寛, 柴田 義宏, 三ツ木 健二, 江崎 泰斗, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2023年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • 進行胃癌に対する薬物療法の現況 腹膜播種を有する胃癌に対するRAM+PTX併用とRAM+nab-PTX併用に関する第II相比較試験(State of the art of pharmacotherapy for advanced gastric cancer Phase II trial of RAM combined with PTX vs nab-PTX for gastric cancer with peritoneal dissemination)

    Hirata Kenro, Hamamoto Yasuo, Shoji Hirokazu, Hara Hiroki, Kondoh Chihiro, Yasui Hisateru, Kajiwara Takeshi, Baba Eishi, Ando Takayuki, Sugimoto Naotoshi, Okano Naohiro, Kawakami Hisato, Katsuya Hiroo, Nagase Michitaka, Moriwaki Toshikazu, Yoshimura Kenichi, Ando Masahiko, Yamazaki Kentaro, Hironaka Shuichi, Muro Kei

    日本胃癌学会総会記事  2022年3月  (一社)日本胃癌学会

     詳細を見る

    記述言語:英語  

  • 通過障害・経口摂取不能例に対する治療戦略 高度腹膜転移を有する切除不能胃癌に対するmFOLFOX6の第II相試験(WJOG10517G)

    舛石 俊樹, 原 浩樹, 安藤 孝将, 川上 武志, 山本 祥之, 杉本 直俊, 白石 和寛, 江崎 泰斗, 根来 裕二, 筑木 隆雄, 澤井 寛明, 中村 将人, 稲墻 崇, 篠原 雄大, 川上 賢太郎, 馬場 英司, 近藤 千紘, 吉村 健一, 中島 貴子, 室 圭

    日本胃癌学会総会記事  2023年2月  (一社)日本胃癌学会

     詳細を見る

    記述言語:英語  

  • 血中の疲弊前駆PD-1陽性T細胞はPD-1阻害薬に反応し、食道癌の治療効果と関連している(Circulating stem-like PD-1+CD8 T cells responding to PD-1 blockade predict clinical outcomes in esophageal cancer)

    田ノ上 絢郎, 大村 洋文, 山口 享子, 土橋 賢司, 田村 真吾, 磯部 大地, 有山 寛, 江崎 泰斗, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2022年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • 血中の疲弊前駆PD-1陽性T細胞はPD-1阻害薬に反応し、食道癌の治療効果と関連している(Circulating stem-like PD-1+ CD8 T cells responding to PD-1 blockade predict clinical outcomes in esophageal cancer)

    田ノ上 絢郎, 大村 洋文, 山口 享子, 土橋 賢司, 田村 真吾, 磯部 大地, 有山 寛, 江崎 泰斗, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2022年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • 臓器横断的ながん治療の現状と課題・九州大学の診療体制

    馬場 英司

    日本臨床薬理学会学術総会抄録集  2024年1月  (一社)日本臨床薬理学会

     詳細を見る

    記述言語:日本語  

  • 腫瘍遺伝子変異量(TMB) 乳癌におけるバイオマーカーとしての意義

    久保 真, 森崎 隆史, 溝口 公久, 中垣 環, 馬場 英司, 中村 雅史

    日本乳癌学会総会プログラム抄録集  2023年6月  (一社)日本乳癌学会

     詳細を見る

    記述言語:日本語  

  • 胃癌発癌モデルを用いた遺伝子発現解析に基づく胃印環細胞癌の新規治療標的の探索(Potential therapeutic targets discovery by transcriptome analysis of signet ring carcinoma model)

    山口 享子, 吉弘 知恭, 有山 寛, 土橋 賢司, 草場 仁志, 赤司 浩一, 馬場 英司

    日本胃癌学会総会記事  2022年3月  (一社)日本胃癌学会

     詳細を見る

    記述言語:英語  

  • 胃癌に対する外科治療

    坊岡 英祐, 島田 英昭, 草野 央, 藤城 光弘, 川上 尚人, 馬場 英司, 朴 成和

    日本胃癌学会総会記事  2023年2月  (一社)日本胃癌学会

     詳細を見る

    記述言語:日本語  

  • 癌ゲノム医療の成果と課題 九州大学病院がんエキスパートパネルにおける消化器悪性腫瘍のがんゲノム検査の現状とC-CATデータを用いた研究について

    磯部 大地, 伊東 守, 山口 享子, 上野 翔平, 土橋 賢司, 馬場 英司

    日本消化器病学会雑誌  2024年3月  (一財)日本消化器病学会

     詳細を見る

    記述言語:日本語  

  • 消化器領域におけるがん免疫療法の現状と課題 ニボルマブ治療を受けた切除不能進行食道癌患者における末梢血中の疲弊細胞の意義

    田ノ上 絢郎, 大村 洋文, 土橋 賢司, 篠原 雄大, 伊東 守, 山口 享子, 田村 真吾, 下川 穂積, 磯部 大地, 柴田 義宏, 有山 寛, 田中 吏佐, 草場 仁志, 江崎 泰斗, 三ツ木 健二, 赤司 浩一, 馬場 英司

    日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集  2022年6月  日本消化器病学会-九州支部

     詳細を見る

    記述言語:日本語  

  • 悪性軟部腫瘍の希少性と多様性に対して、われわれはどう対峙すべきか 多職種連携の重要性と地域希少がんセンターに求められる役割

    遠藤 誠, 松本 嘉寛, 土橋 賢司, 馬場 英司, 中島 康晴

    日本整形外科学会雑誌  2022年6月  (公社)日本整形外科学会

     詳細を見る

    記述言語:日本語  

  • 希少がんの治療戦略 信頼と絆に基づく肉腫のチーム医療

    遠藤 誠, 土橋 賢司, 松本 嘉寛, 坂本 節子, 鍋島 央, 飯田 圭一郎, 藤原 稔史, 伊東 守, 磯部 大地, 有山 寛, 赤司 浩一, 馬場 英司, 中島 康晴

    日本癌治療学会学術集会抄録集  2022年10月  (一社)日本癌治療学会

     詳細を見る

    記述言語:英語  

  • 免疫チェックポイント阻害薬併用療法によるB細胞の分化と抗腫瘍効果ならびに有害事象との関連性について(B cell differentiation by combined immune checkpoint blockade is associated with tumor suppression and adverse events)

    上原 康輝, 田ノ上 絢郎, 山口 享子, 大村 洋文, 伊東 守, 土橋 賢司, 田村 真吾, 磯部 大地, 山元 英崇, 小田 義直, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2023年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • 九州の基礎・臨床研究:腫瘍免疫・自己免疫・ゲノム 消化器がんの腫瘍免疫における上皮間葉転換、エピトランスクリプトームの関わりと今後の展望

    土橋 賢司, 馬場 英司

    日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集  2023年5月  日本消化器病学会-九州支部

     詳細を見る

    記述言語:日本語  

  • ガイドラインに基づく切除不能再発・進行胃癌の薬物療法

    馬場 英司

    日本胃癌学会総会記事  2023年2月  (一社)日本胃癌学会

     詳細を見る

    記述言語:日本語  

  • がん診療ガイドラインの最近の動向 胃癌治療ガイドライン第6版改訂のポイント

    寺島 雅典, 馬場 英司

    日本癌治療学会学術集会抄録集  2022年10月  (一社)日本癌治療学会

     詳細を見る

    記述言語:日本語  

  • がん診療ガイドラインの最近の動向 成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン改訂のポイント

    馬場 英司

    日本癌治療学会学術集会抄録集  2022年10月  (一社)日本癌治療学会

     詳細を見る

    記述言語:日本語  

  • TPX2の増幅は大腸癌細胞株におけるオキサリプラチン感受性の潜在的なバイオマーカーとなる(The amplification of TPX2 is a potential biomarker of oxaliplatin-susceptibility in colorectal cancer)

    上野 翔平, 磯部 大地, 田口 綾祐, 土橋 賢司, 有山 寛, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2022年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • TPX2の増幅はCINフェノタイプの大腸癌のオキサリプラチン感受性のバイオマーカーである(TPX2-amplified is a biomarker of oxaliplatin-sensitivity of colorectal cancers(CRCs) with CIN phenotype)

    上野 翔平, 磯部 大地, 田口 綾祐, 土橋 賢司, 赤司 浩一, 馬場 英司

    日本癌学会総会記事  2023年9月  (一社)日本癌学会

     詳細を見る

    記述言語:英語  

  • Precision Medicineを目指した消化器診療の展望 がんゲノム検査に基づく消化器がんの薬物療法

    馬場 英司

    日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集  2022年12月  日本消化器病学会-九州支部

     詳細を見る

    記述言語:日本語  

▼全件表示

MISC

  • 日本臨床腫瘍学会/日本癌治療学会/日本小児血液・がん学会が主導するDNAミスマッチ修復機能欠損(dMMR)固形がんに対する診断および免疫チェックポイント阻害薬を用いた診療に関する臨床推奨事項第3版(Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient(dMMR) tumors, third edition)

    Mishima Saori, Naito Yoichi, Akagi Kiwamu, Hayashi Naomi, Hirasawa Akira, Hishiki Tomoro, Igarashi Ataru, Ikeda Masafumi, Kadowaki Shigenori, Kajiyama Hiroaki, Kato Motohiro, Kenmotsu Hirotsugu, Kodera Yasuhiro, Komine Keigo, Koyama Takafumi, Maeda Osamu, Miyachi Mitsuru, Nishihara Hiroshi, Nishiyama Hiroyuki, Ohga Shouichi, Okamoto Wataru, Oki Eiji, Ono Shigeru, Sanada Masashi, Sekine Ikuo, Takano Tadao, Tao Kayoko, Terashima Keita, Tsuchihara Katsuya, Yatabe Yasushi, Yoshino Takayuki, Baba Eishi, Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, Japanese Society of Pediatric Hematology/Oncology

    International Journal of Clinical Oncology   28 ( 10 )   1237 - 1258   2023年10月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • 【胆道癌と膵癌のリスクファクター】リスクファクターに応じたがんのサーベイランス

    大村 洋文, 馬場 英司

    胆と膵   44 ( 9 )   803 - 806   2023年9月   ISSN:0388-9408

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    がん発症のリスクファクターとして生活習慣や環境要因などが報告されており,複数のがん種が共通のリスクファクターを有することが知られている。胆道癌については膵・胆管合流異常や肝内結石症などが,膵癌では家族歴(遺伝性膵癌症候群)や膵管内乳頭粘液性腫瘍などが特徴的なリスクファクターである。また近年がん遺伝子パネルが保険診療で用いられ標的治療や臨床試験へのアクセスを高める試みがなされているが,偶発的に遺伝性腫瘍に関連する生殖細胞系列変異が検出されることもある。リスクファクターに応じた胆道癌や膵臓癌に対する適切なサーベイランスの頻度,期間について確立されたものは限られている。またサーベイランスが長期となる場合は患者の精神的,経済的負担も考慮して行う。(著者抄録)

  • 日本臨床腫瘍学会/日本癌治療学会/日本小児血液・がん学会が主導する、腫瘍変異負荷の高い腫瘍患者の診断と免疫療法の使用に関する臨床推奨事項(Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors)

    Mishima Saori, Naito Yoichi, Akagi Kiwamu, Hayashi Naomi, Hirasawa Akira, Hishiki Tomoro, Igarashi Ataru, Ikeda Masafumi, Kadowaki Shigenori, Kajiyama Hiroaki, Kato Motohiro, Kenmotsu Hirotsugu, Kodera Yasuhiro, Komine Keigo, Koyama Takafumi, Maeda Osamu, Miyachi Mitsuru, Nishihara Hiroshi, Nishiyama Hiroyuki, Ohga Shouichi, Okamoto Wataru, Oki Eiji, Ono Shigeru, Sanada Masashi, Sekine Ikuo, Takano Tadao, Tao Kayoko, Terashima Keita, Tsuchihara Katsuya, Yatabe Yasushi, Yoshino Takayuki, Baba Eishi, Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, Japanese Society of Pediatric Hematology/Oncology

    International Journal of Clinical Oncology   28 ( 8 )   941 - 955   2023年8月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • 【免疫チェックポイント阻害剤の副作用-irAEの発生メカニズムとその対処方法】チーム,医療連携で対応するirAE

    加藤 俊介, 馬場 英司, 下村 昭彦

    カレントテラピー   41 ( 7 )   664 - 669   2023年7月   ISSN:0287-8445

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)ライフメディコム  

  • 日本臨床腫瘍学会/日本癌治療学会/日本小児血液・がん学会が主導する神経栄養因子受容体チロシンキナーゼ融合遺伝子陽性の進行固形癌成人および小児患者における診断とトロポミオシン受容体キナーゼ阻害薬の使用に関する臨床推奨事項(Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors)

    Naito Yoichi, Mishima Saori, Akagi Kiwamu, Hayashi Naomi, Hirasawa Akira, Hishiki Tomoro, Igarashi Ataru, Ikeda Masafumi, Kadowaki Shigenori, Kajiyama Hiroaki, Kato Motohiro, Kenmotsu Hirotsugu, Kodera Yasuhiro, Komine Keigo, Koyama Takafumi, Maeda Osamu, Miyachi Mitsuru, Nishihara Hiroshi, Nishiyama Hiroyuki, Ohga Shouichi, Okamoto Wataru, Oki Eiji, Ono Shigeru, Sanada Masashi, Sekine Ikuo, Takano Tadao, Tao Kayoko, Terashima Keita, Tsuchihara Katsuya, Yatabe Yasushi, Yoshino Takayuki, Baba Eishi, Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, Japanese Society of Pediatric Hematology/Oncology

    International Journal of Clinical Oncology   28 ( 7 )   827 - 840   2023年7月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • 【食道・胃・大腸癌の最新情報】進行再発消化管癌に対する最新の集学的治療

    山口 享子, 馬場 英司

    臨牀と研究   100 ( 6 )   721 - 724   2023年6月   ISSN:0021-4965

     詳細を見る

    記述言語:日本語   出版者・発行元:大道学館出版部  

  • 希少がん入門(第79回) 九州地方における希少がん診療の現状と今後の展望

    土橋 賢司, 坂本 節子, 遠藤 誠, 馬場 英司

    Clinic Magazine   50 ( 3 )   28 - 29   2023年5月   ISSN:0389-7451

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)ドラッグマガジン  

  • 胃癌治療ガイドライン 2021年改訂 第6版(Japanese Gastric Cancer Treatment Guidelines 2021(6th edition))

    Baba Eishi, Terashima Masanori, Fujishiro Mitsuhiro, Japanese Gastric Cancer Association

    Gastric Cancer   26 ( 1 )   1 - 25   2023年1月   ISSN:1436-3291

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • パンデミックと学会活動

    馬場 英司, 磯部 大地, 有山 寛

    腫瘍内科   30 ( 6 )   681 - 684   2022年12月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

  • 【外来で行う消化器がん薬物療法のコツ-専門医からのアドバイス】がん診療におけるがん薬物療法の位置づけ 胃がん

    大村 洋文, 有山 寛, 馬場 英司

    臨床消化器内科   37 ( 11 )   1404 - 1409   2022年9月   ISSN:0911-601X

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本メディカルセンター  

    <文献概要>胃がんは,わが国で罹患率,死亡者数ともに高い悪性腫瘍の一つである.胃がんに対するがん薬物療法は,治癒切除例における再発予防目的および切除不能・再発症例に対する延命・症状緩和目的で選択される.近年薬物療法の開発が進み,pStage III症例に対する術後補助化学療法としてS-1+ドセタキセル(DTX)併用療法の有効性が示された.また切除不能・再発症例の一次治療でニボルマブが化学療法との併用でup-frontに使用されるようになり,またHER2陽性例に対するトラスツズマブ・デルクステカンなど,三次治療においても延命効果が期待される薬剤が開発されている.胃がんにおける薬物療法について解説していく.

  • 【がん免疫療法の展望:免疫チェックポイント阻害薬の併用療法に中心に】免疫チェックポイント阻害薬の併用療法のエビデンス 免疫チェックポイント阻害薬と化学療法

    磯部 大地, 馬場 英司

    腫瘍内科   30 ( 1 )   8 - 17   2022年7月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

  • 【第3期がんプロフェッショナル養成プランの成果-その2-】新ニーズに対応する九州がんプロ養成プラン

    大田 恵一, 馬場 英司

    癌と化学療法   49 ( 6 )   642 - 645   2022年6月   ISSN:0385-0684

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    本邦では小児がんや希少がんを専門とする医療人材、また小児・AYA世代、高齢者などライフステージに応じたがん診療に対応できる人材が十分でないと考えられる。また、九州は離島・僻地が多く、それらの地域におけるがん対策も必要とされる。一方で、ゲノム医療の実用化が加速し、がんゲノム医療を適切に臨床応用および研究開発できる人材の育成はこれからのがん医療において重要な課題である。「新ニーズに対応する九州がんプロ養成プラン」は、がんゲノム医療、小児・AYA世代・希少がん、ライフステージに応じたがん対策といった重要なニーズに対応できる人材を育成することを目的として九州内の10大学が参画するプロジェクトである。われわれは、この10大学が協同してこの5年間で様々な事業を展開した。本プランに沿った講義、研修会、研究発表会、海外施設訪問研修、僻地・離島病院実習、専門医資格取得サポートなどを精力的に行い、本プランの履修生からも好評を得ている。本プランをとおして、がんゲノム医療や希少がん、ライフステージに応じたがん医療について習熟した履修生は多く、将来のがん医療を担う者も多く輩出できたと思われる。本プランは令和3年度で終了となるが、九州におけるがん専門医療人材の数と質を維持するために今後も各大学と連携し各種事業を継続していく準備を行っている。(著者抄録)

  • 【消化管がん(食道、胃、大腸)診療の進歩と展望】消化管がんに対する免疫チェックポイント阻害薬を用いた併用療法の可能性

    有山 寛, 草場 仁志, 馬場 英司

    腫瘍内科   29 ( 6 )   716 - 721   2022年6月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

  • 【がんに対する新しい治療法と未来型医療】新しいがん治療法 抗体薬物複合体(ADC)

    磯部 大地, 馬場 英司

    腫瘍内科   29 ( 5 )   535 - 543   2022年5月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

  • 【希少がんに対する診療提供体制の現状と展望】地域における希少がん診療提供体制 九州の場合

    土橋 賢司, 馬場 英司

    医学のあゆみ   281 ( 4 )   305 - 309   2022年4月   ISSN:0039-2359

     詳細を見る

    記述言語:日本語   出版者・発行元:医歯薬出版(株)  

    希少がん診療体制の構築は、がん医療の重要課題である。国立がん研究センター中央病病院の希少がんセンター、希少がんホットラインに続き、大阪国際がんセンターや九州大学病院でもこれらが設置された。がんゲノム医療の拡大により医療機関間での希少がん患者の紹介が増えている傾向はあるが、当院の希少がんホットラインの相談状況やMASTER KEYプロジェクト登録者状況からは、九州地方での希少がん診療ネットワーク構築のニーズが浮かび上がる。また、希少がん診療はがんゲノム医療の対象となる前、とくに診断の段階から医療連携体制の構築が必要である。当院希少がんセンターは、各病院と連携していきながら九州地方の実情に沿った実用性のある希少がん診療ネットワーク構築を目指す。(著者抄録)

  • 小児、思春期・若年がん患者の妊孕性温存に関する日本癌治療学会診療ガイドライン2017年版(第1部)(Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1)

    Harada Miyuki, Kimura Fuminori, Takai Yasushi, Nakajima Takeshi, Ushijima Kimio, Kobayashi Hiroaki, Satoh Toyomi, Tozawa Akiko, Sugimoto Kohei, Saji Shigehira, Shimizu Chikako, Akiyama Kyoko, Bando Hiroko, Kuwahara Akira, Furui Tatsuro, Okada Hiroshi, Kawai Koji, Shinohara Nobuo, Nagao Koichi, Kitajima Michio, Suenobu Souichi, Soejima Toshinori, Miyachi Mitsuru, Miyoshi Yoko, Yoneda Akihiro, Horie Akihito, Ishida Yasushi, Usui Noriko, Kanda Yoshinobu, Fujii Nobuharu, Endo Makoto, Nakayama Robert, Hoshi Manabu, Yonemoto Tsukasa, Kiyotani Chikako, Okita Natsuko, Baba Eishi, Muto Manabu, Kikuchi Iwaho, Morishige Ken-ichirou, Tsugawa Koichiro, Nishiyama Hiroyuki, Hosoi Hajime, Tanimoto Mitsune, Kawai Akira, Sugiyama Kazuhiko, Boku Narikazu, Yonemura Masato, Hayashi Naoko, Aoki Daisuke, Osuga Yutaka, Suzuki Nao, Japan Society of Clinical Oncology

    International Journal of Clinical Oncology   27 ( 2 )   265 - 280   2022年2月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • 小児、思春期・若年がん患者の妊孕性温存に関する日本癌治療学会診療ガイドライン2017年版(第2部)(Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2)

    Tozawa Akiko, Kimura Fuminori, Takai Yasushi, Nakajima Takeshi, Ushijima Kimio, Kobayashi Hiroaki, Satoh Toyomi, Harada Miyuki, Sugimoto Kohei, Saji Shigehira, Shimizu Chikako, Akiyama Kyoko, Bando Hiroko, Kuwahara Akira, Furui Tatsuro, Okada Hiroshi, Kawai Koji, Shinohara Nobuo, Nagao Koichi, Kitajima Michio, Suenobu Souichi, Soejima Toshinori, Miyachi Mitsuru, Miyoshi Yoko, Yoneda Akihiro, Horie Akihito, Ishida Yasushi, Usui Noriko, Kanda Yoshinobu, Fujii Nobuharu, Endo Makoto, Nakayama Robert, Hoshi Manabu, Yonemoto Tsukasa, Kiyotani Chikako, Okita Natsuko, Baba Eishi, Muto Manabu, Kikuchi Iwaho, Morishige Ken-ichirou, Tsugawa Koichiro, Nishiyama Hiroyuki, Hosoi Hajime, Tanimoto Mitsune, Kawai Akira, Sugiyama Kazuhiko, Boku Narikazu, Yonemura Masato, Hayashi Naoko, Aoki Daisuke, Suzuki Nao, Osuga Yutaka, Japan Society of Clinical Oncology

    International Journal of Clinical Oncology   27 ( 2 )   281 - 300   2022年2月   ISSN:1341-9625

     詳細を見る

    記述言語:英語   出版者・発行元:シュプリンガー・ジャパン(株)  

  • 【がんゲノム医療の進歩と問題点】臓器横断的がんゲノム医療の現状と将来展望

    山口 享子, 伊東 守, 馬場 英司

    腫瘍内科   29 ( 1 )   11 - 16   2022年1月   ISSN:1881-6568

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

  • DNMT3Bは患者由来の左側大腸癌オルガノイド形成能を維持する

    田口綾祐, 磯部大地, 上野翔平, 菊繁吉謙, 土橋賢司, 有山寛, 赤司浩一, 馬場英司

    日本癌学会学術総会抄録集(Web)   81st   2022年

     詳細を見る

  • 3週毎S-1+CDDP療法により4年以上有効性を維持している胃癌骨髄癌腫症の一例

    草野亘, 土橋賢司, 田口綾祐, 吉弘知恭, 古川佳那美, 大村洋文, 伊東守, 磯部大地, 有山寛, 草場仁志, 赤司浩一, 馬場英司

    日本臨床腫瘍学会学術集会(CD-ROM)   19th   2022年

     詳細を見る

  • 血中の疲弊前駆PD-1陽性T細胞はPD-1阻害薬に反応し,食道癌の治療効果と関連している

    田ノ上絢郎, 大村洋文, 山口享子, 土橋賢司, 田村真吾, 磯部大地, 有山寛, 江崎泰斗, 赤司浩一, 馬場英司

    日本癌学会学術総会抄録集(Web)   81st   2022年

     詳細を見る

  • ニボルマブ治療を受けた切除不能進行食道癌患者における末梢血中の疲弊細胞の意義

    田ノ上絢郎, 大村洋文, 土橋賢司, 篠原雄大, 伊東守, 山口享子, 田村真吾, 下川穂積, 磯部大地, 柴田義宏, 有山寛, 田中吏佐, 草場仁志, 江崎泰斗, 三ツ木健二, 赤司浩一, 馬場英司

    日本消化器病学会九州支部例会・日本消化器内視鏡学会九州支部例会プログラム・抄録集   119th-113th   2022年

     詳細を見る

  • TPX2の増幅は大腸癌細胞株におけるオキサリプラチン感受性の潜在的なバイオマーカーとなる

    上野翔平, 磯部大地, 田口綾祐, 土橋賢司, 有山寛, 赤司浩一, 馬場英司

    日本癌学会学術総会抄録集(Web)   81st   2022年

     詳細を見る

  • Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy

    Kyoko Yamaguchi, Kenji Tsuchihashi, Kunihiro Tsuji, Yosuke Kito, Kenro Tanoue, Hirofumi Ohmura, Mamoru Ito, Taichi Isobe, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Medicine   2021年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1097/md.0000000000025773

  • Thrombocytopenia Caused by Dexamethasone in a Patient with Colorectal Cancer

    Ryosuke Taguchi, Kenji Tsuchihashi, Yuta Okumura, Michitaka Nakano, Tomoyasu Yoshihiro, Hirofumi Ohmura, Nobuhiro Tsuruta, Fumiyasu Hanamura, Kyoko Yamaguchi, Mamoru Ito, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    Internal Medicine   2020年10月

     詳細を見る

    記述言語:その他  

    DOI: 10.2169/internalmedicine.4785-20

  • OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. 査読

    Hirofumi Ohmura, Kyoko Yamaguchi, Fumiyasu Hanamura, Mamoru Ito, Akitaka Makiyama, Keita Uchino, Hozumi Shimokawa, Shingo Tamura, Taito Esaki, Kenji Mitsugi, Yoshihiro Shibata, Hisanobu Oda, Kenji Tsuchihashi, Hiroshi Ariyama, Hitoshi Kusaba, Yoshinao Oda, Koichi Akashi, Eishi Baba

    British journal of cancer   2020年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1038/s41416-020-0810-1

  • Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.

    Saori Mishima, Hiroya Taniguchi, Kiwamu Akagi, Eishi Baba, Yutaka Fujiwara, Akira Hirasawa, Masafumi Ikeda, Osamu Maeda, Kei Muro, Hiroshi Nishihara, Hiroyki Nishiyama, Tadao Takano, Katsuya Tsuchihara, Yasushi Yatabe, Yasuhiro Kodera, Takayuki Yoshino

    International journal of clinical oncology   2020年2月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s10147-019-01498-8

  • Fluorescence Signal Amplification by Using β-Galactosidase for Flow Cytometry; Advantages of an Endogenous Activity-Free Enzyme.

    2020年2月

     詳細を見る

    記述言語:英語  

    We previously proposed using a hydrolysis enzyme for fluorescent signal amplification in flow cytometric detection of antigen proteins, which was named the catalyzed reporter penetration (CARP) method. In this method, antigen proteins are labeled with enzyme-modified antibodies, and then fluorophore-modified substrates stain cells by penetrating the cell membrane upon hydrolysis of the substrate. We proved the concept by using alkaline phosphatase (AP) as the hydrolysis enzyme. However, a required prior inactivation process of endogenous AP activity on the cell surface risked disrupting recognition of antigen proteins by antibodies. In this report, the CARP method was extended to β-galactosidase (β-gal) as an amplification enzyme, which circumvented the requirement of an initial inactivation process because endogenous β-gal activity on the surface of examined cells was found to be negligible. The substrate structure for β-gal was optimized and used for the CARP method. The CARP method showed significantly higher fluorescent signals than a conventional method using fluorophore-modified antibodies. Moreover, the degree of amplification of the fluorescence signal was higher for antigens with low expression levels, showing that the CARP method is a suitable signal amplification method over current conventional approaches.

    DOI: 10.1021/acs.analchem.9b04471

  • Methylation of drug resistance‐related genes in chemotherapy‐sensitive Epstein–Barr virus‐associated gastric cancer

    2020年1月

     詳細を見る

    記述言語:その他  

    DOI: 10.1002/2211-5463.12765

  • Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer 査読

    Kyoko Yamaguchi, Mamoru Ito, Hirofumi Ohmura, Fumiyasu Hanamura, Michitaka Nakano, Kenji Tsuchihashi, Shuntaro Nagai, Hiroshi Ariyama, Hitoshi Kusaba, Hidetaka Yamamoto, Yoshinao Oda, Masafumi Nakamura, Koichi Akashi, Eishi Baba

    OncoImmunology   2020年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1080/2162402X.2020.1724763

  • Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients 査読

    Kotoe Takayoshi, Hitoshi Kusaba, Tomomi Aikawa, Sakuya Koreishi, Kosuke Sagara, Michitaka Nakano, Masato Komoda, Mihoko Kono, Mitsuhiro Fukata, Takeshi Arita, Taito Esaki, Koichi Akashi, Eishi Baba

    2019年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s10120-019-00930-2

  • Analysis of response evaluation criteria in solid tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer 査読

    Shiho Kawagoe, Masahiro Nakano, Keita Uchino, Kohei Arimizu, Tatsuhiro Kajitani, Hozumi Shimokawa, Tetsuya Kusumoto, Koji Ikejiri, Eishi Baba

    2019年9月

     詳細を見る

    記述言語:英語  

    DOI: 10.3892/mco.2019.1894

  • Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. 査読

    Yoshihiro T, Kusaba H, Makiyama A, Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T, Takayoshi K, Esaki T, Shimokawa H, Tsuchihashi K, Ariyama H, Akashi K, Baba E

    International journal of clinical oncology   2019年5月

     詳細を見る

    記述言語:その他  

    Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.

    DOI: 10.1007/s10147-018-01391-w

  • aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer. 査読

    Yoshihiko Fujita, Masataka Taguri, Kentaro Yamazaki, Junji Tsurutani, Kazuko Sakai, Takahiro Tsushima, Michitaka Nagase, Hiroshi Tamagawa, Shinya Ueda, Takao Tamura, Yasushi Tsuji, Kohei Murata, Koichi Taira, Tadamichi Denda, Toshikazu Moriwaki, Sadao Funai, Takako Eguchi Nakajima, Kei Muro, Akihito Tsuji, Motoki Yoshida, Koichi Suyama, Takuya Kurimoto, Naotoshi Sugimoto, Eishi Baba, Nobuhiko Seki, Mikio Sato, Takaya Shimura, Narikazu Boku, Ichinosuke Hyodo, Takeharu Yamanaka, Kazuto Nishio

    The oncologist   2019年3月

     詳細を見る

    記述言語:英語  

    DOI: 10.1634/theoncologist.2018-0119

  • 【分子標的薬の最適な治療シーケンス】 分子標的薬の最適な治療シーケンス 胃がん

    有山 寛, 馬場 英司

    がん分子標的治療   2019年2月

     詳細を見る

    記述言語:日本語  

    がんの分子生物学的特性の理解が深まるにつれ、胃がんにおいても分子標的薬の開発が進んでいる。現在、切除不能進行・再発胃がんに対する分子標的薬の治療シーケンスとしては、HER2陽性胃がんに対しては1次治療としてトラスツズマブを使用することが推奨される。2次治療においては血管新生阻害薬であるラムシルマブの有効性が確認され、3次治療においては抗PD-1抗体であるニボルマブが使用可能となった。これらの分子標的薬については今後胃がんにおける不均質性の克服や治療効果を予測するバイオマーカーの同定が必要であり、その結果precision medicineがますます加速していくものと考えられる。このように個々の病態に応じて適切な治療法を選択することで、胃がんの治療成績がさらに向上していくことが期待される。(著者抄録)

  • Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer. 査読

    Nakano M, Kikushige Y, Miyawaki K, Kunisaki Y, Mizuno S, Takenaka K, Tamura S, Okumura Y, Ito M, Ariyama H, Kusaba H, Nakamura M, Maeda T, Baba E, Akashi K

    Oncogene   2019年2月

     詳細を見る

    記述言語:その他  

    Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer.

    DOI: 10.1038/s41388-018-0480-0

  • 【胃癌治療ガイドライン最新版を読み解く-改定のポイントとその背景】 ガイドラインにみる胃癌化学療法 補助化学療法

    馬場 英司, 有山 寛

    臨床外科   2018年10月

     詳細を見る

    記述言語:日本語  

    <文献概要>ポイント ◆胃癌術後補助化学療法の標準治療はS-1あるいはCapeOXである.今後はS-1+ドセタキセルも含め,各レジメンの使い分けが必要である.◆術後補助化学療法後早期の再発に対する化学療法は,少なくとも薬剤を変更して行うことが適切と考えられる.◆SP療法による術前化学療法は,高度リンパ節転移を有する症例において有効と考えられるが,今後さらなるエビデンスの蓄積が必要である.

  • 【胃癌のすべて】 薬物療法 切除不能進行・再発胃癌の二次・三次化学療法の開発

    馬場 英司, 有山 寛

    医学のあゆみ   2018年9月

     詳細を見る

    記述言語:日本語  

    わが国を中心とした臨床試験の結果から、パクリタキセルやイリノテカンなどの殺細胞性抗がん薬の二次治療、三次治療におけるポジションが確立されていった。また、HER2陽性胃癌に対するトラスツズマブの一次治療での有効性が確認され、血管新生阻害薬であるラムシルマブも二次治療においてパクリタキセル(PTX)との併用で生存期間の延長を示した。さらにニボルマブも三次治療における標準治療となり、ほかのがん種と同様に胃癌化学療法における免疫チェックポイント阻害薬の開発が進んでいる。その一方で多くの分子標的薬が有効性を示すことができておらず、トラスツズマブの継続投与の有効性も明らかでない。殺細胞性抗がん薬に加えて、分子標的薬の一次耐性・二次耐性機序を解明しバイオマーカーを同定することが今後ますます重要となり、これらの耐性メカニズムを踏まえた有効な薬剤の選択が求められる。(著者抄録)

  • 腫瘍生物学におけるエクソソーム研究の現状と展望(The Exosome Biology in Cancer: Current Topics and Perspectives) 査読

    山本 雄介, 馬場 英司

    日本癌学会総会記事   2018年9月

     詳細を見る

    記述言語:英語  

  • 【2020年代に向けた胃がん化学療法】 どの患者に、どのレジメンを、どう用いるか 二次治療のレジメン選択は?

    奥村 祐太, 土橋 賢司, 馬場 英司

    臨床腫瘍プラクティス   2018年5月

     詳細を見る

    記述言語:日本語  

    <View Points!>▼ヒト型抗VEGFR-2モノクローナル抗体ラムシルマブ(RAM)とパクリタキセル(PAC)の併用療法が推奨されるレジメンである。▼PAC(毎週法)、ドセタキセル、イリノテカン、RAMも条件付きで推奨されるレジメンである。▼ABSOLUTE試験の結果から、ナブパクリタキセル(nab-PAC)(毎週法)も条件付きで推奨されるレジメンである。▼nab-PACは特に腹水や腹膜播種症例に対して、従来のPACと比較して高い有効性が示唆されているが、RAMとの併用では骨髄抑制に注意が必要である。▼HER2陽性胃がんに対する二次治療のトラスツズマブ(Tamb)の効果は明らかになっていない。PAC(毎週法)へのTmabの上乗せ効果を検討するWJOG7112G試験が進行中である。(著者抄録)

  • 【知っておきたい感染によるがん診療の知識】 トピックス EBVと胃がん、免疫チェックポイント療法

    有山 寛, 馬場 英司

    臨牀と研究   2018年2月

     詳細を見る

    記述言語:日本語  

  • 新たなステージに入ったがん幹細胞研究 胃印環細胞癌における癌幹細胞とニッチ

    有山 寛, 早河 翼, 馬場 英司, 赤司 浩一, Wang Timothy

    日本癌学会総会記事   2017年9月

     詳細を見る

    記述言語:英語  

  • 難治がん 治療標的の同定と創薬への展望 胃組織幹細胞と印環細胞癌発癌モデルマウス

    有山 寛, 早河 翼, 馬場 英司, 赤司 浩一, Wang Timothy

    2017年6月

     詳細を見る

    記述言語:日本語  

  • 胃印環細胞癌発癌マウスモデルの構築(Establishment of mouse model of diffuse type gastric cancer)

    有山 寛, 早河 翼, 馬場 英司, 赤司 浩一, Wang Timothy

    日本胃癌学会総会記事   2017年3月

     詳細を見る

    記述言語:英語  

  • Primary malignant melanoma of the esophagus successfully treated with nivolumab: A case report

    Kyoko Inadomi, Hozumi Kumagai, Shuji Arita, Kotoe Takayoshi, Hiroshi Uchi, Hidetaka Yamamoto, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

    ANNALS OF ONCOLOGY   2015年11月

     詳細を見る

    記述言語:英語  

  • 【血管新生阻害研究の進歩】

    赤司 浩一, 高倉 伸幸, 米満 吉和, 馬場 英司

    がん分子標的治療   2013年12月

     詳細を見る

    記述言語:日本語  

    腫瘍組織において、血管新生は栄養の供給と腫瘍増大に不可欠であるだけでなく、がん幹細胞から腫瘍が発生する過程で必要な微小環境を作るうえでも重要と考えられている。血管新生を阻害する薬剤の開発には、正常な血管新生のメカニズムに関して十分な理解が必要であり、近年の基礎研究の急速な進歩に伴い血管新生に関わる分子が徐々に明らかになってきている。特に血管内皮増殖因子(VEGF)は、血管内皮細胞の発生や内皮細胞による管腔形成、またその後の増殖機構にも関与する重要な分子であることがわかってきた。血管新生に関わる分子をターゲットとした薬剤の開発も進み、大腸がんなどでは抗VEGF抗体製剤であるベバシズマブの臨床的有用性が報告されている。また血管新生阻害剤の作用機序が腫瘍細胞への栄養供給を断つ、いわゆる「兵糧攻め」だけではないことも明らかになってきた。新規薬剤の臨床試験も数多く実施され、より有効性が期待される血管新生阻害剤も登場しつつある。しかし、血管新生阻害剤によって高い効果が得られる患者を選別するバイオマーカーはいまだみつかっておらず、血管新生阻害剤の耐性メカニズムの解明ならびに耐性克服など、早急に解決すべき問題も多い。今後さらに血管新生に関する分子機構の理解を深め、がん治療を進展させる必要がある。(著者抄録)

  • がん薬物療法専門医講座 がん薬物療法専門医のための模擬テスト(36)解答と解説

    内野 慶太, 草場 仁志, 馬場 英司

    腫瘍内科   2013年6月

     詳細を見る

    記述言語:日本語  

  • 固形がんの免疫・抗体療法 II.基礎研究の進歩と展望 抗体療法 抗体療法の現状と開発動向

    馬場英司, 草場仁志, 中野修治

    日本臨床   2012年12月

     詳細を見る

    記述言語:日本語  

  • The Voice on the Scene 進行膵がんの標準レジメンと投与の実際

    草場 仁志, 馬場 英司, 中野 修治

    メディカルオンコロジスト   2006年9月

     詳細を見る

    記述言語:日本語  

▼全件表示

所属学協会

  • 日本がんサポーティブケア学会

  • 日本がん分子標的治療学会

  • 日本免疫学会

  • 日本内科学会

  • 日本消化器内視鏡学会

  • 日本消化器病学会

  • 日本癌学会

  • 日本癌治療学会

  • 日本胃癌学会

  • 日本臨床腫瘍学会

  • 日本食道学会

  • 日本腫瘍循環器学会

  • American Society of Clinical Oncology

  • European Society for Medical Oncology

  • American Association of Immunologists

  • 日本消化器病学会

      詳細を見る

  • 日本消化器内視鏡学会

      詳細を見る

  • 日本内科学会

      詳細を見る

  • 日本免疫学会

      詳細を見る

  • 日本がん分子標的治療学会

      詳細を見る

  • 日本がんサポーティブケア学会

      詳細を見る

  • European Society of Medical Oncology

      詳細を見る

  • 日本癌学会

      詳細を見る

  • American society of clinical oncology

      詳細を見る

  • 米国臨床腫瘍学会

      詳細を見る

  • 米国免疫学会

      詳細を見る

  • 欧州臨床腫瘍学会

      詳細を見る

  • 日本食道学会

      詳細を見る

  • 日本臨床腫瘍学会

      詳細を見る

  • 日本腫瘍循環器学会

      詳細を見る

  • 日本胃癌学会

      詳細を見る

  • 日本癌治療学会

      詳細を見る

▼全件表示

委員歴

  • 日本臨床腫瘍学会   監事   国内

    2024年3月 - 2024年5月   

  • American Society of Clinical Oncology   Asia Pacific Regional Council   国際

    2022年5月 - 2024年5月   

  • 九州大学病院   がんセンター センター長  

    2021年4月 - 現在   

      詳細を見る

    団体区分:その他

    researchmap

  • 日本腫瘍循環器学会   国内交流委員   国内

    2021年4月 - 2024年5月   

  • 日本腫瘍循環器学会   国内交流委員  

    2021年4月 - 2022年3月   

      詳細を見る

  • 九州大学病院   希少がんセンター センター長  

    2020年12月 - 現在   

      詳細を見る

    団体区分:その他

    researchmap

  • 日本胃癌学会   ガイドライン作成委員会委員長  

    2020年4月 - 現在   

      詳細を見る

  • 日本胃癌学会   ガイドライン作成委員会委員長   国内

    2020年4月 - 2024年5月   

  • 日本胃癌学会   代議員  

    2018年1月 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本癌治療学会   代議員   国内

    2015年7月 - 2025年5月   

  • 日本臨床腫瘍学会   理事   国内

    2015年7月 - 2024年2月   

  • 日本臨床腫瘍学会   ガイドライン委員会委員長   国内

    2015年7月 - 2024年2月   

  • 日本癌治療学会   代議員  

    2015年 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

  • 日本臨床腫瘍学会   理事  

    2015年 - 現在   

      詳細を見る

    団体区分:学協会

    日本臨床腫瘍学会

    researchmap

  • 西日本がん研究機構   理事  

    2009年6月 - 現在   

      詳細を見る

  • 西日本がん研究機構   理事   国内

    2009年6月 - 2024年5月   

  • 西日本がん研究機構   運営委員  

    2008年4月   

      詳細を見る

  • 九州大学   緩和ケア委員  

    2007年4月   

      詳細を見る

    団体区分:その他

    researchmap

  • 九州大学   外来化学療法室運営委員  

    2006年4月   

      詳細を見る

    団体区分:その他

    researchmap

  • 日本臨床腫瘍学会   評議員  

    2005年4月   

      詳細を見る

▼全件表示

学術貢献活動

  • 新臨床腫瘍学第8版

    2024年1月 - 2024年5月

     詳細を見る

    種別:学会・研究会等 

  • 学術集会長

    日本臨床腫瘍学会  ( 福岡市 ) 2023年3月

     詳細を見る

    種別:大会・シンポジウム等 

    参加者数:6,500

  • 学術論文等の審査

    役割:査読

    2023年

     詳細を見る

    種別:査読等 

    外国語雑誌 査読論文数:12

    日本語雑誌 査読論文数:0

    国際会議録 査読論文数:0

    国内会議録 査読論文数:0

  • 学術論文等の審査

    役割:査読

    2022年

     詳細を見る

    種別:査読等 

    外国語雑誌 査読論文数:27

    日本語雑誌 査読論文数:1

  • 胃癌治療ガイドライン改訂第7版

    2021年7月 - 2024年5月

     詳細を見る

    種別:学会・研究会等 

  • 成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン第3版

    2021年1月 - 2024年3月

     詳細を見る

    種別:学会・研究会等 

  • 学術論文等の審査

    役割:査読

    2021年

     詳細を見る

    種別:査読等 

    外国語雑誌 査読論文数:22

  • 新臨床腫瘍学第7版

    2020年4月 - 2023年12月

     詳細を見る

    種別:学会・研究会等 

  • 学術論文等の審査

    役割:査読

    2020年

     詳細を見る

    種別:査読等 

    外国語雑誌 査読論文数:16

  • 新臨床腫瘍学第6版

    2019年5月 - 2020年7月

     詳細を見る

    種別:学会・研究会等 

  • 学術論文等の審査

    役割:査読

    2019年

     詳細を見る

    種別:査読等 

    外国語雑誌 査読論文数:14

  • 入門腫瘍内科学第3版

    2018年12月 - 2020年7月

     詳細を見る

    種別:学会・研究会等 

  • 胃癌治療ガイドライン改訂第6版

    2018年4月 - 2021年6月

     詳細を見る

    種別:学会・研究会等 

  • 学術論文等の審査

    役割:査読

    2018年

     詳細を見る

    種別:査読等 

    外国語雑誌 査読論文数:16

  • がん免疫療法ガイドライン改訂第2版

    2017年6月 - 2020年3月

     詳細を見る